kidney

INTERNATIONAL

Editor
Roscoe R. Robinson, Nashville

Assistant Editors
Claude Amiel, Paris
Vincent W. Dennis, Durham

Editorial Board
Thomas E. Andreoli, Houston
Vittorio E. Andreucci, Naples
A. W. Asscher, Cardiff
Peter Balint, Budapest
Jonas Bergstrom, Stockholm
Roland C. Blantz, San Diego
Adalbert Bohle, Tubingen
Jean-Philippe Bonjour, Berne
Vittorio Bonomini, Bologna
Barry M. Brenner, Boston
Neal S. Bricker, Los Angeles
Hans R. Brunner, Lausanne
J. S. Cameron, London
Jack W. Coburn, Los Angeles
Ramzi Cotran, Boston
William G. Couser, Seattle
Hugh E. deWardener, London
Jean Dormont, Clamart
R. Dzurik, Bratislava
Laurence E. Earley, Philadelphia
Bryan T. Emmerson, Brisbane
Marilyn G. Farquhar, New Haven
Thomas F. Ferris, Minneapolis
Eli A. Friedman, Brooklyn
Gerhard Giebisch, New Haven
Carmelo Giordano, Naples
Richard J. Glassock, Los Angeles
Jared J. Grantham, Kansas City
J. P. Grünfeld, Paris
Robert A. Gutman, Durham
Renée Habib, Paris
Jean Hamburger, Paris
John Hayslett, New Haven
Lee W. Henderson, San Diego
Robert H. Heptinstall, Baltimore
Norman K. Hollenberg, Boston
Malcolm A. Holliday, San Francisco
Nishio Honda, Hamamatsu
Rex L. Jamison, Stanford
Colin I. Johnston, Melbourne
Arthur C. Kennedy, Glasgow
D. N. S. Kerr, Newcastle-upon-Tyne
Fredrik Kiil, Oslo
Priscilla Kincaid-Smith, Melbourne
Saulo Klahr, St. Louis
Horst Klinkmann, Rostock
Franklyn G. Knox, Rochester, Minn.
Juha P. Kokko, Dallas
Franciszek Kokot, Katowice
W. Kriz, Heidelberg
Neil A. Kurtzman, Chicago
Paul H. Lambert, Geneva
Jacob Lemann, Jr., Milwaukee
David Z. Levine, Ottawa
Peter J. Little, Riyadh
Guy Lemieux, Montreal
Manuel Martinez-Maldonado, San Juan
Shaul G. Massry, Los Angeles
Joel Menard, Paris
Alfred F. Michael, Minneapolis
Paul Michielsen, Louvain
John F. Moorhead, London
François Morel, Paris
Liliane Morel-Maroger, Paris
L. Gabriel Navar, Birmingham
Alphonse Nizet, Liege
Karl D. Nolph, Columbia
Jack Orloff, Bethesda
Tadeusz Orlowski, Warsaw
D. Keith Peters, London
Georges Peters, Lausanne
R. T. Popovich, Austin
Mordecai M. Popovtzer, Jerusalem
Jaime Borrero Ramirez, Medellin
Gabriel Richet, Paris
George E. Schreiner, Washington, D.C.
Robert W. Schrier, Denver
Donald W. Seldin, Dallas
Fred L. Shapiro, Minneapolis
David P. Simpson, Madison
Jay H. Stein, San Antonio
Wadi N. Suki, Houston
Richard L. Tannen, Ann Arbor
Klaus Thurau, Munich
C. Craig Tisher, Gainesville
Bruno Truniger, Lucerne
Karl J. Ullrich, Frankfurt
Heinz Valtin, Hanover
Pierre Verroust, Paris
Herman Villarreal, Mexico, D.F.
Mackenzie Walser, Baltimore
Clark D. West, Cincinnati
Guillermo Whittembury, Caracas
Curtis B. Wilson, La Jolla
Douglas R. Wilson, Toronto

Manuscript Editor
Brenna Nichols, Nashville

Editorial Assistants
Sharon D. Lee, Durham
Joan Adams Sesma, Nashville
André Ulmann, Paris

Springer International

The exclusive copyright for all languages and for all countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Printed in the United States of America by The William Byrd Press Inc., Richmond, Virginia

© 1983 by International Society of Nephrology

Author Index For Volume 24

Abboud HE: Catabolism of histamine in the isolated glomeruli and tubules of the rat kidney 534
Abe H (abst)..... S16-338
Abe H: *see* Ando et al S16-23
Abels-Fransen GJ (abst)..... 415
Abernethy JD (abst) 409
Abraham J: *see* Mahajan et al..... S16-310
Abras E: *see* Walser et al S16-285
Abu-Hamdan DK: *see* Mahajan et al S16-310
Acchiardo S (abst) S16-345, S16-346
Acchiardo SR, Moore LW, Latour PA: Malnutrition as the main factor in morbidity and mortality of hemodialysis patients S16-199
Acitelli S (abst) S16-336
Adam A (abst) S16-329
Adami (abst)..... 129
Adams PH (abst)..... S16-349
Ader J-L (abst) 124
Adler AJ (abst)..... S16-333
Adorno D (abst)..... 412
Adu D (abst)..... 428
Aeikens B (abst) 280
Afiouni N (abst)..... 407
Agrafiotis A (abst)..... 136
Aguado S (abst)..... 272
Agus ZS: Oncogenic hypophosphatemic osteomalacia ... 113
Ahlberg M: *see* Alvestrand et al..... S16-268
Ahlenc-Gelas F (abst)..... 134
Ahmad M: *see* Mehta et al 782
Ahonen J (abst) 418
Aladjem M, Modan M, Lusky A, Georgi R, Orda S, Eshkol A, Lotan D, Boichis H: Idiopathic hypercalciuria: A familial generalized renal hyperexcretory state 549
Albertazzi A (abst)..... 129, S16-327, S16-331
Alberti KGMM (abst)..... S16-
Albouze G (abst)..... 820
Alcazar JM (abst)..... 268, 273
Alexandre GPJ (abst) 506
Alexopoulos E (abst) 415
Alferez C (abst)..... 268
Alfonso L (abst) 826
Alfred H: *see* Spector et al..... 663
Alhenc-Gelas F: *see* Misumi et al 58
Aliot E (abst)..... 821
Allegri L (abst) 824
Allegrini J (abst) 134
Alloatti S (abst)..... 131, S16-341
Almeida IT (abst) S16-337
Alomran A (abst)..... 413
Alongi SV: *see* Shen et al S16-145
Alonso S (abst) 133, 270
Alsina J (abst) 134, 269
Alt JM (abst) 275
Alterman L: *see* Bank et al..... 185
Altomonte M (abst)..... 422
Alvarez Grande J (abst)..... 130, 268
Alvestrand A, Ahlberg M, Bergström J: Retardation of the progression of renal insufficiency in patients treated with low-protein diets S16-268
Alvestrand A, Fürst P, Bergström J: Intracellular amino acids in uremia..... S16-9
Alvestrand A: *see* Bergström et al..... S16-153
Alvestrand A: *see* DeFronzo et al S16-102
Amadori A, Candi P, Sasdelli M, Massai G, Favilla S, Passaleva A, Ricci M: Hemodialysis leukopenia and complement function with different dialyzers 775
Amend W (abst) 414
Anaya F (abst)..... 418
Ancona G (abst) 129
Andersen RC: *see* Rao et al 210
Ando A (abst)..... S16-338
Ando A, Mikami H, Orita Y, Fujii M, Okada A, Abe H, Chiku K, Natori Y: Influence of chronic renal failure on protein synthesis in rat liver and muscle S16-23
Andonian C (abst)..... 820
Andrassy K (abst) 275, 413
Andrejak M (abst)..... 822
Andres A (abst)..... 269
Andres E (abst)..... 134
Andress D, Felsenfeld AJ, Voigts A, Llach F: Parathyroid hormone response to hypocalcemia in hemodialysis patients with osteomalacia 364
Andreu L (abst) 272, 427
Andreucci VE (abst) 422, 423, 426, 427, 826
Andujar J (abst)..... 134
Anema J (abst)..... 408
Ang KS (abst) 137
Angeli A (abst)..... S16-337
Angelini C (abst) S16-332
Aoyagi K, Ohba S, Narita M, Tojo S: Regulation of biosynthesis of guanidinosuccinic acid in isolated rat hepatocytes and in vivo S16-224
Aponte GW: *see* Kurokawa et al..... 754
Aprile M (abst) 826
Aranda JL (abst)..... 268
Arant BS Jr: *see* Engle et al 358
Aranzabal J (abst)..... 271
Arbus GS, Hardy BE, Balfe JW, Churchill BM, Steele BT, Baumal R, Curtis RN: Cadaveric renal transplants in children under 6 years of age S15-111
Arcangeli A (abst)..... S16-351
Argemi B: *see* Olmer M..... S16-175
Arias M (abst) 272
Arico S (abst)..... 824
Arieff AI: *see* Mahoney et al 170
Arisi L (abst)..... S16-327, S16-341
Arnold WC, Danford D, Holliday MA: Effects of caloric supplementation on growth in children with uremia 205
Aroldi A (abst) 138, 425
Arrizabalaga P (abst) 427
Ash SR, Bungu ZTJ, Regnier FE: Anion exchange chromatography and double-diffusion cells for the study of middle molecules 250
Assmann KJM (abst) 408
Assmann KJM, Tangelder MM, Lange WPJ, Tadema TM, Koene RAP: Membranous glomerulonephritis in the mouse 303
Assogba U (abst)..... 418
Attman P-O (abst)..... S16-345, S16-346

Avedillo J (abst) 272
Ayed K (abst) 125
Aynedjian HS: *see* Bank et al 185
Aynedjian HS: *see* Neugarten et al 330
Azer M (abst) S16-346

Bacchi M (abst) S16-327
Bacri JL (abst) S16-344
Baczyk K (abst) S16-338, S16-339
Baczynski R: *see* Brautbar et al 53
Baggio B (abst) 126
Baglin A (abst) 129
Bailey RR: *see* Ikram et al 371
Bakker WW (abst) 410
Balado P (abst) 271
Balavoine F (abst) 404
Balcke P (abst) 419, S16-328
Baldamus CA (abst) 275
Baldi R (abst) 824
Baldini E (abst) 133
Baldrati L (abst) S16-331
Baldrati L: *see* Scolari et al S16-77
Balducci A (abst) S16-336
Baldwin DS: *see* Neugarten et al 595
Balestrieri G (abst) 827
Balfe JW (abst) 424, S16-345
Balfe JW: *see* Arbus et al S15-111
Ballanti P (abst) 128
Ballarín J (abst) 124
Baluarte HJ: *see* Gruskin et al S15-95
Balzola F (abst) 135, S16-337
Bank N, Alterman L, Aynedjian HS: Selective deep nephron hyperfiltration in uninephrectomized spontaneously hypertensive rats 185
Bank N: *see* Neugarten et al 330
Bankir L (abst) 406
Banks R (abst) 423
Barat A (abst) 268
Barbiano di Belgioioso G (abst) 825
Barceló P (abst) 124, 274
Barlassina C (abst) 129
Barrientos A (abst) 268
Barril G (abst) 133
Barrio V (abst) 270
Barsotti G (abst) 824, S16-346, S16-347
Barsotti G, Morelli E, Giannoni A, Guiducci A, Lupetti S, Giovannetti S: Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: A controlled trial S16-278
Barthe P (abst) S16-328, S16-343
Barthelemy A (abst) 413
Basile A (abst) 427, 825
Basolo B (abst) 128, 423, 824, 827
Bataille P (abst) 419, 820, 822
Battilana G (abst) 127, 130
Baud L (abst) 404
Bauer JH: *see* Kimura et al 542
Baumal R: *see* Arbus et al S15-111
Baumelou A (abst) 129, S16-336
Baverel G (abst) 124
Bayle F (abst) 827
Bazzato G (abst) S16-329
Bazzato G: *see* Guarnieri et al S16-187
Beastall G (abst) 269
Beaud JM (abst) 406
Beaufils H (abst) 129
Bechstein P (abst) 413, 418
Becker K: *see* Leschke et al S16-143
Beck-Nielsen H (abst) 427
Beekhuis H (abst) 410
Belardi P (abst) S16-341
Bellinghieri G (abst) 125
Bellini G (abst) 127, 130
Bello I (abst) 273
Beltrandi E (abst) 127, 824
Ben Ayed H (abst) 125
Bender-Götze C (abst) 277
Bene MC (abst) 125, 405
Benhamou E (abst) 138
Benizzelli U (abst) 132
Ben Maïz H (abst) 125
Bennington MJ: *see* Michael et al 74
Beretta R (abst) 125
Berger B (abst) 414
Berger J (abst) 408
Bergrem H (abst) 418
Bergström J, Alvestrand A, Fürst P, Hultman E, Widstam-Attorps U: Muscle intracellular electrolytes in patients with uremia S16-153
Bergström J: *see* Alvestrand et al S16-9, S16-268
Berland Y (abst) 820
Berland Y: *see* Olmer et al S16-175
Berlyne GM (abst) S16-333
Bernardi A (abst) S16-334
Bernasconi P (abst) 827
Beroniade V (abst) 423
Bertazzo L (abst) 126
Berthoux FC (abst) 131
Berthoux R (abst) 131
Bertocchio P (abst) 822
Bertoli M (abst) S16-332, S16-347
Bertoli S (abst) 825
Bertram HP (abst) 279
Bettinelli A (abst) 421
Beukhof JR (abst) 408
Biagi R (abst) 824
Biagini G (abst) 127, 824
Bianchetti A (abst) 127
Bianchi C (abst) 125
Bianchi G (abst) 129, 132
Bianchi R (abst) S16-346
Bianchini G (abst) 128
Biasia A (abst) S16-334
Biava C (abst) 414
Bichet DG, Groves BM, Schrier RW: Mechanisms of improvement of water and sodium excretion by immersion in decompensated cirrhotic patients 788
Bing RF (abst) 426
Binswanger U (abst) 275
Bistrian B (abst) S16-342
Bizzi S (abst) S16-327
Blantz RC: *see* Cheung et al 104
Blas SD: *see* Nieman et al S16-167
Bleumink E (abst) 410
Blevins RB (abst) S16-340
Blomhoff JP (abst) S16-341
Blumenkrantz MJ (abst) S16-332, S16-345
Blumenkrantz MJ: *see* Kopple et al S16-295
Boberg U: *see* Ståhl et al 323
Boesken WH (abst) 275
Boffa GA (abst) 822
Boggio-Bertinet D (abst) 135, S16-337

Bohle A (abst) 276, 278
Böhles HJ: *see* Michalk et al S15-16
Boichis H: *see* Aladjem et al 549
Boldrini G (abst) S16-338
Bolli P (abst) 280
Bommer J (abst) 413, 422
Bonadio M (abst) 125
Bonino F (abst) 824
Bonjour J-P: *see* Taylor et al 37
Bono F (abst) S16-338
Bonomini V (abst) 414, 824, S16-331, S16-331, S16-336
Bonomini V: *see* Scolari et al S16-77
Bonucci E (abst) 128, S16-333
Bonzel KE (abst) S16-343
Borghetti A (abst) 826
Bories P (abst) S16-327
Borsatti A (abst) 126
Bosch JP (abst) S16-335
Bosi E (abst) 428
Bossi P (abst) 131
Botella J (abst) 126
Bottini AT: *see* Gulyassy et al S16-238
Bouissou F (abst) S16-328, S16-343
Boulpaep EL: *see* Maunsbach et al 610
Bourdeau A (abst) 821
Bourke E (abst) 412
Bourne JR, Teschan PE: Computer methods, uremic encephalopathy, and adequacy of dialysis 496
Bournerias F (abst) 421
Bowman C (abst) 406
Boxer LA: *see* Ivanovich et al 758
Bradley JA (abst) 414
Brandis M (abst) 277
Brando B (abst) 417
Branger B (abst) 404
Brangier J (abst) 138
Brasa S (abst) 411
Braun G (abst) 416
Braun W (abst) S16-331
Brautbar N: Skeletal myopathy in uremia: Abnormal energy metabolism S16-81
Brautbar N, Carpenter C, Baczynski R, Kohan R, Massry SG: Impaired energy metabolism in skeletal muscle during phosphate depletion 53
Bray SH (abst) S16-347
Bremer HJ (abst) 277
Brennan BL (abst) S16-342
Brenner BM: *see* Meyer et al S16-243
Brentjens JR: *see* Van Liew et al 160
Brevi L (abst) 136
Brezis M, Rosen S, Silva P, Epstein FH: Selective glutathione depletion on function and structure of the isolated perfused rat kidney 178
Briefel G: *see* Spector et al 663
Briggs J (abst) 282
Briggs JD (abst) 126, 269, 414
Briggs WA: *see* Mahajan et al S16-310
Briggs WA, Sillix DH, Mahajan S, McDonald FD: Leukocyte metabolism and function in uremia S16-93
Briso-Montiano JM (abst) 269
Brocks P (abst) 426
Brodehl J (abst) 277
Brown CB (abst) 417
Brown RC (abst) 421
Brown RC: *see* Lucas et al S16-171
Browning M (abst) 423
Broyer M (abst) 129, 132, 411, S16-343, S16-344, S16-349, S16-349
Broyer M, Guillot M, Niaudet P, Kleinknecht C, Dartois AM, Jean G: Comparison of three low-nitrogen diets containing essential amino acids and their alpha analogues for severely uremic children S16-290
Broyer M, Niaudet P, Champion G, Jean G, Chopin N, Czernichow P: Nutritional and metabolic studies in children on continuous peritoneal dialysis S15-106
Broyer M: *see* Kleinknecht et al S15-40
Broyer M: *see* Laourari et al S16-248
Brunner F (abst) 414
Brunner FP (abst) 280, 411
Bruno M (abst) 134
Brunois JP (abst) 820
Brun-Pascaud M: *see* Girard et al 795
Bruzzone M: *see* Tizianello et al S16-17
Brynger H (abst) 411, 418
Bucciante G (abst) S16-334
Bucht H (abst) S16-346
Buddensiek P: *see* Wizemann et al S16-218
Buemi M (abst) 826
Bueno R (abst) 268, 272, 416
Buerkert J: *see* Klahr et al 579
Bühler FR (abst) 280
Bulla M (abst) 277
Bulzomi MR (abst) 128, 824
Bunch TW (abst) 425
Bundschu D: *see* Sprenger et al S16-315
Bungu ZTJ: *see* Ash et al 250
Burger U (abst) S16-328
Burnel D (abst) 405
Burns G (abst) S16-339
Burns G: *see* Metcoff et al S16-87
Burrin J (abst) S16-329
Buscaroli A (abst) S16-331
Buscaroli A: *see* Scolari et al S16-77
Busnach G (abst) 417
Bussolino F (abst) 137
Bustamante J (abst) 269
Butz M (abst) S16-334
Buzio C (abst) S16-331

Cabanne JF (abst) 404
Cabrol C (abst) 413
Cachofeiro MV (abst) 271
Cagnoli L (abst) 824
Cagnoli L: *see* Zucchelli et al 649
Cahl GM (abst) 413
Calabrese G (abst) S16-347, 824
Calay G (abst) S16-329
Calderini MC (abst) S16-341
Callard P (abst) 415
Calò L (abst) 126
Cambi V (abst) S16-327, S16-338
Campana G (abst) 826
Campanacci L (abst) 127, 130, S16-329
Campanacci L: *see* Guarnieri et al S16-187
Camuiri C (abst) S16-334
Camussi G (abst) 137
Canavese C (abst) 135, 137
Cancarini GC (abst) 411
Candi P: *see* Amadori et al 775
Cannata J (abst) 126, 416
Cannata JB (abst) 269
Cantaluppi A (abst) 411

Cantaro S (abst) 126
Cantù P (abst) 133
Capelli M (abst) S16-336
Capitanio L (abst) 421
Cappelli P (abst) S16-327
Capuano A (abst) 426, 826
Caputo A (abst) 427
Caralps A (abst) 134, 269
Caramelo C (abst) 271
Cardelli R (abst) 135, S16-337
Carlier PG (abst) 127
Carney RM: *see* Goldberg et al S16-303
Carozzi S (abst) 132
Carpenter C: *see* Brautbar et al 53
Carraro M (abst) 130
Carretero OA: *see* Omata et al 714
Carretta R (abst) 127
Caruso U (abst) S16-327
Casado S (abst) 271
Casanova S: *see* Zucchelli et al 649
Casciani CU (abst) 128, 412, S16-327
Castagneto M (abst) S16-338, S16-340
Castelao AM (abst) 134, 269
Castelnovo C (abst) 425
Castiglione A (abst) 825
Castrillo JM (abst) 271
Castro LA (abst) 278
Catherwood BD: *see* Cheung et al 104
Cathomen M (abst) 131
Catizone L (abst) 127
Cattaneo MT (abst) 125
Cattaneo R (abst) 827
Catto GRD (abst) 413
Cattran DC (abst) 424
Caudarella R (abst) 127
Causse E (abst) S16-328
Cavallo T, Goldman M, Graves K, Lambert P-H: Altered glomerular permeability in the early phase of immune complex nephritis 632
Caverzasio J: *see* Taylor et al 37
Cecchin E (abst) 427, 825, S16-338
Cekański A (abst) 426
Celma ML (abst) 268
Cenacchi G (abst) 824
Cerf M (abst) 821
Cessot I (abst) 821
Challah S (abst) 411
Chalopin JM (abst) 404
Champailler A (abst) 131
Champion G: *see* Broyer et al S15-106
Chan Y-L, Mason RS, Parmentier M, Savdie E, Lissner D, Posen S: Vitamin D metabolism in nephrotic rats 336
Chanard J (abst) 820
Chantler C: *see* Dalton et al S15-11, S16-61
Chantler C: *see* Jones et al 95
Chantler C: *see* Mak et al S15-22, S16-128
Chappell TR: *see* Henrich et al 240
Charon S (abst) 820
Charransol G (abst) 419, 820
Chenoweth DE, Cheung AK, Henderson LW: Anaphylatoxin formation during hemodialysis: Effects of different dialyzer membranes 764
Chenoweth DE, Cheung AK, Ward DM, Henderson LW: Anaphylatoxin formation during hemodialysis: Comparison of new and re-used dialyzers 770
Chenoweth DE: *see* Ivanovich et al 758
Cherian G (abst) S16-345
Chesney RW, Gusowski N, Friedman AL: Renal adaptation to altered dietary sulfur amino acid intake occurs at luminal brushborder membrane 588
Chesney RW, Hamstra AJ, Phelps M, DeLuca HF: Vitamin D metabolites in renal insufficiency and other vitamin D disorders of children S15-63
Cheung AK, Manolagas SC, Catherwood BD, Mosely CA Jr, Mitas JA II, Blantz RC, Deftos LJ: Determinants of serum $1,25(OH)_2D$ levels in renal disease... 104
Cheung AK: *see* Chenoweth et al 764
Cheung AK: *see* Chenoweth et al 770
Cheung HS: *see* Maierhofer et al 555
Chevet D (abst) 405, 407
Chiarini C (abst) 138, 412, 828
Chiku K: *see* Ando et al S16-23
Chini M (abst) 129
Chmiel J (abst) S16-339
Chodak GW, Gill WB, Wald V, Spargo B: Diagnosis of renal parenchymal diseases by a modified open kidney biopsy technique 804
Chopin N: *see* Broyer et al S15-106
Chou S-Y (abst) S16-333
Chung TG: *see* Saito et al S16-234
Churchill BM: *see* Arbus et al S15-111
Churg J: *see* Morita et al 1
Cianciaruso B (abst) 423
Ciancioni C (abst) S16-347
Ciardella F (abst) S16-346
Cieciura L (abst) 415
Cinotti GA (abst) 128
Cioni L (abst) 127
Cirillo C: *see* Giordano et al S16-71
Citterio F (abst) S16-340
Civati G (abst) 135, 417
Clark AS: *see* Mitch et al S16-2
Clark WF (abst) 424
Clarke IA, Ormrod DJ, Miller TE: Host immune status in uremia. V. Effect of uremia on resistance to bacterial infection 66
Cledes J (abst) 404, 405
Clement J (abst) 409
Cloix JF (abst) 821
Coburn JW: *see* Kraut et al 644
Cockrell S (abst) S16-345, S16-346
Coe FL: Uric acid and calcium oxalate nephrolithiasis .. 392
Coen G (abst) 128
Coevoet B (abst) 130, 419, 422, 820
Cohen B (abst) ..... S16-335 , S16-340
Cohen L: *see* Michelson et al 246
Cohen SL (abst) S16-347
Cohn SH (abst) S16-342
Coleman TH, Forristal J, Kosaka T, West CD: Inherited complement component deficiencies in membranoproliferative glomerulonephritis 681
Coles GA (abst) 421
Coles GA: *see* Lucas et al S16-171
Coli L (abst) S16-333
Coli L: *see* Scolari et al S16-77
Coli U: *see* Guarnieri et al S16-187
Collart F (abst) 420
Colleen S (abst) 425
Colon S (abst) 13
Colonna GP (abst) 824
Colussi G (abst) 138, 425
Conesa J (abst) 270

Consolo F (abst) 125
Conte G (abst) 422, 426, 826
Cooper JH: *see* Sigler et al S16-97
Coplon NS (abst) 416
Coppo R (abst) 128, 423, 825, 827
Coratelli P (abst) 131
Cordonnier D (abst) 128, 423, 827
Corlianó C (abst) 826
Corradi A (abst) S16-327, S16-338
Corsi M (abst) S16-328, S16-332
Cortés C (abst) 271
Corti D (abst) 136
Corvol P: *see* Misumi et al 58
Cosci P (abst) 138, 425
Costanzo R (abst) 133, 827
Costiloe P (abst) S16-339
Cotorruelo JG (abst) 272
Cournot-Witmer G (abst) 417, S16-349
Courouce AM (abst) 138
Covarsí A (abst) 124
Cravotto E (abst) S16-327
Cristofano C (abst) S16-347, 824
Crosnier J (abst) 138
Cross RE: *see* Falk et al 110
Cuesta V (abst) 126, 416
Cunningham EE: *see* Nieman et al S16-167
Curatola G (abst) 825
Curtis RN: *see* Arbus et al S15-111
Cusi D (abst) 129
Cuthbertson B (abst) 417
Czarnecki R (abst) S16-339
Czernichow P: *see* Broyer et al S15-106

Daelemans P (abst) 130
Dagher FJ: *see* Shen et al S16-147
Daha MR (abst) 408, 409
Dalac S (abst) 404
Dal Canton A (abst) 422, 426, 427, 826
Dalet F (abst) 124
Dalldorf FG: *see* Jennette et al 377
Dallosta V (abst) 132
Dal Monte PR (abst) 127
Dalton N: *see* Jones et al 95
Dalton RN, Chantler C: Metabolism of orally administered branched-chain α-keto acids S15-11
Dalton RN, Chantler C: The relationship between branched-chain amino and α-keto acids in blood in uremia S16-61
D'Amaro J: *see* Wing et al 507
Damiani E (abst) 125
D'Amico G (abst) 422, 827
Dana A (abst) 820
Danford D: *see* Arnold et al 205
D'Angelo A (abst) S16-
D'Angelo A: *see* Maschio et al S16-
Daniele PG (abst) 134
Danielson BG (abst) 419
Dankner RE: *see* Michelson et al 246
D'Anna F (abst) 426, 427, 826
D'Antuono G (abst) 127
Darai G (abst) 413
Dard S (abst) 129, 821
Dardi F (abst) S16-329
Dardi F: *see* Guarnieri et al S16-187
Dartois AM (abst) S16-343
Dartois AM: *see* Broyer et al S16-290
Dartois A-M: *see* Kleinknecht et al S15-40
Dathe G (abst) 413
D'Avanzo L (abst) 426, 826
Davidson W (abst) S16-350
Davidson WD (abst) S16-332
Davies M (abst) 415
Davignon A: *see* O'Regan et al S15-77
Davin JC (abst) 415
Davis FB: *see* Nieman et al S16-167
Davis JM, Emslie KR, Sweet RS, Walker LL, Naughton RJ, Skinner SL, Tange JD: Early functional and morphological changes in renal tubular necrosis due to p-aminophenol 740
Davis PJ: *see* Nieman et al S16-167
Davis TA, Karl IE, Goldberg AP, Harter HR: Effects of exercise training on muscle protein catabolism in uremia S16-52
Davison AM (abst) 426
De Alvaro F (abst) 269
De Besi L (abst) 129
De Blasi V (abst) 826
De Boor J: *see* Wizemann et al S16-218
Debus E (abst) S16-341
Dechaux M (abst) 129
Dechenne C (abst) 415
Dechenne CH (abst) 132
De Clippele M (abst) 138
De Covadonga Sra (abst) 268
Deelder AM (abst) 409
Deetien P (abst) 281
Deferrari G, Garibotto G, Robaudo C, Lutman M, Viviani G, Sala R, Tizianello A: Glucose interorgan exchange in chronic renal failure S16-115
Deferrari G: *see* Tizianello et al S16-17
De Ferrari ME (abst) 425
Defilippi PG (abst) 827
Defilló G (abst) 272
De Francisco ALM (abst) 272
De Fremont JF (abst) 130, 419, 422, 820
DeFronzo RA, Smith D, Alvestrand A: Insulin action in uremia S16-102
Deftos LJ: *see* Cheung et al 104
Degli Esposti E (abst) 138, 412, 828
Degos F (abst) 138
De Graeve J (abst) S16-327, S16-328
De Groc F (abst) 136, S16-336
Deinhardt F (abst) 413
De Jong PE (abst) 423, 427
Delarue F (abst) 404
De la Torre L (abst) 271
Del Hoyo J (abst) 271
D'Elia JA (abst) S16-342
De Ligny B (abst) 125, 405
Dell'Aira AE (abst) S16-332
Dell'Oro C (abst) 827
Delmez JA: *see* Goldberg et al S16-303
Delons S (abst) 405, S16-347
Del Pino D (abst) 271
Del Rió G (abst) 124, 274
Del Rosso G (abst) 129, S16-327
DeLuca HF: *see* Chesney et al S15-63
De March A (abst) 412, 828
De Marchi S (abst) 427, 825, S16-338
De Marco N (abst) 825
De Meo F (abst) S16-336
De Mestier P (abst) 821

Denneberg T (abst) ... 420, S16-334, S16-340
De Paoli P (abst) ... 825
Depner A (abst) ... S16-337
De Ranieri E (abst) ... 406
Desailly I (abst) ... 422
De Sancho JL (abst) ... 271
Deschodt G (abst) ... 404
Deteix P (abst) ... 135, S16-351
De The H (abst) ... 821
De Vinuesa SG (abst) ... 133, 270
Devynck MA (abst) ... 821
De Wardener HE: *see* Gordon et al ... 455
Deykin D: Uremic bleeding ... 698
De Zeeuw D (abst) ... 422, 423, 427
Dhondt JL (abst) ... 138
Di Dio G (abst) ... S16-328
Diekmann L (abst) ... 277, S16-343
Díez J (abst) ... 130, 273
Di Felice A (abst) ... S16-331
Di Filippo S (abst) ... 133, 827
Dijkhuis FWJ (abst) ... 410
Di Landro D (abst) ... S16-348
Di Leo VA: *see* Giordano et al ... S16-71
Di Maio G (abst) ... S16-349
Di Marco V (abst) ... S16-332
Di Nucci GD (abst) ... 412
Di Stefano C (abst) ... 125
Dkhissi H (abst) ... 130, 822
Dodd NJ (abst) ... 420
Dogliani M (abst) ... 137
Donadio C (abst) ... 125
Donadon W (abst) ... 825
Donato D (abst) ... S16-334
Donckerwolcke RA (abst) ... 411
Donini U: *see* Zucchelli et al ... 649
Donker AJM (abst) ... 408, 414
Donne C (abst) ... 135
Donnelly PK (abst) ... 413
Dorhout Mees EJ (abst) ... 415
Dornfeld L (abst) ... S16-337
Dostal G (abst) ... 427
Dracon M (abst) ... 138, 415
Dratwa M (abst) ... 420
Droz D (abst) ... 406, 820
Drüeke T (abst) ... 417
Drüeke T, Lacour B, Roullet J-B, Funck-Bretano J-L: Recent advances in factors that alter lipid metabolism in chronic renal failure ... S16-134
Druml W (abst) ... S16-328
Druml W, Laggner A, Widhalm K, Kleinberger G, Lenz K: Lipid metabolism in acute renal failure ... S16-139
Dryl T (abst) ... S16-339
Dubernard JM (abst) ... 428
Dubois CH (abst) ... 415
Dubose TD Jr: *see* Mehta et al ... 782
Dubost C (abst) ... 417
Ducharme G: *see* O'Regan et al ... S15-77
Duheille J (abst) ... 125
Dumbauld SL, Rutsky EA, McDaniel HG: Carbohydrate metabolism during fasting in chronic hemodialysis patients ... 222
Dunn SR: *see* Lele et al ... S16-229
Dupont E (abst) ... 130
Duranti E (abst) ... 424
Durasin I (abst) ... 276
Dutch Society of Nephrology (abst) ... 408
Dutta S (abst) ... S16-339
Dutta S: *see* Metcoff et al ... S16-87

Eby B: *see* Lau et al ... 10
Eche J-P (abst) ... 124
Edefonti A (abst) ... 421, S16-344
Edward N (abst) ... 413, 417
Egido J (abst) ... 424
Ehrich JH (abst) ... 277
Eigler FW (abst) ... 427
Eisenhauer T: *see* Leschke et al ... S16-143
Elghozi JL (abst) ... 821
Elli M (abst) ... 412, S16-327
Ellis KJ (abst) ... S16-342
El Matri A (abst) ... 125
El Nahas AM (abst) ... 424
Eloy L (abst) ... 406
El Shahat Y (abst) ... 136
El Yafi S (abst) ... 428
Emslie KR: *see* Davis et al ... 740
Endres W (abst) ... 277
Englaro E (abst) ... 130
Engle WD, Arant BS Jr: Renal handling of beta-2-microglobulin in the human neonate ... 358
Epstein FH: *see* Brezis et al ... 178
Errasti P (abst) ... 130, 269, 273
Ers P (abst) ... S16-329
Escallada R (abst) ... 272
Eshkol A: *see* Aladjem et al ... 549
Esposito C (abst) ... 422
Esposito R: *see* Giordano et al ... S16-71
Essich H-J: *see* Michalk et al ... S15-16
European Dialysis and Transplant Association (abst) ... 411
Evan AP: *see* Gardner et al ... 43
Eyquem A (abst) ... 821

Fabris A (abst) ... 828, S16-333
Fabris A: *see* Maschio et al ... S16-273
Fabris B (abst) ... 127
Faccini L (abst) ... 130
Faccini L: *see* Guarnieri et al ... S16-187
Faguet P (abst) ... S16-348
Falk RJ, Mattern WD, Lamanna RW, Gitelman HJ, Parker NC, Cross RE, Rastall JR: Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine ... 110
Falk RJ: *see* Michael et al ... 74
Faller B (abst) ... 406
Farrell PC: Kinetic modeling: Applications in renal and related diseases ... 487
Fassbinder W (abst) ... 413, 417, 418
Fassbinder W: *see* Thevenod et al ... 227
Faubert PF (abst) ... S16-333
Fauchet R (abst) ... 137
Faure G (abst) ... 125, 405
Favilla S: *see* Amadori et al ... 775
Federico S (abst) ... 423
Feduska N (abst) ... 414
Feiner HD: *see* Neugarten et al ... 595
Feinstein EI, Kopple JD, Silberman H, Massry SG: Total parenteral nutrition with high or low nitrogen intakes in patients with acute renal failure ... S16-319
Feinstein EI: *see* Kaptein et al ... S16-180
Feldhoff C (abst) ... 277
Feliciangeli G (abst) ... S16-331
Feliciangeli G: *see* Scolari et al ... S16-77

Fellström B (abst) 419
Felsenfeld AJ: *see* Andress et al 364
Ferguson CW: *see* Williams et al 691
Fernandez-Fernandez J (abst) 126
Fernandez-Repollet E, LeFurgey A, Hardy MA, Tisher CC: Structural and functional response of toad urinary bladder to LiCl 719
Fernández Vega F (abst) 130
Ferrarese P (abst) S16-333
Ferrario F (abst) 825
Ferrario G (abst) 136
Ferré J (abst) 274
Fiddler W: *see* Lele et al S16-229
Fievet P (abst) 130, 422, 822
Figueredo MA (abst) 273
Finaz J (abst) S16-351
Fine RN (abst) S16-345
Fine RN: *see* Salusky et al S15-101
Finistauri D (abst) 128
Fischer D: *see* Mehta et al 782
Fiselier T (abst) 409
Fish AJ: *see* Michael et al 74
Flamigni C (abst) 412, 828
Flatmark AF (abst) 418
Fleisch H: *see* Taylor et al 37
Fleuren GJ (abst) 408
Flugel-Link R (abst) S16-351
Flugel-Link RM: *see* Salusky et al S16-43
Flynn CT (abst) 428
Fogazzi GB (abst) 825
Foidart JB (abst) 132
Foidart JM (abst) 415
Folio D (abst) S16-343
Fontenaille C (abst) 135
Fornasieri A (abst) 827
Forristal J: *see* Coleman et al 681
Forsythe SB: *see* Williams et al 691
Foucault C (abst) 418
Fournier A (abst) 130, 419, 422, 820, 821, 822
Fragola J (abst) 412
Francais C (abst) 135
Francais P (abst) 135
Francis DMA (abst) 413
Franckson M (abst) S16-335
Franco GC (abst) S16-348
Franco P (abst) S16-349
Franklin S (abst) S16-350
Franz H-E: *see* Sprenger et al S16-315
Franz KA (abst) 276
Frascà G (abst) 414, 824
Freeman RB (abst) 424
Frei U (abst) 413
French Society of Nephrology (abst) 124, 404, 820
Frick A (abst) 276
Friedman AL: *see* Chesney et al 588
Friedman PA: *see* Kelly et al 233
Fries J (abst) 276
Frisina N (abst) 826
Frisk B (abst) 418
Fröhling P (abst) S16-350, S16-350
Fuchs C: *see* Leschke et al S16-143
Fuiano G (abst) 422
Fujibayashi S: *see* Kurokawa et al 754
Fujii M (abst) S16-338
Fujii M: *see* Ando et al S16-23
Fujita T, Sato Y: Natriuretic and antihypertensive effects of potassium in DOCA-salt hypertensive rats 731
Funck-Bretano J-L: *see* Drüeke et al S16-134
Furci L (abst) 133
Fürsch A (abst) 418
Fürst P: *see* Alvestrand et al S16-9
Fürst P: *see* Bergström et al S16-153
Fuschini G (abst) 412, 828
Fusco MS (abst) S16-348

Gaggi R (abst) 138
Gagnadoux MF (abst) 129
Gahl GM (abst) 412
Galato R (abst) 421, S16-344
Galian A (abst) 406
Gallego JL (abst) 126
Gallego N (abst) 131, 274
Galli P (abst) 133
Galloway DJ (abst) 414
Galy C (abst) 419, 820, 821
Gammaro L (abst) 828
Gammaro L: *see* Maschio et al S16-273
Gandjbakhch I (abst) 413
Ganeval D (abst) 131
Garcia A (abst) 268
Garcia-Aguado C (abst) 273
Garcia Ortiz JR (abst) 268
Garcia Robles R (abst) 268
Gardner KD Jr, Evan AP: Renal cystic disease induced by diphenylthiazole 43
Garibotto G: *see* Deferrari et al S16-115
Garibotto G: *see* Tizianello et al S16-17
Garo B (abst) 405
Garrett LE Jr: *see* Stead et al 446
Gärtner HV (abst) 276
Gasparotto L (abst) 129
Gasparotto ML (abst) S16-348
Gatti M (abst) 129
Gaucher A (abst) 405
Gaussourgues Ph (abst) S16-351
Gavin JR III: *see* Goldberg et al S16-303
Gekle D (abst) 277
Gelet A (abst) 428
Gelpi C (abst) 124
Geltman EM: *see* Goldberg et al S16-303
Genetet B (abst) 137
Genin C (abst) 131
Genin M (abst) S16-329
Genin M: *see* Kamm et al S16-58
Geniteau M (abst) 407
Georgi R: *see* Aladjem et al 549
Gerbaulet C (abst) 132
German-speaking Society of Nephrology (abst) 275
Germinario C (abst) 827
Geronemus RP (abst) S16-335
Geschöll-Bauer B (abst) 277
Ghio L (abst) 421
Giacchino F (abst) 128, 131, 824, S16-341
Giachino G (abst) 131, S16-341
Giangrande A (abst) 133
Giani M (abst) 421, S16-344
Giannattasio M (abst) 131
Giannini S (abst) S16-333
Giannoni A: *see* Barsotti et al S16-278
Gibby OM (abst) 428
Gilgenkrantz JM (abst) 821
Gill WB: *see* Chodak et al 804

Gillet A (abst) 822
Gilli G (abst) S16-344
Gilli G, Mehls O, Wallstein B, Schärer K: Prediction of adult height in children with chronic renal insufficiency S15-48
Ginardi V (abst) S16-332
Ginsberg HN (abst) S16-335
Giorcelli G (abst) S16-328
Giordano C, Mazzola G, Esposito R, Longhi R, Vecchio G, Di Leo VA, Pluvio M, Cirillo C: Peritoneal ammonia, a possible inhibitor for blood amino acid loss S16-71
Giovannetti S (abst) 824, S16-346, S16-347
Giovannetti S: *see* Barsotti et al S16-278
Giovannini I (abst) S16-338, S16-340
Girard P, Brun-Pascaud M, Pocidalo J-J: Acid-base status of awake rats after cannulation of aorta and vena cava 795
Giraudo G (abst) S16-341
Girolami J-P (abst) 124
Gise HV (abst) 276, 278
Gitelman HJ: *see* Falk et al 110
Giuliani-Piccari G (abst) 127
Giuliano G (abst) 128
Glassock RJ: Nutrition, immunology, and renal disease S16-194
Glez-Sainz J (abst) 416
Glöckner WM (abst) 276
Gluckman JC (abst) 418
Gokel JM (abst) 278
Goldberg AP, Geltman EM, Hagberg JM, Gavin JR III, Delmez JA, Carney RM, Naumowicz A, Oldfield MH, Harter HR: Therapeutic benefits of exercise training for hemodialysis patients S16-303
Goldberg AP: *see* Davis et al S16-52
Goldman M: *see* Cavallo et al 632
Goldsmith DI: *see* Taki et al 602
Gomez P (abst) 134, 136
Gómez Berné J (abst) 271
Gómez Campderá F (abst) 271
Gomez Roldan C (abst) 268
Gomez-Ullate P (abst) 271
Gonella M (abst) S16-339
Goñi M (abst) 273
Gonthier R (abst) 131
Gonzales S (abst) 132
Gonzalez C (abst) 133, 270
Gonzalez MT (abst) 134
González Sainz J (abst) 272
Gonzálo A (abst) 131, 274
Gordge MP (abst) 420
Gordon EM: *see* Kraut et al 644
Gordon K: *see* Knapp et al 474
Gordon M, Venn JC, Gower PE, de Wardener HE: Experience in the computer handling of clinical data for dialysis and transplantation units 455
Gore SM: Graft survival after renal transplantation: Agenda for analysis 516
Gottschalk IS (abst) 279
Götz K-H (abst) S16-350, S16-350
Gower PE: *see* Gordon et al 455
Graben N (abst) 427
Grabensee B (abst) 284
Graefe U (abst) 279
Graf H (abst) S16-328
Grandmougin M (abst) 135
Grandvuillemin M (abst) 820
Grani T (abst) 424
Granolleras C (abst) 404
Grasselli G (abst) 125
Grasso C (abst) 827
Graves K: *see* Cavallo et al 632
Gray RW: *see* Maierhofer et al 555
Graziani G (abst) 138, 411, 425
Grebe S: *see* Wizemann et al S16-218
Grégoire I (abst) 419, 820
Gregor R (abst) 277
Grekas D (abst) S16-333
Greminger P (abst) 279
Gretz N (abst) 277, 411, S16-348, S16-348
Gretz N, Korb E, Strauch M: Low-protein diet supplemented by keto acids in chronic renal failure: A prospective controlled study S16-263
Gretz N, Manz F, Strauch M: Predictability of the progression of chronic renal failure S15-2
Gretz T (abst) S16-348
Grillo C (abst) 417
Griño JM (abst) 134, 269
Grob P (abst) 275
Grodstein G (abst) S16-350
Groll J (abst) 281
Gröne H-J (abst) 277
Grossmann I (abst) 415
Grote K (abst) 277
Groves BM: *see* Bichet et al 788
Grube S (abst) 412
Grünfeld JP (abst) 406, 820
Grüntzig A (abst) 279
Grupe WE, Harmon WE, Spinozzi NS: Protein and energy requirements in children receiving chronic hemodialysis S15-6
Gruskin AB, Rosenblum H, Baluarte HJ, Morgenstern BZ, Polinsky MS, Perlman SA: Transperitoneal solute movement in children S15-95
Grüttner R (abst) 277
Grützmacher P (abst) 417
Grützmacher P: *see* Thevenod et al 227
Grzegorzowska A (abst) S16-339
Guarena C (abst) 824
Guarner F (abst) 273
Guarnieri G, Toigo G, Situlin R, Faccini L, Coli U, Landini S, Bazzato G, Dardi F, Campanacci L: Muscle biopsy studies in chronically uremic patients: Evidence for malnutrition S16-187
Guarnieri GF (abst) S16-329
Guastoni C (abst) 135
Gubler M-C: *see* Laouari et al S16-248
Guder WG (abst) 277
Guenel J (abst) 135
Guèris J (abst) 821
Guiberteau R (abst) S16-332, S16-348
Guidi E (abst) 132
Guiducci A: *see* Barsotti et al S16-278
Guillot M (abst) S16-344
Guillot M: *see* Broyer et al S16-290
Gulyassy PF (abst) S16-339
Gulyassy PF, Bottini AT, Jarrard EA, Stanfel LA: Isolation of inhibitors of ligand-albumin-binding from uremic body fluids and normal urine S16-238
Guntupalli J: *see* Lau et al 10
Gurland HJ (abst) 278
Gusowski N: *see* Chesney et al 588

Gutierrez JR (abst) 268
Gutierrez Millet V (abst) 273
Gutman S: *see* Nieman et al S16-167
Gutsche H-U (abst) 278

Haaiman JJ (abst) 408
Haas M (abst) 408
Habersetzer R (abst) 278
Habib R (abst) 132, S16-349
Häfner S: *see* Oertel et al S15-34
Hagberg JM: *see* Goldberg et al S16-303
Hagege J (abst) 404
Hagge W (abst) 277
Halie LM (abst) 408
Hall DA (abst) 416
Halperin ML, Jungas RL: Metabolic production and renal disposal of hydrogen ions 709
Halvorsen S: *see* Wideröe et al S16-208
Hamilton DNH (abst) 414
Hammer C (abst) 278
Hammerschmidt DE: *see* Ivanovich et al 758
Hammond WE: *see* Stead et al 446
Hamstra AJ: *see* Chesney et al S15-63
Hanning R (abst) S16-345
Hanover B (abst) 427
Hansen AP (abst) S16-336
Hansen HE (abst) 427, S16-336
Harant P (abst) S16-343
Harder F (abst) 280
Hardin JM (abst) 821
Hardonk MJ (abst) 410
Hardy BE: *see* Arbus et al S15-111
Hardy MA: *see* Fernandez-Repollet et al 719
Harmon WE: *see* Grupe et al S15-6
Harrington TM (abst) 425
Harrison A (abst) S16-349
Harrison P (abst) 423
Harter HR: *see* Davis et al S16-52
Harter HR: *see* Goldberg et al S16-303
Hasling C (abst) 427
Haycock G: *see* Jones et al 95
Haycock GB: *see* Mak et al S15-22, S16-128
Hayry P (abst) 418
Hayslett JP: *see* Martin et al 386
Healy JC (abst) 131
Heaton A (abst) S16-329, S16-331
Heidbreder E: *see* Heidland et al S16-27
Heidland A (abst) S16-330, S16-331, S16-351
Heidland A, Hörl WH, Heller N, Heine H, Neumann S, Heidbreder E: Proteolytic enzymes and catabolism: Enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis S16-27
Heidland A: *see* Hörl et al S16-37
Heilenbrecht D: *see* Schneider et al S15-89
Heine H: *see* Heidland et al S16-27
Heller N: *see* Heidland et al S16-27
Helmchen U (abst) 277
Henderson LW: *see* Chenoweth et al 764
Henderson LW: *see* Chenoweth et al 770
Hennemann H (abst) 277
Henrich WL, Woodard TD, Meyer BD, Chappell TR, Rubin LJ: High sodium bicarbonate and acetate hemodialysis: Double-blind crossover comparison of hemodynamic and ventilatory effects 240
Henry D (abst) S16-350
Henry RR (abst) S16-342
Heremans C (abst) S16-329
Herlin P (abst) 406
Hernando L (abst) 424
Heron JF (abst) 406
Herrera J (abst) 126, 269, 416
Herrera Pombo JL (abst) 272
Herrero E (abst) 136
Herrmann T (abst) 131
Herve JP (abst) 404, 405
Herzog U (abst) 275
Hessburg T: *see* Mahajan et al S16-310
Hewitt IK (abst) S16-345
Hildebrandt C (abst) 281
Hill K: *see* Sakhaee et al 348
Hillebrand G (abst) 278
Hirasawa Y (abst) 412
Hirata K: *see* Kikuchi et al S16-254
Hjøllund E (abst) 427
Hobby P (abst) 414
Hoedemaeker PJ (abst) 410
Hoenich N (abst) 420
Hoffler D (abst) 416
Hofmann J (abst) 275
Hollander J: *see* Kamm et al S16-58
Holliday MA: *see* Arnold et al 205
Holliday MA: *see* Schärer et al S15-1
Hollingsworth P (abst) 423
Hood S (abst) S16-347
Hood VL (abst) S16-339
Hoorntje SJ (abst) 414
Hörl WH (abst) S16-330, S16-331, S16-351
Hörl WH: *see* Heidland et al S16-27
Hörl WH: *see* Riegel et al S16-48
Hörl WH, Stepinski J, Schäfer RM, Heidland A: Role of proteases in hypercatabolic patients with renal failure S16-37
Horn H (abst) 276
Horst R: *see* Kraut et al 644
Hosokawa S (abst) S16-351
Hubinot C (abst) S16-335
Hulter HN: *see* Kurtz et al 670
Hulthén L (abst) 280
Hultman E: *see* Bergström et al S16-153
Humphreys MH (abst) S16-342
Hund E: *see* Rauh et al S15-27
Hunt JS (abst) 132
Huot D: *see* Kleinknecht et al S15-40
Huriet C (abst) 405, 821
Hutin MF (abst) 405

Iaccarino V (abst) 427
Idatte JM (abst) 820
Iengo A (abst) 427, 825
Ikram H, Lynn KL, Bailey RR, Little PJ: Cardiovascular changes in chronic hemodialysis patients 371
Imbasciati E (abst) 825
Imbert-Teboul M (abst) 134
Imperiali P (abst) 424
International Congress on Nutrition and Metabolism in Renal Disease S16
International Workshop on Chronic Renal Failure in Children S15
Iskandar SS: *see* Jennette et al 377
Italian Society of Nephrology (abst) 124, 824
Itoh S: *see* Omata et al 714
Ivanovich P, Chenoweth DE, Schmidt R, Klinkmann H,

Boxer LA, Jacob HS, Hammerschmidt DE: Symptoms and activation of granulocytes and complement with two dialysis membranes 758
Ivory K (abst) 416
Izzo JL Jr, Sterns RH: Abnormal norepinephrine release in uremia S16-221

Jabary NS (abst) 269
Jacob HS: *see* Ivanovich et al 758
Jacobs C (abst) 136, 411
Jacobsen SC (abst) 427
Jahn HA, Schohn DC, Koehl C, Schmitt RL: Increased plasma ammonia may inhibit cellular release of branched-chain amino acids in systemic portal encephalopathy S16-67
Jakubowski HD (abst) 427
Jamison RL: A patient with polyuria and hyponatremia . 256
Jansen M (abst) 409
Jarrard EA: *see* Gulyassy et al S16-338
Jean G (abst) S16-344, S16-349
Jean G: *see* Broyer et al S15-106, S16-290
Jennette JC, Iskandar SS, Dalldorf FG: Pathologic differentiation between lupus and nonlupus membranous glomerulopathy 377
Jeppsson JO (abst) 420
Jervell J (abst) 418
Jilderda JF (abst) 422
Jilg W (abst) 413
Jimenez del Cerro L (abst) 268
Jodal U (abst) S16-345
Jofré R (abst) 270, 418
Johnson M (abst) S16-337
Johnston DG (abst) S16-329
Jonas D (abst) 413
Jones M (abst) S16-349
Jones M (abst) S16-351
Jones MR: *see* Salusky et al S16-43
Jones R, Dalton N, Turner C, Start K, Haycock G, Chantler C: Oral essential aminoacid and ketoacid supplements in children with chronic renal failure ... 95
Jones WJ: *see* Martin et al 386
Jørgensen F (abst) 426
Jorgetti V (abst) 417
Jouquan J (abst) 405
Jover JA (abst) 273
Juge J (abst) 131
Junćo E (abst) 270
Jung A: *see* Taylor et al 37
Jungas RL: *see* Halperin et al 709
Jungers P (abst) 131, 138, 820, S16-348
Junor BJR (abst) 126, 269, 414
Juret P (abst) 406
Jus A (abst) 825

Kablitz D (abst) 427
Kahn T: *see* Safirstein et al 526
Kakuhara T (abst) S16-336
Kalhan SC: *see* Ricanati et al S16-121
Kamm DE (abst) S16-329
Kamm DE, Gennin M, Kuchmy B, Hollander J: Diuretic-induced azotemia: Unmasking the role of increased peripheral catabolism through evisceration-hepatectomy S16-58
Kanfer A (abst) 415
Kaptein EM, Feinstein EI, Nicoloff JT, Massry SG: Alterations of serum reverse triiodothyronine and thyroxine kinetics in chronic renal failure: Role of nutritional status, chronic illness, uremia, and hemodialysis S16-180
Karl IE: *see* Davis et al S16-52
Karlström B (abst) 419
Kaschube I (abst) S16-350, S16-350
Kassirer JP: Is renal biopsy necessary for optimal management of the idiopathic nephrotic syndrome? 561
Kazmierczak A (abst) 404
Keller F (abst) 281
Kellner C (abst) 280
Kelly RA, Wilcox CS, Mitch WE, Meyer TW, Souney PF, Rayment CM, Friedman PA, Swartz SL: Response of the kidney to furosemide. II. Effect of captopril on sodium balance 233
Kem DC: *see* Perez et al 656
Kenouch S (abst) 129
Kerr DNS (abst) S16-329, S16-331, S16-333
Keshaviah PR: *see* Kimura et al 542
Kessler M (abst) 125, 405, 821
Keusch G (abst) 275
Kheder A (abst) 125
Kidawa Z (abst) 415
Kihlber R (abst) S16-334
Kikuchi H, Matsushita T, Hirata K: Improved dietary treatment with low protein and phosphorus restriction in uremic rats S16-254
Kimura G, Van Stone JC, Bauer JH, Keshaviah PR: A simulation study on transcellular fluid shifts induced by hemodialysis 542
Kindler M (abst) 420
Kingswood C (abst) 423
Kiowski W (abst) 280
Kirchner KA (abst) 409
Klahr S, Buerkert J, Purkerson ML: Role of dietary factors in the progression of chronic renal disease 579
Klare B (abst) 277
Klatzmann D (abst) 418
Kleinberger G (abst) S16-328
Kleinberger G: *see* Druml et al S16-139
Kleinknecht C (abst) S16-349, S16-349
Kleinknecht C, Broyer M, Huot D, Marti-Henneberg C, Dartois A-M: Growth and development of nondialyzed children with chronic renal failure S15-40
Kleinknecht C: *see* Broyer et al S16-290
Kleinknecht C: *see* Laouari et al S16-248
Kleinknecht D (abst) 415
Klingebiel T (abst) 278
Klingmüller D (abst) 279
Klinkmann H: *see* Ivanovich et al 758
Klooker P: *see* Kreusser et al S15-83
Klotman PE, Yarger WE: Reduction of renal blood flow and proximal bicarbonate reabsorption in rats by gentamicin 638
Knapp MS: Computing, mathematics and the nephrologist 433
Knapp MS, Smith AFM, Trimble IM, Pownall R, Gordon K: Mathematical and statistical aids to evaluate data from renal patients 474
Knebel L (abst) 283, 419
Kneissler U (abst) 277
Knoll O (abst) 279
Knox FG (abst) 272
Koch KM (abst) 417
Koch K-M: *see* Thevenod et al 227
Kochen W: *see* Schneider et al S15-89

Koderisch J (abst) 275
Koehl C: *see* Jahn et al S16-67
Koene RAP (abst) 408
Koene RAP: *see* Assmann et al 303
Kohan R: *see* Brautbar et al 53
Kohaut EC (abst) S16-344
Kohira S (abst) S16-351
Kohler H (abst) 416
Koide H (abst) S16-336
Kokot F (abst) 426
Kolff WJ (abst) 427
Koller C (abst) 278
Komninos Z (abst) S16-335
Koomans HA (abst) 415
Kopczyński Z (abst) S16-339
Kopple J (abst) S16-350, S16-350
Kopple JD (abst) S16-345
Kopple JD, Blumenkrantz MJ: Nutritional requirements for patients undergoing continuous ambulatory peritoneal dialysis S16-295
Kopple JD, Massry SG, Olmer M: Introduction S16-1
Kopple JD: *see* Feinstein et al S16-319
Kopple JD: *see* Salusky et al S15-101
Kopple JD: *see* Salusky et al S16-43
Kopsa H (abst) 419, S16-346
Korb E (abst) S16-348
Korb E: *see* Gretz et al S16-263
Kosaka T: *see* Coleman et al 681
Koshikawa S (abst) 412
Kosmidou I (abst) 415
Köthe U: *see* Leschke et al S16-143
Kouki F (abst) 125
Kramer HJ (abst) 279
Kramer P (abst) 411
Kramer W (abst) 420
Kratz W: *see* Sprenger et al 143
Krause PH (abst) 281, S16-334
Kraut JA, Gordon EM, Ransom JC, Horst R, Slatopolsky E, Coburn JW, Kurokawa K: Effect of chronic metabolic acidosis on vitamin D metabolism in humans 644
Kreusser W (abst) 275
Kreusser W, Mann J, Rambausek M, Klooker P, Mehls O, Ritz E: Cardiac function in experimental uremia S15-83
Kronevi T (abst) S16-334
Kubota M (abst) S16-336
Kuchmy B (abst) S16-329
Kuchmy B: *see* Kamm et al S16-58
Kuhlmann U (abst) 279
Kühn K (abst) 279, 280
Kuiper KJ (abst) 423
Kulbe KD (abst) 417
Kulczycki A Jr: *see* Michelson et al 246
Kurokawa K, Aponte GW, Fujibayashi S, Yamada T: Somatostatin-like immunoreactivity in the glomerulus of rat kidney 754
Kurokawa K: *see* Kraut et al 644
Kurtz I, Maher T, Hulter HN, Schambelan M, Sebastian A: Effect of diet on plasma acid-base composition in normal humans 670
Kurtzman NA: Acquired distal renal tubular açidosis 807

Labeeuw M (abst) 132
Lacour B: *see* Drüeke et al S16-134
Ladefoged J (abst) 411
Laederich J (abst) 415
Lafforgue B (abst) 820
Laggner A (abst) S16-328
Laggner A: *see* Druml et al S16-139
La Greca G (abst) 129
Lagrue G (abst) 821, 821
Laird NM (abst) S16-342
Lamanna RW: *see* Falk et al 110
Lambert P-H: *see* Cavallo 632
Lameire N (abst) 410
Lamm LU: *see* Wing et al 507
Lamperi S (abst) 132, S16-349
Lampreabe I (abst) 271
Land W (abst) 278
Landais P (abst) 820
Landini S: *see* Guarnieri et al S16-187
Lang F (abst) 281
Lange WPJ: *see* Assmann et al 303
Langer KH (abst) 279
Langford HG (abst) 409
Langhoff E (abst) 411
Langlois JP (abst) 412
Laouari D (abst) S16-349, S16-349
Laouari D, Kleinknecht C, Gubler M-C, Broyer M: Adverse effects of proteins on remnant kidney: Dissociation from that of other nutrients S16-248
Laplanche A (abst) 138
Larsson L: *see* Ståhl et al 323
Larsson O (abst) S16-346
Latif AB (abst) 424
Latour PA: *see* Acchiardo et al S16-199
Lau K, Guntupalli J, Eby B: Effects of somatostatin on phosphate transport: Evidence for the role of basal insulin 10
Laurent B (abst) 131
Laurent J (abst) 821, 821
Laurent P (abst) 131
Lauzurica R (abst) 126
La Vecchia N (abst) 426
Lavecchia N (abst) 826
Lavergne A (abst) 417
Laville M (abst) S16-351
Lawrence WE: *see* Meyer et al S16-243
Lazzari E (abst) S16-336
Lecea A (abst) 271
Lecharpentier Y (abst) 417
Lechler R (abst) 424
Le Cloirec D (abst) 407
LeFurgey A: *see* Fernandez-Repollet et al 719
Legrain M (abst) 136, 412, S16-336
Lele PS, Dunn SR, Simenhoff ML, Fiddler W, Pensabene JW: Evidence for generation of the precarcinogen nitrosodimethylamine in the small intestine in chronic renal failure S16-229
Lemaitre V (abst) 415
Lemann J Jr: *see* Maierhofer et al 555
Lemau D (abst) 131
Lenz K (abst) S16-328
Lenz K: *see* Druml et al S16-139
Le Pogamp P (abst) 407
Leroy D (abst) 129, 405
Leroy JP (abst) 404
Lesavre P (abst) 135
Leschke M, Rumpf KW, Eisenhauer T, Fuchs C, Becker K, Köthe U, Scheler F: Quantitative assessment of carnitine loss during hemodialysis and hemofiltra-

tion S16-143
Le Talaer JY (abst) 406
Leupold D (abst) 277
Levine DZ (abst) 278
Levine S (abst) 282, S16-342
Levy M (abst) 132
Lewis AE: *see* Sprenger et al 143
Lewis K: *see* Sprenger et al S16-315
Liaño F (abst) 269
Lichey J (abst) 281
Lichtwald K: *see* Oertel et al S15-34
Liebaers I (abst) 130
Lijnen P (abst) 409
Limido A (abst) 133
Linari F (abst) 134, 420
Linas SL: *see* Paller et al 342
Lindberg T (abst) S16-340
Lindergård B (abst) 425
Lindholm B (abst) S16-330
Lindsay RM (abst) 424
Line D (abst) 821
Linton AL (abst) 424
Lison AE (abst) 279
Lissner D: *see* Chan et al 336
Lithell H (abst) 419
Little PJ: *see* Ikram et al 371
Ljunghall S (abst) 419
Llach F: *see* Andress et al 364
Llamazares C (abst) 272
Lobeck H (abst) 281, S16-334
Locatelli F (abst) 133, 827
Lockwood CM (abst) 404, 406
Löhr H (abst) 277
Longhi R: *see* Giordano et al S16-71
Lopez N (abst) 133
López-Gómez JM (abst) 271
López-Lillo J (abst) 274
López-Novoa JM (abst) 271
López-Pedret J (abst) 272, 427
Lorenz P (abst) 126
Lorenzano E (abst) 138
Lorenzi S (abst) 129
Lörtscher A (abst) 280
Loschiavo C (abst) 828
Loschiavo C: *see* Maschio et al S16-273
Lotan D: *see* Aladjem et al 549
Loute G (abst) S16-329
Lucas PA (abst) 421
Lucas PA, Brown RC, Woodhead JS, Coles GA: Ratio of parathyroid hormone to 1,25 dihydroxycholecalciferol in early renal failure S16-171
Lucchini S (abst) 125
Luciani G (abst) S16-340
Luciano L (abst) 279
Luger A (abst) S16-328
Lukens CW: *see* Shen et al S16-147
Lund EW (abst) S16-341
Luño J (abst) 133, 270
Lupetti S: *see* Barsotti et al S16-278
Lupi P (abst) 129
Lupo A (abst) 828
Lupo A: *see* Maschio et al S16-273
Luque A (abst) 271
Lüscher T (abst) 279
Lusky A: *see* Aladjem et al 549
Lusvarghi E (abst) 133
Lutman M: *see* Deferrari et al S16-115
Lutman M: *see* Tizianello et al S16-17
Lynn KL: *see* Ikram et al 371

Macaluso A (abst) S16-347, 824
Maccaferri M (abst) 127
Maccarone M (abst) 129
Maccheroni M (abst) 127
Macias Nuñez JF (abst) 272
MacKenzie C (abst) 423
MacLeod AM (abst) 413
Maeda K (abst) 412
Maggiore Q (abst) 825
Magnusson MO, Rybka SJ, Stowe NT, Novick AC, Straffon RA: Enhancement of recovery in postischemic acute renal failure with captopril S16-324
Mahajan S: *see* Briggs et al S16-23
Mahajan SK, Abraham J, Hessburg T, Prasad AS, Migdal SD, Abu-Hamdan DK, Briggs WA, McDonald FD: Zinc metabolism and taste acuity in renal transplant recipients S16-310
Mahan JD Jr, Mauer SM, Nevins TE: The Hickman catheter: A new hemodialysis access device for infants and small children 694
Maher T: *see* Kurtz et al 670
Mahieu P (abst) 132, 415
Mahoney CA, Arieff AI: Central and peripheral nervous system effects of chronic renal failure 170
Maierhofer WJ, Gray RW, Cheung HS, Lemann J Jr: Bone resorption stimulated by elevated serum 1,25-$(OH)_2$ vitamin D concentrations in healthy men 555
Maiorca R (abst) 411
Mak RHK, Haycock GB, Chantler C: Glucose intolerance in children with chronic renal failure S15-22
Mak RHK, Turner C, Haycock BG, Chantler C: Secondary hyperparathyroidism and glucose intolerance in children with uremia S16-128
Makdassi R (abst) 821
Malavolta N (abst) 127
Malberti F (abst) 138, 425
Malbrancq JM (abst) 820
Malfi B (abst) 137
Mallick NP (abst) S16-349
Malmusi G (abst) 133
Malvasi L (abst) S16-333
Mampaso F (abst) 131, 274
Man NK (abst) S16-348
Manari A (abst) S16-341
Mandelli F (abst) 412
Mangiarotti G (abst) 133, 135
Mann J (abst) 422
Mann J: *see* Kreusser et al S15-83
Mann JFE (abst) 426
Manolagas SC: *see* Cheung et al 104
Manos J (abst) S16-349
Mańsson W (abst) 425
Manz F (abst) 277
Manz F: *see* Gretz et al S15-2
Marai P (abst) 827
Marangella M (abst) 134, 420
Marcén R (abst) 268, 272, 274, 416
Marchetti J (abst) 134
Marchetti J: *see* Misumi et al 58
Mariani E (abst) 825
Mariani G (abst) 412, S16-339, S16-346
Marin A (abst) 274

Marinangeli G (abst) S16-336
Marín Iranzo R (abst) 268
Marks D (abst) S16-344
Marni A (abst) 425
Marre M: *see* Misumi et al 58
Marshall E: *see* Miller et al 313
Marti-Henneberg C: *see* Kleinknecht et al S15-40
Martin E (abst) 269
Martin RS, Jones WJ, Hayslett JP: Animal model to study the effect of adrenal hormones on epithelial function 386
Martin Comin J (abst) 269
Martina G (abst) 827
Martinez ME (abst) 134, 136, 270
Martinez-Vea A (abst) 272, 427
Martín-Oar JE (abst) 271
Maschio G (abst) 828, S16-333
Maschio G, Oldrizzi L, Tessitore N, D'Angelo A, Valvo E, Lupo A, Loschiavo C, Fabris A, Gammaro L, Rugiu C, Panzetta G: Early dietary protein and phosphorus restriction is effective in delaying progession of chronic renal failure S16-273
Mason DW (abst) 406
Mason J (abst) 280, 283
Mason J, Welsch J, Takabatake T: Disparity between surface and deep nephron function early after renal ischemia 27
Mason RJ (abst) 413
Mason RS: *see* Chan et al 336
Massai G: *see* Amadori et al 775
Massimetti C (abst) 128
Massry SG: Pathogenesis of the anemia of uremia: Role of secondary hyperparathyroidism S16-204
Massry SG: *see* Brautbar et al 53
Massry SG: *see* Feinstein et al S16-319
Massry SG: *see* Kaptein et al S16-180
Massry SG: *see* Kopple et al S16-1
Mastrangelo F (abst) 826
Mastrogiacomo I (abst) 129
Mateos F (abst) 134
Matesanz R (abst) 131, 268, 272, 273, 274, 416
Matina D: *see* O'Regan et al S15-77
Matsushita T: *see* Kikuchi et al S16-254
Matter B (abst) S16-339
Matter B: *see* Metcoff et al S16-87
Mattern WD: *see* Falk et al 110
Matthys E (abst) 410
Matuchansky C (abst) 406
Matzke GR (abst) S16-340
Mauer SM: *see* Mahan et al 694
Maunsbach AB, Boulpaep EL: Paracellular shunt ultrastructure and changes in fluid transport in Necturus proximal tubule 610
Mauri JM (abst) 134
Maxwell JG (abst) 427
Maxwell M (abst) S16-337
Mazzaferro S (abst) 128
Mazzola G: *see* Giordano et al S16-71
Mazzuca N (abst) S16-346
McClelland DBL (abst) 417
McDaniel HG: *see* Dumbauld et al 222
McDonald FD: *see* Briggs et al S16-93
McDonald FD: *see* Mahajan et al S16-310
McGeown M (abst) S16-330
McGurk JG (abst) S16-331
McKenna BA (abst) 424
McKenna F (abst) 426
McMaster P (abst) 428
McWhinnie DL (abst) 414
Mebel M (abst) 415
Mehls O (abst) S16-344
Mehls O, Ritz E: Skeletal growth in experimental uremia S15-53
Mehls O: *see* Gilli et al S15-48
Mehls O: *see* Kreusser et al S15-83
Mehls O: *see* Rauh et al S15-27
Mehls O: *see* Scharer et al S15-1
Mehta BR, Fischer D, Ahmad M, Dubose TD Jr: Effects of acetate and bicarbonate hemodialysis on cardiac function in chronic dialysis patients 782
Meisinger E (abst) S16-348, S16-350
Melcion C (abst) 824
Meloni C (abst) 412
Menard J: *see* Misumi et al 58
Mendes V (abst) 417
Mertani E (abst) 412
Méry JP (abst) 129, 415, 821
Messa F (abst) 128
Messina M (abst) 128, 137
Metaxas P (abst) 415
Metcoff J (abst) S16-339
Metcoff J, Dutta S, Burns G, Pederson J, Matter B, Rennert O: Effects of amino acid infusions on cell metabolism in hemodialyzed patients with uremia S16-87
Metivier F (abst) 418
Meyer BD: *see* Henrich et al 240
Meyer E (abst) 279
Meyer P (abst) 821
Meyer TW, Lawrence WE, Brenner BM: Dietary protein and the progression of renal disease S16-243
Meyer TW: *see* Kelly et al 233
Meyrier A (abst) 135, 822
Michael AF, Yang J-Y, Falk RJ, Bennington MJ, Scheinman JI, Vernier RL, Fish AJ: Monoclonal antibodies to human renal basement membranes: Heterogenic and ontogenic changes 74
Michael J (abst) 428
Michalk D (abst) 277
Michalk DV, Essich H-J, Böhles H-J, Schärer K: Taurine metabolism in experimental renal failure S15-16
Michelson EA, Cohen L, Dankner RE, Kulczycki A Jr: Eosinophilia and pulmonary dysfunction during Cuprophan hemodialysis 246
Michoudet C (abst) 124
Middendorf F (abst) S16-343
Migdal SD: *see* Mahajan et al S16-310
Migone L (abst) S16-338
Miguel JL (abst) 134, 136
Mihatsch MJ (abst) 280
Mikami H (abst) S16-338
Mikami H: *see* Ando et al S16-23
Milan G (abst) S16-334
Miller DG (abst) S16-342
Miller P: *see* Safirstein et al 526
Miller TE, Marshall E, Nelson J: Infection-induced immunosuppression in pyelonephritis: Characteristics of the suppressor cell(s) 313
Miller TE: *see* Clarke et al 66
Mimran A (abst) S16-335
Minar E (abst) 419
Minetti L (abst) 138, 417, 421, 425
Mion C (abst) S16-335

Mion H (abst) ... 404
Miossec P (abst) ... 405
Mirete D (abst) ... 274
Misumi J, Alhenc-Gelas F, Marre M, Marchetti J, Corvol P, Menard J: Regulation of kallikrein and renin release by the isolated perfused rat kidney ... 58
Mitas JA II: *see* Cheung et al ... 104
Mitch WE, Clark AS: Muscle protein turnover in uremia ... S16-2
Mitch WE: *see* Kelly et al ... 233
Mitch WE: *see* Walser et al ... S16-285
Mizoguchi M (abst) ... S16-336
Mockel J (abst) ... S16-335
Modan M: *see* Aladjem et al ... 549
Moisan A (abst) ... 407
Molea N (abst) ... S16-346
Moller GA (abst) ... 280
Molzahn M (abst) ... 281, S16-334
Monga G (abst) ... 128
Monnens L (abst) ... 409
Monnier N (abst) ... 421
Montagna G (abst) ... S16-341
Montagnac R (abst) ... 822
Montanari A (abst) ... 826
Montenegro J (abst) ... 271
Montero A (abst) ... 134, 136
Montinaro AM (abst) ... 826
Montoliu J (abst) ... 272, 427
Monzón A (abst) ... 273
Moore L (abst) ... S16-345, S16-346
Moore LW: *see* Acchiardo et al ... S16-199
Moran J (abst) ... 271
Morbiato F (abst) ... S16-333
Morelli E (abst) ... S16-346
Morelli E: *see* Barsotti et al ... S16-278
Morel-Maroger L (abst) ... 135, 406, 415
Morgan DB, Will EJ: Selection, presentation, and interpretation of biochemical data in renal failure ... 438
Morganti A (abst) ... 422
Morgenstern BZ: *see* Gruskin et al ... S15-95
Moriero E (abst) ... S16-349
Morin RJ (abst) ... S16-332
Morinière P (abst) ... 822
Morita T, Churg J: Mesangiolysis ... 1
Morley P (abst) ... 414
Morris PJ (abst) ... 269
Mosconi G: *see* Scolari et al ... S16-77
Mosely CA Jr: *see* Cheung et al ... 104
Moskovtchenko JF (abst) ... 124, S16-351
Mougeno B (abst) ... 135
Mountokalakis T (abst) ... S16-335
Mourad G (abst) ... S16-335
Moutel MG (abst) ... 135
Moynot A (abst) ... 820
Muirhead N (abst) ... S16-331
Muller FB (abst) ... 280
Müller-Wiefel DE, Schärer K: Serum erythropoietin levels in children with chronic renal failure ... S15-70
Münchmeyer M (abst) ... S16-330
Münchmeyer M: *see* Riegel et al ... S16-48
Muñiz R (abst) ... 271
Münzel R (abst) ... 279
Mussat T (abst) ... 413
Myking OL (abst) ... 421

Nakagawa S (abst) ... 412
Nanni-Costa A (abst) ... 414
Napoli M (abst) ... 826
Naret C (abst) ... S16-347
Narita M: *see* Aoyagi et al ... S16-224
Naso A (abst) ... S16-348
Natori Y: *see* Ando et al ... S16-23
Naughton RJ: *see* Davis et al ... 740
Naumowicz A: *see* Goldberg et al ... S16-303
Navarro JL (abst) ... 273
Navas J (abst) ... 273
Navis GJ (abst) ... 427
Neild GH (abst) ... 416
Neilson EG, Zakheim B: T cell regulation, anti-idiotypic immunity, and the nephritogenic immune response . 289
Nelson J: *see* Miller et al ... 313
Nelson P (abst) ... S16-345
Nemeth J (abst) ... 417
Netter P (abst) ... 405
Neugarten J, Aynedjian HS, Bank N: Role of tubular obstruction in acute renal failure due to gentamicin. 330
Neugarten J, Feiner HD, Schacht RG, Baldwin DS: Amelioration of experimental glomerulonephritis by dietary protein restriction ... 595
Neumann KH (abst) ... 280
Neumann S: *see* Heidland et al ... S16-27
Neumayer H-H (abst) ... 281
Neuweg M (abst) ... 276
Nevins TE: *see* Mahan et al ... 694
Niaudet P (abst) ... 129
Niaudet P: *see* Broyer et al ... S15-106, S16-290
Nicar M: *see* Sakhaee et al ... 348
Nicholls AJ (abst) ... 417
Nicoloff JT: *see* Kaptein et al ... S16-180
Nieman LK, Davis FB, Davis PJ, Cunningham EE, Gutman S, Blas SD, Schoenl M: Effect of endstage renal disease on responsiveness to calmodulin and thyroid hormone of calcium-ATPase in human red blood cells ... S16-167
Nilsen T (abst) ... S16-341
Nista P (abst) ... 827
Noble B: *see* Van Liew et al ... 160
Noël C (abst) ... 138
Nogues R (abst) ... 269
Norbeck HE (abst) ... S16-330
Novarini A (abst) ... 826
Novick A (abst) ... S16-331
Novick AC: *see* Magnusson et al ... S16-324
Ntra CS (abst) ... 268

Oberholzer M (abst) ... 280
Oberleithner H (abst) ... 281
O'Brien TJ: *see* Rao et al ... 210
Ocharan J (abst) ... 271
Ockhuizen T (abst) ... 408
Odenman I (abst) ... S16-345
Oei HY (abst) ... 415
Oertel PJ, Lichtwald K, Häfner S, Rauh W, Schonberg D, Schärer K: Hypothalamo-pituitary-gonadal axis in children with chronic renal failure ... S15-34
Offermann G (abst) ... 281, S16-334
Ohba S: *see* Aoyagi et al ... S16-224
Ohno J (abst) ... S16-336
Ohta K: *see* Saito et al ... S16-234
Okada A (abst) ... S16-338
Okada A: *see* Ando et al ... S16-23
Oken DE: Theoretical analysis of pathogenetic mecha-

nisms in experimental acute renal failure 16
Oldfield MH: *see* Goldberg et al S16-303
Oldrizzi L (abst) 828
Oldrizzi L: *see* Maschio et al S16-273
Olivas E (abst) 133, 418
Olivieri W (abst) 280, 822
Olmer M (abst) 820
Olmer M, Berland Y, Argemi B: Absence of secondary hyperparathyroidism in most patients with renal hypercalciuria S16-175
Olmer M: *see* Kopple et al S16-1
Olsen MJ (abst) 272
Omata K, Carretero OA, Itoh S, Scicli AG: Active and inactive kallikrein in rabbit connecting tubules and urine during low and normal sodium intake 714
Orda S: *see* Aladjem et al 549
O'Regan S, Matina D, Ducharme G, Davignon A: Echocardiographic assessment of cardiac function in children with chronic renal failure S15-77
Orfila J (abst) 130
Orita Y (abst) S16-338
Orita Y: *see* Ando et al S16-23
Orkisz S (abst) 415
Ormrod DJ: *see* Clarke et al 66
Orofino L (abst) 131, 269
Orskov H (abst) S16-336
Orsoni G (abst) S16-331, S16-336
Ortalda V (abst) 828
Orte L (abst) 273, 274
Ortega F (abst) 268
Ortega Suárez F (abst) 130
Orti F (abst) 270
Ortuño J (abst) 131, 268, 272, 273, 274, 416
Oster JR: *see* Perez et al 656
Ota K (abst) 412
Ott F (abst) 277
Oules R (abst) 404

Pabico RC (abst) 424
Pabst R, Sterzel RB: Cell renewal of glomerular cell types in normal rats. An autoradiographic analysis . 626
Pacitti A (abst) 133, 135
Paillard F (abst) 822
Paineau J (abst) 135
Pak CYC: *see* Sakhaee et al 348
Palazzi P (abst) 136
Paleologo G (abst) 127
Paller MS, Linas SL: Role of vasopressin in support of blood pressure in potassium deficient rats 342
Palmarini D (abst) 127
Palmiotti D (abst) 128
Panarello G (abst) S16-334
Panicucci F (abst) S16-346
Panizo A (abst) 130
Pansiot S (abst) 412
Panzetta G (abst) 828
Panzetta G: *see* Maschio et al S16-273
Papa A (abst) 426, 826
Papadimitriou M (abst) 415
Papadoyannakis N (abst) S16-330
Papagalanis N (abst) S16-330
Paravicini M (abst) 283
Pardo A (abst) 273
Parker NC: *see* Falk et al 110
Parkinson J (abst) S16-333
Parmentier M (abst) S16-329
Parmentier M: *see* Chan et al 336
Parsons V (abst) 420
Pasquali S (abst) 824
Pasquali S: *see* Zucchelli et al 649
Passaleva A: *see* Amadori et al 775
Passerone G: *see* Tizianello et al S16-17
Pastor JM (abst) 272
Pastore A (abst) 826
Patel H (abst) S16-335, S16-340
Pati C (abst) 129
Patiño R (abst) 273
Patte D (abst) 406
Payen J (abst) 406
Pechinot A (abst) 404
Pecoraro C (abst) 423
Pederson J (abst) S16-339
Pederson J: *see* Metcoff et al S16-87
Pedrini L (abst) 133, 827
Peer P (abst) 409
Pellet H (abst) 135
Pellet M (abst) 124
Pelleya R: *see* Perez et al 656
Pelosi G (abst) S16-351
Peloso GC (abst) S16-349
Pensabene JW: *see* Lele et al S16-229
Pentoriero G (abst) 138
Peral V (abst) 126, 416
Perego A (abst) 135
Perez GO, Pelleya R, Oster JR, Kem DC, Vaamonde CA: Blunted kaliuresis after an acute potassium load in patients with chronic renal failure 656
Perez Diaz V (abst) 269
Perez-Fontan M (abst) 270
Perez-Garcia R (abst) 418
Pérez Lorente F (abst) 268
Perin N (abst) S16-348
Perlman SA: *see* Gruskin et al S15-95
Pernollet MG (abst) 821
Persson AEG: *see* Ståhl et al 323
Pertosa G (abst) 827
Peters DK (abst) 404
Petersen VP (abst) 427
Peterson LN (abst) 278
Pfitzer P (abst) 284
Phelps M: *see* Chesney et al S15-63
Picca M (abst) 421
Picciotto G (abst) 423, 827
Piccoli G (abst) 128, 131, 423, 825, 827, S16-341
Piera L (abst) 134
Piercy E (abst) S16-342
Pierides AM (abst) 425
Pierre D (abst) 406
Pilone N (abst) 127
Pingitore R (abst) S16-347
Piron M (abst) 420
Pirotsky E (abst) 821, 824
Pirson Y (abst) 406
Pistor K (abst) 277
Pittiruti M (abst) S16-340
Plais Y (abst) 404
Plaza JJ (abst) 268
Pleskof L (abst) 422
Pluvio M: *see* Giordano et al S16-71
Pocidalo J-J: *see* Girard et al 795
Poignet JL (abst) 412, S16-336
Pola P (abst) S16-327

Polinsky MS: *see* Gruskin et al S15-95
Pollak VE: Computerization of the medical record: Use in care of patients with endstage renal disease 464
Pommer W (abst) 281, S16-334
Ponsi MC (abst) S16-343
Ponti R (abst) 133, 827
Ponticelli C (abst) 411, 425
Pontiroli AE (abst) 428
Pontoriero G (abst) 425
Portalksa E: *see* Sadowski et al 800
Porush JG (abst) S16-333
Posborg V (abst) S16-336
Posen S: *see* Chan et al 336
Potempa J (abst) 283
Pouliadis G (abst) 279
Poveda R (abst) 134
Power DA (abst) 413
Pownall R: *see* Knapp et al 474
Pozet N (abst) 132, S16-351
Pozza G (abst) 428
Pozzi C (abst) 827
Praddaude F (abst) 124
Prager R (abst) S16-328
Prandini R (abst) S16-331
Prandini R: *see* Scolari et al S16-77
Prasad AS: *see* Mahajan et al S16-310
Preudhomme Y (abst) 130
Prieto C (abst) 273
Princi P (abst) 125
Proietti R (abst) S16-351
Proto G (abst) 427, 825
Proud G (abst) 413
Pruna A (abst) 130, 419, 820, 822
Psimenos G (abst) S16-335
Puppis E (abst) 130
Purkerson ML: *see* Klahr et al 579
Purroy A (abst) 130, 273
Pürschel S (abst) 277

Quaia P (abst) S16-338
Quarello F (abst) 131, S16-341
Quaretti P (abst) S16-341
Quereda C (abst) 268, 269, 272, 416
Quiñones L (abst) 268
Quintanilla AP (abst) S16-330

Raab R (abst) 413
Rademark C (abst) 425
Radl I (abst) 408
Radtke HW (abst) 417
Radtke HW: *see* Thevenod et al 227
Ragni A (abst) 825
Raif W (abst) 275
Raimondi A (abst) S16-334
Ralcke P (abst) S16-346
Rambaud JC (abst) 406
Rambausek M (abst) 422
Rambausek M: *see* Kreusser et al S15-83
Ramee MP (abst) 137, 405
Rammer L: *see* Stähl et al 323
Ramos J (abst) 126
Ramos JM (abst) S16-329, S16-331
Rampton DS (abst) S16-347
Ransom JC: *see* Kraut et al 644
Rao KV, Andersen RC, O'Brien TJ: Factors contributing for improved graft survival in recipients of kidney transplants 210
Rapado A (abst) 272, 274
Rascher W: *see* Rauh et al S15-27
Raspiller A (abst) 405
Rastall JR: *see* Falk et al 110
Rauh W, Hund E, Sohl G, Rascher W, Mehls O, Schärer K: Vasoactive hormones in children with chronic renal failure S15-27
Rauh W: *see* Oertel et al S15-34
Ravet W (abst) S16-349
Rayment CM: *see* Kelly et al 233
Reale E (abst) 279
Rebaiz K (abst) 136
Rebibo D (abst) 131
Redaelli B (abst) 137
Redaelli L (abst) 825
Rees AJ (abst) 424
Regnier FE: *see* Ash et al 250
Reichard GA: *see* Sigler et al S16-97
Rennert O: *see* Metcoff et al S16-87
Rennke HG: *see* Weening et al 152
Resano M (abst) 133, 270
Reubi C (abst) 276
Reveillaud RJ (abst) 421
Revert L (abst) 272, 427
Ricanati ES, Tserng K-Y, Kalhan SC: Glucose metabolism in chronic renal failure: Adaptive responses to continuous glucose infusion S16-121
Ricci M: *see* Amadori et al 775
Riegel W (abst) S16-330
Riegel W, Stepinsky J, Muñchmeyer M, Hörl WH: Effect of serine on gluconeogenic ability of hepatocytes in acute uremia S16-48
Rifle G (abst) 404
Riggio P (abst) S16-327
Rigoni A (abst) 130
Rindi P (abst) 127
Ringoir S (abst) 138, 420
Rink W (abst) S16-341
Ritter L (abst) 283
Ritz E (abst) 275, 283, 413, 419, 422, 426
Ritz E: Role of intracellular calcium and calmodulin in cellular metabolism: Possible implications for renal failure S16-161
Ritz E: *see* Kreusser et al S15-83
Ritz E: *see* Mehls et al S15-53
Rivera F (abst) 272, 424
Rivolta E (abst) 132
Rizzelli S (abst) 826
Rizzo G (abst) 127
Rizzoli E (abst) 127
Robaudo C: *see* Deferrari et al S16-115
Robaudo C: *see* Tizianello et al S16-17
Robert A (abst) 822
Roberts C (abst) S16-350
Robertson WG (abst) 424
Roca M (abst) 269
Roccatello D (abst) 423, 827
Rodicio J (abst) 268
Rodicio JL (abst) 273
Rodriguez JA (abst) 134
Rodriguez JL (abst) 124
Rodriguez-Carmona A (abst) 134, 270
Rodriguez-Mahou M (abst) 273
Rodriguez-Puyol D (abst) 271
Rogland B (abst) 425

Rohrbach R (abst) 275
Rollino C (abst) 827
Romagnol GF (abst) S16-332
Romagnoli GF (abst) 129, S16-348
Romano G (abst) 422
Rombolà G (abst) 138, 425
Romero JC (abst) 272
Romero R (abst) 134
Ronco P (abst) 135, 407, 824
Ronzani M (abst) 134
Roos JC (abst) 409
Rorive GL (abst) 127
Rosen S: *see* Brezis et al 178
Rosenblum H: *see* Gruskin et al S15-95
Rosenfeld J (abst) 821
Roskam G (abst) 410
Rossi E (abst) S16-327
Rossi L (abst) 824
Rottembourg J (abst) 136, 412, 413, 418, S16-336
Roullet J-B: *see* Drüeke et al S16-134
Rousaud A (abst) 124
Rubin LJ: *see* Henrich et al 240
Ruffatti A (abst) S16-332, S16-348
Rugiu (abst) 828
Rugiu C: *see* Maschio et al S16-273
Ruilope L (abst) 268
Ruiz Alegria P (abst) 416
Rumpelt H-J (abst) 276
Rumpf KW: *see* Leschke et al S16-143
Russell GI (abst) 426
Russo D (abst) 422, 427
Rustia R (abst) 130
Rutsky EA: *see* Dumbauld et al 222
Rybka SJ: *see* Magnusson et al S16-324
Ryckelynck JP (abst) 406

Sabater J (abst) 274
Sabatier JC (abst) 131, 406
Sabbatini M (abst) 422
Saccaggi A (abst) 421, S16-344
Sadler JH: *see* Shen et al S16-147
Sadowski J, Portalska E: Dynamic evaluation of renal electrolyte gradient by in situ tissue impedance studies 800
Safirstein R, Miller P, Kahn T: Cortical and papillary absorptive defects in gentamicin nephrotoxicity 526
Sainte-Laudy J (abst) 821
Saito A, Takagi T, Chung TG, Ohta K: Serum levels of polyamines in patients with chronic renal failure S16-234
Sakellariou G (abst) 415
Sakhaee K, Nicar M, Hill K, Pak CYC: Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts 348
Sala C (abst) 422
Sala R: *see* Deferrari et al S16-115
Salata H (abst) 271
Salem NG (abst) S16-340
Salinas M (abst) 134, 136, 270
Salomone M (abst) 133, 135
Salusky I (abst) S16-351
Salusky IB (abst) S16-345
Salusky IB, Flugel-Link RM, Jones M, Kopple JD: Effect of acute uremia on protein degradation and amino acid release in the rat hemicorpus S16-43
Salusky IB, Kopple JD, Fine RN: Continuous ambulatory peritoneal dialysis in pediatric patients: A 20-month experience S15-101
Salvatierra O (abst) 414
Sampol J (abst) 822
Sanchez M (abst) 270
Sanchez Sicilia L (abst) 134, 136, 270
Sancho J (abst) 268, 424
Sandberg L (abst) 418
Sanengen T: *see* Wideröe et al S16-208
Sani E (abst) 826
Sansegundo D (abst) 269
Santaularia JM (abst) 124, 274
Santini G (abst) 824
Santini GF (abst) 427
Santoro A (abst) 138, 412, 828
Sanz-Guajardo D (abst) 126
Saporiti E (abst) 129
Saracho R (abst) 271
Sargent J (abst) S16-331
Sasaoka T (abst) 412
Sasdelli M (abst) 424
Sasdelli M: *see* Amadori et al 775
Sato Y: *see* Fujita et al 731
Saudax E (abst) 405
Saudreau F (abst) 407
Savazzi AM (abst) 133
Savdie E: *see* Chan et al 336
Savica V (abst) 125
Savin VJ: Ultrafiltration in single isolated human glomeruli 748
Scalamogna A (abst) 411
Scalia A (abst) 422
Schacht RG: *see* Neugarten et al 595
Schäfer RM (abst) S16-331, S16-351
Schäfer RM: *see* Hörl et al S16-37
Schambelan M: *see* Kurtz et al 670
Schandene L (abst) 420
Schärer K (abst) S16-344
Schärer K, Mehls O, Holliday MA: Introduction S15-1
Schärer K: *see* Gilli et al S15-48
Schärer K: *see* Michalk et al S15-16
Schärer K: *see* Muller-Wiefel et al S15-70
Schärer K: *see* Oertel et al S15-34
Schärer K: *see* Rauh et al S15-27
Scheinman JI: *see* Michael et al 74
Scheler F (abst) 283
Scheler F: *see* Leschke et al S16-143
Schena FP (abst) 826, 827
Scheuermann E (abst) 413, 418
Schianchi P (abst) 826
Schillinger F (abst) 822
Schindera F (abst) 277
Schinella D (abst) 427, 825, S16-334
Schlatter E (abst) 277
Schlepper M (abst) 420
Schlondorff D (abst) 282
Schmicker R (abst) 350, S16-350
Schmidt H (abst) 277
Schmidt P (abst) 419, S16-328, S16-346
Schmidt R: *see* Ivanovich et al 758
Schmidt-Gayk H (abst) 419
Schmitt RL: *see* Jahn et al S16-67
Schmitz J: *see* Sprenger et al S16-315
Schmitz O (abst) 427, S16-336
Schneider AL, Wacarda L, von Klitzing E, Kochen W, Heilenbrecht D: Experimental observations on peri-

toneal transport in rabbits S15-89
Schneider E (abst)..... 279
Schneider H (abst) 417
Schnermann J (abst)..... 282
Schoenfeld PY (abst) S16-342, S16-342
Schoenl M: *see* Nieman et al S16-167
Schoeppe W (abst)..... 413, 417, 418
Schoeppe W: *see* Thevenod et al..... 227
Schohn DC: *see* Jahn et al..... S16-67
Schollmeyer P (abst) 275, 283
Scholz D (abst) 415
Scholze J (abst) 415
Schonberg D: *see* Oertel et al..... S15-34
Schott S (abst)..... 275
Schrader J (abst)..... 283
Schrier RW: *see* Bichet et al..... 788
Schubert G (abst) 282
Schudrowitsch L (abst) 281
Schulte-Wissermann H (abst)..... 277
Schultze G (abst)..... 281, S16-334
Schurek HJ (abst)..... 280
Schütterle G (abst)..... 420, S16-341, S16-341
Schütterle G: *see* Wizemann et al S16-218
Schuur KH (abst) 423
Schwartz G (abst)..... 282
Schwers J (abst)..... S16-335
Sciarra M (abst)..... S16-351
Scicli AG: *see* Omata et al 714
Scolari MP (abst)..... S16-331, S16-331
Scolari MP, Stefoni S, Mosconi G, Coli L, Feliciangeli G, Baldrati L, Buscaroli A, Prandini R, Bonomini V: Effects of renal substitutive programs on amino acid patterns in chronic uremia..... S16-77
Scurr DS (abst) 424
Sebastian A: *see* Kurtz et al..... 670
Sebert JL (abst)..... 821
Secchi A (abst) 428
Segoloni G (abst)..... 137
Segoloni GP (abst)..... 135, 136, S16-337
Selgas R (abst)..... 270
Selwood NH (abst)..... 411
Selwood NH: *see* Wing et al..... 507
Sena M (abst)..... 423
Serafini E (abst)..... 129
Sergeant V (abst)..... 424
Sessa A (abst)..... 136, 824
Severi B (abst)..... 824
Sfeir RE: *see* Shen et al..... S16-147
Sforza C (abst)..... 427
Sforzini S (abst)..... 137
Sganga G (abst)..... S16-338, S16-340
Shah G (abst)..... S16-350
Shaldon S (abst) 404
Shambaugh GE III (abst)..... S16-330
Shen SY, Lukens CW, Alongi SV, Sfeir RE, Dagher FJ, Sadler JH: Patient profile and effect of dietary therapy on post-transplant hyperlipidemia S16-147
Shenton BK (abst) 413
Shewan G (abst) 413
Shimamura T: Focal glomerulosclerosis in obese Zucker rats and prevention of its development..... S16-259
Sieberth HG (abst) 276
Siedlecki M: *see* Spector et al 663
Siegenthaler W (abst)..... 279
Sigler MH, Skutches CL, Teehan, BP, Cooper JH, Reichard GA: Acetate and energy metabolism during hemodialysis..... S16-97
Sigström L (abst)..... S16-345
Silberman H: *see* Feinstein et al S16-319
Sillix DH: *see* Briggs et al..... S16-93
Silva P: *see* Brezis et al..... 178
Simenhoff ML: *see* Lele et al..... S16-229
Simon N (abst)..... 137
Simon P (abst) 137
Simoni I (abst)..... 826
Sinico R (abst)..... 827
Sirbat D (abst)..... 405
Sis J (abst) 426
Situlin R (abst)..... S16-329
Situlin R: *see* Guarnieri et al..... S16-187
Skinner SL: *see* Davis et al..... 740
Skutches CL: *see* Sigler et al S16-97
Slama G (abst)..... S16-336
Slatopolsky E: *see* Kraut et al 644
Slooff MJH (abst) 414
Smeby LC (abst)..... 421, S16-337
Smith AFM: *see* Knapp et al 474
Smith D: *see* DeFronzo et al..... S16-102
Smith L (abst) 418
Smith V (abst)..... 419, 425
Smolens P, Venkatachalam M, Stein JH: Myeloma kidney cast nephropathy in a rat model of multiple myeloma..... 192
Société de Néphrologie (abst)..... 128
Sohl G: *see* Rauh et al S15-27
Solary E (abst)..... 404
Solbiati L (abst)..... 133
Solera M-L (abst) S16-327, S16-328
Sonego S (abst) 134
Souney PF: *see* Kelly et al 233
Sousa F (abst) 272
Southwest Pediatric Nephrology Study Group: Childhood nephrotic syndrome associated with diffuse mesangial hypercellularity 87
Spanish Society of Nephrology (abst) 124, 268
Spargo B: *see* Chodak et al..... 804
Spector D, Alfred H, Siedlecki M, Briefel G: A controlled study of the effect of indomethacin in uremic pericarditis 663
Spichtin HP (abst)..... 280
Spinozzi NS: *see* Grupe et al S15-6
Spitzer A: *see* Taki et al 602
Splendiani G (abst) S16-336
Spohn B: *see* Sprenger et al S16-315
Sprenger KBG, Bundschu D, Lewis K, Spohn B, Schmitz H, Franz H-E: Improvement of uremic neuropathy and hypogeusia by dialysate zinc supplementation: A double-blind study S16-315
Sprenger KBG, Kratz W, Lewis AE, Stadtmüller U: Kinetic modeling of hemodialysis, hemofiltration, and hemodiafiltration 143
Spring M (abst) S16-341
Squiccimarro G (abst) 133
Squifflet JP (abst) 406
Sraer J (abst) 404
Sraer JD (abst)..... 404
Stadler J (abst)..... 278
Stadtmüller U: *see* Sprenger et al 143
Stahl AK (abst) 283
Ståhl E, Boberg U, Larsson L, Rammer L, Persson AEG: Effect of renal tubular obstruction on stop-flow pressure and glomerular deposition of fibrin dur-

ing intravascular coagulation in the rat 323
Stanfel LA: *see* Gulyassy et al S16-238
Start K: *see* Jones et al 95
Stead WW: Evolution of technology brings computers to the bedside 436
Stead WW, Garrett LE Jr, Hammond WE: Practicing nephrology with a computerized medical record 446
Steele BT: *see* Arbus et al S15-111
Stefani F (abst) 127
Stefanidis CJ (abst) S16-345
Stefoni S (abst) S16-331
Stefoni S: *see* Scolari et al S16-77
Stein JH: *see* Smolens et al 192
Steinmuller DR (abst) S16-331
Stenberg P (abst) 420
Stephen RL (abst) 427
Stepinski J: *see* Hörl et al S16-37
Stepinski J: *see* Riegel et al S16-48
Sterner G (abst) S16-334, S16-340
Sterns RH: *see* Izzo et al S16-221
Sterzel RB: *see* Pabst et al 626
Stevens E (abst) 409
Stevenson JA (abst) S16-332
Stewart KN (abst) 413
Stolte H (abst) 275
Stortoni F (abst) S16-327
Stowe NT: *see* Magnusson et al S16-324
Strada A (abst) 411
Straffon RA: *see* Magnusson et al S16-324
Stratta P (abst) 137
Strauch M (abst) S16-348, S16-348
Strauch M: *see* Gretz et al S15-2, S16-263
Streicher E (abst) 417
Strippoli P (abst) 412
Struch M (abst) S16-350
Stucchi C (abst) S16-344
Stummvoll HK (abst) S16-328
Sturani A (abst) 138, 412, 828
Suc J-M (abst) 124
Suc M (abst) S16-327
Surian M (abst) 138, 425
Sutton RAL: *see* Watanabe et al 353
Swales JD (abst) 426
Swartz SL: *see* Kelly et al 233
Sweet RS: *see* Davis et al 740
Swenson RS (abst) 416
Szmeja K (abst) S16-339

Taccone-Gallucci M (abst) 128, 412
Tacquet A (abst) 138
Tadema TM: *see* Assmann et al 303
Tagnochetti T (abst) 125
Tahiri Y (abst) 822
Takabatake T: *see* Mason et al 27
Takagi T: *see* Saito et al S16-234
Taki M, Goldsmith DI, Spitzer A: Impact of age on effects of ureteral obstruction on renal function 602
Talin d'Eyzac A (abst) S16-332, S16-348
Tancredi M (abst) S16-336
Tange JD: *see* Davis et al 740
Tangelder MM: *see* Assmann et al 303
Tanter Y (abst) 404
Taube D (abst) 414
Taylor CM, Caverzasio J, Jung A, Trechsel U, Fleisch H, Bonjour J-P: Unilateral nephrectomy and 1,25-dihydroxyvitamin D_3 37
Taylor RMR (abst) 413
Teehan, BP: *see* Sigler et al S16-97
Tegzess AM (abst) 414
Tejedor A (abst) 406
Tepper T (abst) 422
Teruel JL (abst) 268, 269, 272, 416
Teschan PE: *see* Bourne et al 496
Tesio F (abst) 427, 825, S16-329, S16-334, S16-338
Tessitore N (abst) 828
Tessitore N: *see* Maschio et al S16-273
The TH (abst) 410
Thea A (abst) 133
Thevenod F, Radtke HW, Grützmacher P, Vincent E, Koch K-M, Schoeppe W, Fassbinder W: Deficient feedback regulation of erythropoiesis in kidney transplant patients with polycythemia 227
Thiel G (abst) 280
Thiernesse R (abst) 136
Thoenes C (abst) 278
Thoenes GH (abst) 283
Thoenes W (abst) 276
Thomas D (abst) 130
Thormann J (abst) 420
Thoua Y (abst) 130
Thuillier Y (abst) 136
Thurston H (abst) 426
Tielemans C (abst) 420
Tincani A (abst) 827
Ting A (abst) 269
Tisher CC: *see* Fernandez-Repollet et al 719
Tisone G (abst) S16-327
Tizianello A, Deferrari G, Garibotto G, Robaudo C, Lutman M, Passerone G, Bruzzone M: Branched-chain amino acid metabolism in chronic renal failure ... S16-17
Tizianello A: *see* Deferrari et al S16-115
Toigo G (abst) S16-329
Toigo G: *see* Guarnieri et al S16-187
Tojo S: *see* Aoyagi et al S16-224
Tolani M (abst) 822
Toledano D (abst) 413
Tomoyaoshi T (abst) S16-351
Tondolo M (abst) S16-328
Tondriaux A (abst) 822
Ton That H (abst) S16-327
Tonutti L (abst) 127
Töpelmann I (abst) 415
Torhorst J (abst) 283
Torlotin JC (abst) 821
Torras A (abst) 272
Torri-Tarelli L (abst) 136
Toschöpe W (abst) 283
Touchard G (abst) 406
Toupance O (abst) 820
Touraine JL (abst) 428
Tourkantoni A (abst) S16-333
Toussaint C (abst) 130
Traba ML (abst) 274
Traeger J (abst) 124, 132, 428, S16-351
Tramonti G (abst) 125
Transbøl I (abst) 426
Tran Van T (abst) 124
Trechsel U: *see* Taylor et al 37
Treissede D (abst) 404
Tribe C (abst) 423
Triebel F (abst) 418
Trimble IM: *see* Knapp et al 474

Triolo G (abst) ... 135, S16-337
Trivin C (abst) ... 129
Trovato GM (abst) ... S16-332
Trznadel K (abst) ... 415
Tschöpe W (abst) ... 419, S16-334
Tserng K-Y: *see* Ricanati et al ... S16-121
Tual JL (abst) ... 822
Tullio G (abst) ... S16-336
Turner C: *see* Jones et al ... 95
Turner C: *see* Mak et al ... S16-128
Turney JH (abst) ... 428
Turolo L (abst) ... 422
Twardowska-Rajewska J (abst) ... S16-339
Tyler F (abst) ... 427

Uccello F (abst) ... 422
Uddebom G (abst) ... S16-346
Ulman J (abst) ... 426
Usberti M (abst) ... 423
Usera G (abst) ... 273

Vaamonde CA: *see* Perez et al ... 656
Vaccher E (abst) ... S16-338
Vacha GM (abst) ... S16-328
Vagelli G (abst) ... S16-347, 824
Valderrabano F (abst) ... 133, 270, 418
Valdiguie P (abst) ... S16-327
Valentijn RM (abst) ... 408, 409
Valeri M (abst) ... 412
Vallo A (abst) ... 271
Valvo E (abst) ... 828
Valvo E: *see* Maschio et al ... S16-273
Vandelli L (abst) ... 133
Van den Berg CJ (abst) ... 425
Vandenbroucke JM (abst) ... 406
Van de Putte LBA (abst) ... 408
Van der Giessen M (abst) ... 410
Van der Hem GK (abst) ... 408, 410, 422, 423, 427
Van der Woude FJ (abst) ... 410, 414
Vandewalle A (abst) ... 407
Van Es LA (abst) ... 408, 409
Vangelista A (abst) ... 414, 824
Vanherweghem JL (abst) ... S16-335
Vanhille P (abst) ... 138, 415
Vanholder R (abst) ... 138, 420
Van Liebergen FJHM (abst) ... 408
Van Liew JB, Brentjens JR, Noble B: Relationship of kidney function to immunopathology in chronic serum sickness of rats ... 160
Van Munster P (abst) ... 409
Van Regemoorter N (abst) ... 130
Van Son WJ (abst) ... 414
Van Stone JC: *see* Kimura et al ... 542
Vantard G (abst) ... 820
Van Ypersele de Strihou C (abst) ... 406
Vanziro A (abst) ... S16-336
Vargemezis V (abst) ... 415
Vartsky D (abst) ... S16-342
Varvara B (abst) ... 826
Vasconaz F (abst) ... 418
Vasile A (abst) ... S16-329
Vassanelli P (abst) ... S16-333
Vaswani AN (abst) ... S16-342
Vazzola A (abst) ... 132
Vecchio G: *see* Giordano et al ... S16-71
Vendemia F (abst) ... 422
Venkatachalam M: *see* Smolens et al ... 192
Venkatachalam MA: *see* Zager et al ... 620
Venn JC: *see* Gordon et al ... 455
Vercellone A (abst) ... 133, 135, 137, S16-337
Vereerstraeten P (abst) ... 130, 420
Vergani L (abst) ... S16-332
Verger C (abst) ... 406
Vernier RL: *see* Michael et al ... 74
Verroust P (abst) ... 407, 824
Vessby B (abst) ... 419
Vetter K (abst) ... S16-350, S16-350
Vetter W (abst) ... 279
Vezzoli C (abst) ... 129
Vianello A (abst) ... 126
Vigano MR (abst) ... 137
Vignon MC (abst) ... 821
Villalta D (abst) ... 427, 825
Villar F (abst) ... 271
Villaro J (abst) ... 130, 273
Vince AJ (abst) ... S16-347
Vincent E: *see* Thevenod et al ... 227
Vincenti F (abst) ... 414
Virto R (abst) ... 273
Virvidakis C (abst) ... S16-335
Visset J (abst) ... 135
Vistelle R (abst) ... 820
Viviani G: *see* Deferrari et al ... S16-115
Vlamis I (abst) ... 824
Voigts A: *see* Andress et al ... 364
Volpi A (abst) ... 824
Von Bloch L (abst) ... 412
Von Klitzing E: *see* Schneider et al ... S15-89
Von Willebrand E (abst) ... 418
Vos JTWM (abst) ... 410
Voudiklari S (abst) ... S16-335

Wacarda L: *see* Schneider et al ... S15-89
Wager JD (abst) ... S16-347
Wagner K (abst) ... 281
Wald V: *see* Chodak et al ... 804
Walker LL: *see* Davis et al ... 740
Walker P (abst) ... S16-332, S16-343
Walls J (abst) ... 426
Wallstein B: *see* Gilli et al ... S15-48
Walser M, Mitch WE, Abras, E: Supplements containing amino acids and ketoacids in the treatment of chronic uremia ... S16-285
Wang W (abst) ... 281
Ward DM: *see* Chenoweth et al ... 770
Ward M (abst) ... S16-333
Ward MK (abst) ... S16-329, S16-331
Watanabe H, Sutton RAL: Renal calcium handling in familial hypocalciuric hypercalcemia ... 353
Wauquier I (abst) ... 821
Wauters JP (abst) ... 412
Weber H (abst) ... 417
Weber HP (abst) ... 277
Weber M (abst) ... 416
Weening JJ, Rennke HG: Glomerular permeability and polyanion in Adriamycin nephrosis in the rat ... 152
Weestel PF (abst) ... 130
Weglage H (abst) ... 275
Wehbe B (abst) ... 407
Weiler E (abst) ... 279
Weller JM: *see* Williams et al ... 691
Welsch J (abst) ... 280

Welsch J: *see* Mason et al 27
Welsh K (abst) 414
Wennberg A (abst) S16-334, S16-340
Wessel-Aas T (abst) S16-341
West CD: *see* Coleman et al 681
Weston MJ (abst) 420
Wideröe T-E (abst) 421, S16-337, S16-341
Wideröe T-E, Sanengen T, Halvorsen S: Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis S16-208
Widhalm K: *see* Druml et al S16-139
Widstam-Attorps U: *see* Bergström et al S16-153
Wietasch A (abst) 275
Wilcox CS: *see* Kelly et al 233
Will EJ: *see* Morgan et al 438
Willems B (abst) S16-329
Willenbockel U (abst) 277
Williams DG (abst) 414, 416
Williams GW, Weller JM, Ferguson CW, Forsythe SB, Wu S-C: Survival of endstage renal disease patients: Age-adjusted differences in treatment outcomes 691
Williams W (abst) 424
Winer R (abst) S16-350
Wing AJ (abst) 411
Wing AJ, D'Amaro J, Lamm LU, Selwood NH: Evolving methodologies in computerized European Registries 507
Winkelmann M (abst) 284
Wirthensohn G (abst) 277
Wizemann V (abst) 420, S16-341, S16-341
Wizemann V, Buddensiek P, de Boor J, Grebe S, Schütterle G: Gastrointestinal blood loss in patients undergoing maintenance dialysis S16-218
Wolf C (abst) 136
Wolf H (abst) 277, 426
Wolfson M (abst) S16-351
Woodard TD: *see* Henrich et al 240
Woodhead JS: *see* Lucas et al S16-171
Wrong OM (abst) S16-347
Wu S-C: *see* Williams et al 691
Wybran J (abst) 420

Yamada T: *see* Kurokawa et al 754
Yang J-Y: *see* Michael et al 74
Yap PL (abst) 417
Yarger WE: *see* Klotman et al 638
Yasumura S (abst) S16-345
Yoshida M (abst) S16-336
Youinou P (abst) 405

Zager RA, Venkatachalam MA: Potentiation of ischemic renal injury by amino acid infusion 620
Zakheim B: *see* Neilson et al 289
Zanelli P (abst) S16-338
Zanghi F (abst) S16-351
Zawada E Jr (abst) S16-337
Zazgornik J (abst) 419, S16-328, S16-346
Zech P (abst) 132, 135
Zervakis D (abst) S16-335
Zoccali C (abst) 825
Zoob S (abst) 424
Zubimendi JA (abst) 272
Zuccalà A (abst) 138, 412, 828
Zucchelli P (abst) 127, 138, 412, 824, 828
Zucchelli P, Cagnoli L, Casanova S, Donini U, Pasquali S: Focal glomerulosclerosis in patients with unilateral nephrectomy 649
Zucchetta P (abst) 129
Zumkley H (abst) 279
Zussa S (abst) 129

Subject Index For Volume 24

Abdominal complications
in CAPD (abst) 412
Abdominal surgery
and chronic peritoneal dialysis (abst) 135
Acetate
and energy metabolism during hemodialysis S16-97
high sodium bicarbonate dialysis compared to *a.* dialysis 240
Acetohydroxamate
in struvite stones (abst) 425
Acetohydroxamic acid
treatment of ureogenic lithiasis (abst) 124
Acid-base status
after cannulation of aorta and vena cava 795
Acidosis
acquired distal renal tubular *a.*
Nephrology Forum on 807
chronic metabolic *a.*
effects on vitamin D metabolism in humans 644
Acidosis syndrome, acute
caused by acid pH of deionized water in hemodialysis (abst) 269
Acids
metabolic generation of nonvolatile *a.* 709
metabolism of orally administered branched-chain α-keto *a.* S15-11
Adenosine
intracortical distribution of RBF during infusion of (abst) 272
Adrenal hormones
effects on epithelial function 386
Adriamycin
glomerular permeability and polyanion in *A.* nephrosis 152
Age
effects on endstage renal disease patient survival 691
impact of *a.* on effects of ureteral obstruction on renal function 602
Albumin
isolation of inhibitors of ligand:*a.* binding from uremic body fluids and normal urine S16-238
Aldosterone
and corticosterone effects on epithelial function 386
a. response to potassium loading in tubulointerstitial renal disease 656
which type dopaminergic receptor modulates *a.* secretion (abst) 826
1-Alea-hydroxycholecalciferol
treatment of secondary hyperparathyroidism of chronic renal failure (abst) 128
Allergy
postvaccination lipoid nephrosis and *a.* to egg proteins (abst) 821
Allograft, renal
and pretransplant antibodies (abst) 413
cytotoxic suppressor cells in *r. a.* rejection (abst) 414
effects of perioperative blood transfusions on *r. a.* survival (abst) 413
rejection of *r. a.* by urinary cytology (abst) 284
rupture in (abst) 268
Allotransplantation, renal
hepatitis B vaccination after (abst) 275
Aluminum
and renal osteodystrophy (abst) 820
effects on
calcium and PTH metabolism in hemodialysis and CAPD (abst) 269
calcium and PTH response in CAPD (abst) 126
effective *a.* free intestinal phosphate binder in chronic renal failure (abst) 417
history/incidence of *a.*-induced anemia, bone diseases, and progressive encephalopathy (abst) 279
in joint tissues of chronic renal failure (abst) 405
in vivo *a.* absorption by duodenum in chronic uremia (abst) S16-333
s. aluminum
in *a.* regular dialysis unit of North Greece (abst) S16-333
Aluminum hydroxide
effects on hemoglobin and blood transfusions in hemodialysis (abst) 416
risk of *a.* toxicity in *a. h.* therapy (abst) 126
treatment of severe renal failure and vitamin D disorders S15-63
Aluminum toxicity
risk of *a. t.* in *a.* hydroxide therapy (abst) 126
American Rheumatism Association
criteria used in lupus and nonlupus membranous glomerulopathy study 377
Amino acids
acute uremia effects on protein degradation and *a. a.* release in rat hemicorpus S16-43
and alpha analogues in three low-nitrogen diets for severely uremic children S16-290
and keto acid supplements
in children with chronic renal failure 95
to treat chronic uremia S16-285
as therapy in renal failure (abst) S16-328
branched-chain *a. a.* metabolism in chronic renal failure S16-17
effects of
a. a. infusions on cell metabolism in hemodialyzed patients with uremia S16-87
renal substitute programs on *a. a.* patterns in chronic uremia S16-77
in azotemia S16-58
intracellular *a. a.* in uremia S16-9
in uremia S16-2
peritoneal ammonia as possible inhibitor for blood *a. a.* loss S16-71
plasma ammonia effects on cellular release of branched-chain *a. a.* in systemic portal encephalopathy S16-67
potentiation of ischemic renal injury by *a. a.* infusion 620
relationship between branched-chain *a.* and α-keto *a.* in blood in uremia S16-61
taurine metabolism in experimental renal failure ... S15-16
use of keto analogues of essential *a. a.* in chronic renal failure S15-11
Ammonia
colon *a.* reabsorption in uremia (abst) S16-338
peritoneal *a.*
as possible inhibitor for blood amino acid loss S16-7

Ammonium chloride
used to induce metabolic acidosis 644
Amphiuma
chloride reabsorption in diluting segment of *A.* affected by potassium (abst)..... 281
Androgens
as therapy in nonferropenic patients on hemodialysis (abst) 269
Anaphylatoxin
a. formation during hemodialysis 764, 770
Anemia
in chronic endstage renal disease..... S16-218
induced by aluminum in home hemodialysis (abst) 279
pathogenesis of *a.* of uremia..... S16-204
secondary hyperparathyroidism effects on *a.* of end-stage renal failure (abst)..... 417
Anesthesia
open renal biopsy technique performed with local *a.* . 804
Angiotensin II
role in sodium excretion, urinary concentration, and papillary plasma flow (abst)..... S16-333
Angiotensin converting enzyme inhibitors influence on hypercoagulability (abst) 283
Anionic ferritin
in glomerular permeability..... 632
Ankylosing spondylitis
and IgA nephropathy (abst)..... 408
associated with Berger disease (abst) 129
Anorexia
importance of *a.* in preservation of renal function due to deficient phosphorus diets (abst)..... S16-349
Antibodies
amonoclonal *a.*
used to define new pattern of passive Heymann nephritis (abst) 824
antistreptococcal *a.*
and glomerulonephritis (abst) 821
B lymphocyte *a.* in controlled trial of cyclosporin A after renal transplantation (abst) 269
monoclonal *a.*
directed against human factor B (abst)..... 409
lymphocyte subsets in renal graft biopsy detected by (abst) 414
production of *m. a.* against kidney cell populations (abst) 407
used to detect organo-specific antigen on human kidney structures (abst)..... 280
pretransplant *a.*
and renal allograft survival (abst)..... 413
role in IgA nephropathy and ankylosing spondylitis (abst) 408
Antidiuretic hormone
interaction of cyclic AMP and calcium-calmodulin in mechanism of (abst) 282
Antigens
iron overload related to HLA *a.* (abst)..... 412
organospecific *a.*
detected on human kidney structures by monoclonal antibodies (abst) 280
Antiserum
in mouse with membranous glomerulonephritis 303
Aprotinin
effects on captropril associated with tubuloglomerular feedback (abst)..... 282
Arachidonic acid metabolites
associated with macrophages (abst)..... 404
Arginine vasopressin
associated with BP in potassium deficiency..... 342
Ascites
cure for *a.* of dialyzed uremic patients (abst) S16-346
Assay
fetal mouse liver cell used to measure serum erythropoietin in children with chronic renal failure..... S15-70
Autoantibody synthesis
regulation of anti-GBM *a. s.* (abst) 404
Autoimmune nephritis model
regulation of anti-GBM autoantibody synthesis in (abst) 404
Autoimmunity
in thyroiditis in primary renal glycosuria (abst) 825
Autoradiography
a. analysis of cell renewal of glomerular cell types in normal rats 626
Azotemia
induced by diuretics (abst)..... S16-329
induced by diuretics S16-58

Bacterial infection
effect of uremia on resistance to 66
Bacterial lipopolysaccharide
used to study pathogenesis of increased glomerular permeability 632
Baroreflex
b. function affected by cold pressor test in essential hypertension (abst) 127
Bartter syndrome
and polycythemia (abst)..... 822
Bayley-Pinneau method
used to predict adult height in children with chronic renal failure S15-48
Bence Jones proteinuria
in myeloma kidney cast nephropathy 192
Bence Jones tubulopathy
biochemical and morphological findings and therapeutic results of *B. J. t.* (abst) 275
Berger disease, *see* IgA nephropathy
Berger glomerulonephritis
IgA_1 and IgA_2 subclasses in (abst)..... 128
factors of coagulation and fibrinolytic pathways in 137
Bicarbonate
high sodium *b.* dialysis compared to acetate dialysis .. 240
b. reabsorption
reduction of RBF and proximal *b. r.* in rats by gentamicin 638
Biochemical assays
used to study recurrent calcium stone formers (abst) . 127
Biochemical data
selection, presentation, and interpretation of *b. d.* in renal failure 438
Biopsy
muscle *b.* studies in chronic uremia S16-334
Biopsy, renal
lymphocyte subsets detected by monoclonal antibodies in (abst)..... 414
modified open kidney *b.* technique 804
post-*r. b.* follow-up in patients with IgA mesangial deposit glomerulonephritis (abst)..... 825
role in
management of idiopathic nephrotic syndrome, Nephrology Forum on 561
renal transplantation..... 210
used to study focal glomerulosclerosis and proteinuria after nephrectomy..... 649

Biopterin metabolism
in chronic uremia (abst) ... 138
Bleeding
Nephrology Forum on uremic *b.* ... 698
Blood
gastrointestinal *b.* loss in patients on maintenance dialysis ... S16-218
b. interactions of dialysate and membranes (abst) ... 404
relationship between branched-chain amino and α-keto acids in *b.* in uremia ... S16-61
BP
affected by arginine vasopressin in potassium deficiency ... 342
as criterion used to select children in risk for essential hypertension (abst) ... 826
associated with prostaglandin biosynthesis (abst) ... 283
dopaminergic control
in hemodialysis (abst) ... 412
of prolactin, sympathetic tone, and BP in hemodialysis (abst) ... 828
Blood transfusions
effects of perioperative *b. t.* on renal allograft survival (abst) ... 413
Bone resorption
stimulated by elevated serum 1,25-$(OH)_2$-vitamin D concentrations ... 555
Bone scintigraphy
role in diagnosis of renal osteodystrophy (abst) ... 126
Bovine serum albumin
used to induce chronic serum sickness in rats ... 160
Bowman's capsule
rate of cell renewal in *B. c.* cells ... 626
Brain
associated with branched-chain amino acid metabolism in chronic renal failure ... S16-17
role in glucose production related to chronic renal failure ... S16-115
Brush border
new pattern of passive Heymann nephritis defined by amonoclonal antibody directed against (abst) ... 824
Brushborder membrane, luminal
renal adaptation to altered dietary sulfur amino acid intake at ... 588

Calcium
affected by
aluminum in hemodialysis and CAPD (abst) ... 269
cimetidine in primary hyperparathyroidism (abst) ... 821
verapamil in essential hypertension (abst) ... 280
and magnesium tubular handling in stone formers (abst) 132
and PTH response affected by aluminum in CAPD (abst) ... 126
c. excretion
in idiopathic hypercalciuria ... 549
in experimental uremia ... S15-53
recurrent *c.* stone formers observed with biochemical assays and crystalluria study (abst) ... 127
c. resorption stimulated by 1,25-$(OH)_2$-vitamin D ... 555
role of intracellular *c.* and calmodulin in cellular metabolism ... S16-161
Calcium-ATPase
endstage renal disease effects on responsiveness to calmodulin and thyroid hormone of *c.* in erythrocytes ... S16-167
Calcium-calmodulin
interaction with cyclic AMP in mechanism of antidiuretic hormone (abst) ... 282
Calcium oxalate crystallization
inhibitors of *c. o. c.* in urine from stone formers and normal subjects (abst) ... 424
Calcium-phosphorus
c.-p. balance
associated with primary hyperparathyroidism (abst) 274
c.-p. metabolism
affected by CAPD (abst) ... 270
Calcium stone disease
idiopathic *c. s. d.*
critical evaluation of forms of therapy for (abst) ... 420
Calcium stone formers
inhibitor and nucleator activities in (abst) ... 424
Calmodulin
endstage renal disease effects on responsiveness to *c.* and thyroid hormone of calcium-ATPase in erythrocytes ... S16-167
role of intracellular calcium and *c.* in cellular metabolism ... S16-161
Caloric supplementation
effects on growth in uremic children ... 205
Cancer
metastatic breast *c.*
9 hydroxy 2 methylellipticinum effects on (abst) ... 406
Cannulation
acid-base status after ... 795
Captopril
effects on sodium balance ... 233
fails to inhibit tubuloglomerular feedback responses with aprotinin (abst) ... 282
graft function loss with transplant renal artery stenosis after *c.* treatment (abst) ... 414
in sodium/water management in cirrhosis (abst) ... 271
recovery in postischemic acute renal failure with ... S16-324
severe side effects of *c.* in advanced chronic kidney insufficiency (abst) ... 423
Carbohydrate metabolism
during fasting in chronic hemodialysis patients ... 222
studied by hyperglycemia clamp technique in children with chronic renal failure ... S15-22
Carcinogenesis
precarcinogen nitrosodimethylamine in small intestine in chronic renal failure ... S16-229
Cardiac arrhythmia
in chronic dialysis patients (abst) ... 821
Cardiac function
affected by acetate and bicarbonate hemodialysis ... 782
in children with chronic renal failure ... S15-77
in experimental uremia ... S15-83
Cardiovascular changes
in chronic hemodialysis ... 371
Cardiovascular diseases
open heart surgery in endstage renal disease (abst) ... 413
Carnitine
loss of *c.* in hemodialysis and hemofiltration ... S16-143
plasma and muscle levels of *c.* in hemodialysis (abst) ... 125
L-Carnitine
as treatment in hemodialysis (abst) ... S16-332
effects in anemia of hemodialysis patients (abst) ... S16-332
metabolic effects on regular dialysis treatment (abst) ... S16-327
nutritional response patterns to L-*c.* in patients on chronic hemodialysis (abst) ... S16-328
Catabolism
exercise training effects on muscle protein *c.* in

uremia S16-52
role of increased peripheral *c.* unmasked through evisceration hepatectomy S16-58
Catecholamines
myocardial response to *c.* in experimental uremia .. S15-83
Catheter, Hickman
Technical Note on 694
Cefoperazone
in CAPD (abst) 404
Cells
arterial smooth muscle *c.* proliferation in renovascular hypertension (abst) 127
cytotoxic suppressor *c.* in renal allograft rejection (abst) 414
double-diffusion *c.* used to study middle molecules ... 250
endothelial *c.* death linked to systemic familial hyalinosis (abst) 406
isolated from limb of Henle (abst) 406
c. metabolism
effects of amino acid infusions on *c. m.* in uremia S16-87
role of intracellular calcium and calmodulin in *c. m.* S16-161
c. renewal of glomerular cell types in normal rats 626
suppressor *c.*
characteristics of *s. c.* in pyelonephritis 313
in mercuric chloride-induced autoimmune nephritis (abst) 406
Cell-mediated immunity
cells identified in nonspecific suppression of 313
Cellulose phosphate test
used to determine type of hypercalciuria (abst) 283
Cerebro-spinal fluid
sodium in (abst) 273
Chemotactic activity
generated by dialyzer membrane 775
Chloride
in cells of loop of Henle (abst) 277
c. reabsorption in diluting segment of Amphiuma affected by potassium (abst) 281
Chlorothiazide
in familial hypocalciuric hypercalcemia 353
Chromatography
anion exchange *c.* used to study middle molecules 250
Cimetidine
in primary hyperparathyroidism (abst) 821
Cirrhosis
alcoholic liver *c.*
immune complexes containing IgA_1 and IgA_2 in (abst) 825
mechanisms of improvement of water and sodium excretion by immersion in 788
captopril effects on sodium/water management in (abst) 271
insertion of peritoneoveinous shunt in *c.* patients (abst) 821
membranoproliferative glomerulonephritis in (abst).... 131
sodium tubular handling in (abst) 271
Cis-platin nephrotoxicity
enzymuria in evaluation of (abst) 125
Cis-platinum
effects on human kidney proximal tubule (abst) 131
Cloning techniques
in monoclonal antibodies to human renal basement membranes 74
Coagulation disorders
in nephrotic syndrome (abst) 822
Coagulation, intravascular
renal tubular obstruction during 323
Cold pressor test
effects on baroreflex function in essential hypertension (abst) 127
Collagen, type IV
in biopsy specimens of renal interstitial fibrosis (abst) 824
Complement system
affected by monoclonal antibodies (abst) 409
associated with leukopenia in hemodialysis 775
inherited *c.* component deficiencies in membranoproliferative glomerulonephritis 681
symptoms and activation of granulocytes and *c.* with two dialysis membranes 758
Computer model system
used to make physico-chemical studies of urine (abst) 134
Computerized medical record
in nephrology 446
Computer systems
BASIC S16-343
CLINFO 464
CSA 496
CUSUMS 474
DEC 455
ICD-9 464
RSX-11M 455
SPSS 464
TMR 446
Computing in clinical nephrology, Symposium on biochemical data in renal failure in 438
computer methods, uremic encephalopathy, and adequacy of dialysis 496
computerized clinical data for dialysis and transplantation units in 455
computerized medical record in 446
computerized medical record for patients with endstage renal disease 464
graft survival after renal transplantation analyzed 516
introductions to Symposium on 433, 436
kinetic modeling applied to renal and related diseases 487
mathematical/statistical aids to evaluate data from renal patients in 474
use of European Registries in treatment of endstage renal disease 507
Congestive cardiomyopathy
with moderate renal failure treated with CAPD (abst). 136
Corticosteroid therapy
in acute renal failure (abst) 404
ocular changes in idiopathic nephrotic syndrome after (abst) 271
used in Henoch-Schönlein glomerulonephritis (abst)... 409
Corticosterone
and aldosterone effects on epithelial function 386
Cuprophan
eosinophilia and pulmonary dysfunction in *c.* hemodialysis 246
Cyclic AMP
and PTH in idiopathic hypercalciuria S16-175
interaction with calcium-calmodulin in mechanism of antidiuretic hormone (abst) 282
urinary
as index of parathyroid function in hypercalciuria (abst) 134
u. c. excretion in primary hyperparathyroidism and recurrent calcium nephrolithiasis (abst) 138
Cyclophosphamide
effects on peripheral T cell subsets in polyarteritis nodosa (abst) 273
used in Henoch-Schönlein glomerulonephritis (abst) .. 409

Cyclosporin A
as treatment in
kidney transplants (abst) 280
segmental neoprene-injected pancreas transplantation (abst) 428
cortical infarction in rabbits with serum sickness after (abst) 416
in controlled trial after renal transplantation (abst) 269
Cystinosis
multicenter study of 105 patients in Federal Republic of Germany (abst) 277
Cystinuria
treated with alpha-mercaptopropionylglycine (Thiola®) (abst) 420
Cytomegalovirus infection
diagnosed by urinary cytology in renal transplantation (abst) 284

Deferoxamine
used to remove iron during CAPD 110
DOCA-salt
used to induce hypertension 731
Diabetes
diagnosis of protein calorie malnutrition in *d.* patients on hemodialysis and peritoneal dialysis (abst)... S16-342
40-month study of CAPD in insulin-dependent *d.* patients (abst)..... 136
hemofiltration treatment in diabetic uremic patients (abst) 135
reduced intracellular pyruvate availability in..... S16-61
Diabetes mellitus
disorder of magnesium renal tubular transport in (abst) 272
Dialysate
uremic neuropathy and hypogeusia improved by *d.* zinc supplementation..... S16-315
who needs high sodium *d.*? (abst) 827
Dialysis (also *see* Hemodialysis)
associated with humoral immunodepression (abst) 413
chronic *d.*
cardiac arrhythmia in (abst) 821
compared to transplantation in study of effects of age on endstage renal disease patient survival 691
computer methods, uremic encephalopathy, and adequacy of 496
computerized clinical data for..... 455
d. fluid
influence on membrane biocompatibility (abst)..... 270
gastrointestinal blood loss in patients undergoing maintenance *d.*..... S16-218
hemodialysis
acetate and energy metabolism during S16-97
acute acidosis syndrome in (abst) 269
aluminum hydroxide effects on (abst)..... 416
aluminum treatment in (abst) 405
and hemofiltration in systemic portal encephalopathy S16-67
and indomethacin used to treat uremic pericarditis . 663
androgen therapy in nonferropenic patients on (abst) 269
carnitine loss during *h.* and hemofiltration..... S16-143
clinical features of non-A, non-B hepatitis in patients and staff of *h.* center (abst)..... 137
chronic *h.*
carbohydrate metabolism during fasting in 222
cardiovascular changes in 371
hepatitis B vaccination protocols in uremic patients treated with (abst) 138
high sodium bicarbonate and acetate *h.*..... 240
malnutrition as factor in morbidity and mortality of *h.* patients..... S16-199
comparison of cellophane and cellulose acetate membranes in 758
comparison of new and re-used dialyzer membranes in..... 770
different dialyzer membranes used to study leukopenia and complement system in 775
effects of
acetate and bicarbonate *h.* on cardiac function.... 782
aluminum on calcium and PTH metabolism in *h.* and CAPD (abst)..... 269
amino acid infusions on cell metabolism in *h.* patients with uremia S16-87
different dialyzer membranes in 764
enhanced release of granulocyte proteinases in uremic intoxication and during..... S16-27
eosinophilia and pulmonary dysfunction in cuprophan *h.* 246
exercise training for *h.* patients S16-303
Hickman catheter used as new *h.* access device for infants and small children 694
in lupus nephritis (abst) 416
in polycystic kidney disease (abst) 406
kinetic modeling of *h.*, hemofiltration, and hemodiafiltration..... 143
leukocyte metabolism studied in *h.* patients S16-93
muscle biopsy studies done on chronic uremic patients on..... S16-187
new thrombin inhibitor (MD-805) suitable for (abst) 412
non-A-non-B hepatitis in (abst) 272, 416
PTH response to hypocalcemia in..... 364
protein and energy requirements in children on .. S15-6
protein malnutrition in (abst) 405
results of short-term *h.* (abst)..... 412
simulation study on transcellular fluid shifts induced by 542
triiodothyronine and thyroxine in chronic renal failure patients on..... S16-180
vasoactive hormones in children with chronic renal failure on..... S15-27
hepatitis HbS vaccination in (abst) 413
peritoneal
and indomethacin used to treat uremic pericarditis . 663
peritonitis treated in (abst) 130
chronic *p.*
and abdominal surgery in 25 patients (abst)..... 135
continuous ambulatory *p. d.* (CAPD)
abdominal echography and long-term peritoneum efficiency in (abst)..... 133
and renal transplantation (abst) 406
calcium and PTH response affected by aluminum in CAPD (abst)..... 126
carbohydrate metabolism in (abst)..... S16-329
Cefoperazone in (abst)..... 404
correlation between peritonitis and nutritional state in patients on CAPD (abst) S16-341
effects of aluminum on calcium and PTH metabolism in *h.* and CAPD (abst)..... 269
effects of different concentrations of calcium and magnesium in solutions for (abst)..... S16-334
effects on calcium-phosphorus metabolism and PTH (abst) 270
effects on circadian behavior of cortisol and aldosterone (abst)..... S16-337

erythrocytic metabolism and oxidative hemolysis during (abst) S16-341
erythropoietin and uremic toxicity during S16-208
40-month study in insulin-dependent diabetic patients (abst)..... 136
improved lymphocyte transformation in patients on CAPD (abst)..... 411
iron removal during CAPD using deferoxamine ... 110
long-term survival on (abst) 428
multicenter study of physical activity and employment status of United States patients on (abst). 412
muscle biopsy studies done on chronic uremia patients on..... S16-187
1981 report of 450 patients of 21 sample centers in Italy (abst) 136
nutritional/metabolic studies in children on ... S15-106
nutritional requirements for patients on S16-295
oral supplementation of essential amino acids in (abst) S16-349
plasma concentrations and transperitoneal transport of native insulin and C-peptide in patients on (abst) 421
severe abdominal complications in (abst)..... 412
small solutes kinetics in CAPD (abst)..... 270
treatment of congestive cardiomyopathy with moderate renal failure (abst)..... 136
20-month experience of CAPD in pediatric patients S15-101
"Y" connector system to prevent peritonitis in (abst) 411
modeling in..... 487
p. transport in rabbits related to *p. d.* in children with chronic renal failure..... S15-89
report on regular *d.* and transplantation in Europe XIII, 1982, Parts I, II, and III (abst) 411
sodium-dependent transcellular water shift during (abst) 820
total parenteral nutrition for acute renal failure patients on S16-319

Dialysis water
as cause of bone intoxication by aluminum (abst) 820

Dialyzer membranes
comparison of
cellophane and cellulose acetate membranes in hemodialysis..... 758
new and re-used *d. m.* 770
effects of different *d.* membranes in hemodialysis 764
hemodialysis leukopenia and complemented function with different *d. m.*..... 775

Diet
effects on plasma acid-base composition in normal humans..... 670
role of *d.* factors in chronic renal disease 579

Dietary protein
and urea kinetics in hemofiltration (abst)..... 135

Dilatation, percutaneous transluminal
used in renovascular hypertension (abst)..... 279

Diphenylthiazole
used to induce renal cystic disease 43

Donnan effect
related to sieving coefficient (abst) 133

Dopamine
controls
prolactin, sympathetic tone, and BP in hemodialysis patients (abst)..... 828
sympathetic activity and BP in hemodialysis (abst) . 412
d. receptors
role in regulation of renin-angiotensin-aldosterone system (abst) 826

Dyslipidemia
and nutritional factors in hemodialysis patients (abst) S16-332
post-transplant *d.*
diet therapy for (abst)..... S16-331

Echocardiogram
assessed cardiac function in children with chronic renal failure..... S15-77

Echography, abdominal
used to investigate abdominal cavity (abst)..... 133

Eclampsia
hemodynamic effect of magnesium sulfate in (abst).... 822

Egg proteins
postvaccination lipoid nephrosis and allergy to (abst) . 821

Electrocautery
high current *e.* used in open kidney biopsy technique. 804

Electroencephalogram
used in acute renal failure 170

Electrolytes
muscle intracellular *e.* in uremic patients..... S16-153
renal *e.* gradient evaluated by in situ tissue impedance studies..... 800

Encephalopathy
progressive *e.*
induced by aluminum in home hemodialysis (abst) . 279
systemic portal *e.*
plasma ammonia effects on cellular release of branched-chain amino acids in S16-67

Endocrine system
nutritional and *e.* status in patients on regular hemodialysis treatment (abst)..... S16-334
e. response of peritoneal and enteral administered glucose to patients on CAPD (abst) S16-337

Energy
and acetate metabolism during hemodialysis..... S16-97

Enzymuria
and proteinuria in hypertension (abst) 130
used to study
cis-platin effects on human kidney proximal tubule (abst) 131
cis-platin nephrotoxicity (abst)..... 125

Eosinophilia
during cuprophan hemodialysis 246

Epinephrine
effects on potassium metabolism (abst) 272

Epithelial function
adrenal hormone effects on..... 386

Erythrocytes
endstage renal disease effects on responsiveness to calmodulin and thyroid hormone of calcium-ATPase in human *e.*..... S16-167

Erythropoiesis
feedback regulation of *e.* in kidney transplant patients with polycythemia..... 227

Erythropoietin
and uremic toxicity during CAPD S16-208

Ethylene glycol
nephron damage due to *e. g.* poisoning (abst)..... 415

Escherichia coli
experimental infections of bacteremia and peritonitis . 66

European Dialysis and Transplant Association
computerized methodologies used in ... 507
European Registries
evolving methodologies in computerized E. R. ... 507
Eurotransplant
computerized methodologies used in ... 507
Exercise
benefits for hemodialysis patients ... S16-303
e. training effects on muscle protein catabolism in uremia ... S16-52
Extracellular fluid volume
affected by potassium in hypertension ... 731

Fabry disease
associated with rapidly progressive glomerulonephritis with granulomatous hyperplasia of gums (abst) ... 130
discovered by isolated nephrologic symptoms (abst) ... 405
Factor VIII
in severe essential arterial hypertension (abst) ... 273
Fasting
carbohydrate metabolism during *f.* in chronic hemodialysis patients ... 222
Fc receptor blockade
during *Plasmodium yoeli* infection (abst) ... 132
Feedback regulation
of erythropoiesis in renal transplant patients with polycythemia ... 227
Fibrin
affected by renal tubular obstruction ... 323
Fibronectin
in biopsy specimens of renal interstitial fibrosis (abst) 824
significance of *f.* in human glomerulonephritis (abst) ... 827
Fibrosis
renal interstitial *f.*
immunocytochemical and ultrastructural study of (abst) ... 824
Fluid
simulation study on transcellular *f.* shifts induced by hemodialysis ... 542
f. transport
paracellular shunt ultrastructure and changes in *f. t.* in Necturus proximal tubule ... 610
Flumequine
ocular changes during treatment of (abst) ... 405
Furosemide
and captopril effects on BP ... 233
effects on ouabain-resistant rate constant of sodium efflux in hypertension (abst) ... 826
in familial hypocalciuric hypercalcemia ... 353
renal volume response to *f.* in renovascular hypertension (abst) ... 825
response of kidney to ... 233

Gastrointestinal system
blood loss in *g. s.* of patients on maintenance dialysis ... S16-218
Gentamicin
cortical and papillary absorptive defects in *g.* nephrotoxicity ... 526
effects on tubular obstruction in acute renal failure ... 330
reduction of RBF and proximal bicarbonate reabsorption in rats by ... 638
Glomerular basement membrane
influence of GBM width on glomerular capillary wall (abst) ... 280
proteoglycans in (abst) ... 279
Glomerular blood flow
and filtration in different nephron populations after ischemia (abst) ... 280
Glomerular capillary wall
influenced by width of glomerular basement membrane (abst) ... 280
Glomerular diseases
plasma exchange in (abst) ... 133
damaged by *p*-aminophenol ... 740
Glomerular hematuria
urine sediment in (abst) ... 135
Glomerular infiltration
during *Plasmodium yoeli* infection (abst) ... 132
Glomerular permeability
altered *g. p.* in early phase of immune complex nephritis ... 632
and polyanion in Adriamycin nephrosis ... 152
Glomerular polyanion
affected by vasoactive factor in normal rat serum (abst) ... 410
and permeability in Adriamycin nephrosis ... 152
Glomerulonephritis
antistreptococcal antibodies and (abst) ... 821
associated with scleritis (abst) ... 405
chronic *g.*
decreased capacity of serum to solubilize circulating immune complexes in patients with (abst) ... 826
de novo membranous *g.*
following renal transplantation (abst) ... 414
developed from toxic oil syndrome (abst) ... 273
human *g.*
significance of fibronectin in (abst) ... 827
immune-complex *g.*
following allogenic kidney transplantation (abst) ... 283
IgA membranoproliferative *g.*
in alcoholic liver cirrhosis (abst) ... 136
IgA mesangial deposit *g.*
renin release in (abst) ... 138
report of 56 patients observed for 10 years (abst) ... 825
malnutrition effects on ... S16-194
membranoproliferative *g.*
clinical and immunological studies of (abst) ... 274
in cirrhosis (abst) ... 131
inherited complement component deficiencies in ... 681
membranous *g.*
in the mouse ... 303
mesangial IgA *g.*
as cause of terminal renal failure (abst) ... 408
plasma exchange in drug-resistant *g.* with nephrotic syndrome (abst) ... 276
primary IgA
B and T cell function in (abst) ... 824
rapidly progressive *g.*
and granulomatous hyperplasia of gums associated with Fabry disease (abst) ... 130
thrombocytic function in (abst) ... 275
Glomerulopathy
idiopathic membranous *g.*
reticulo-endothelial function in (abst) ... 410
lupus and nonlupus membranous *g.*
pathologic differentiation between ... 377
Glomerulosclerosis, focal
in patients with unilateral nephrectomy ... 649
prevention of *f. g.* in obese Zucker rats ... S16-259

Glomerulus
autoradiographic analysis of cell renewal of *g.* cell types ... 626
g. filtration
g. f. barrier and basement membrane glycoproteins in nephrotoxic serum nephritis (abst) ... 415
GFR
affected by renal ischemia ... 620
affected by renal ischemia in nephrons ... 27
associated with fibrin ... 323
associated with ureteral obstruction ... 602
in experimental acute renal failure ... 16
in intrarenal sodium handling (abst) ... 409
role in uremic hyperprolactinemia (abst) ... 271
isolated *g.*
catabolism of histamine in *i. g.* and tubules of rat kidney ... 534
somatostatin-like immunoreactivity in ... 754
ultrafiltration in single isolated human *g.* ... 748
Glucagon
in management of uremia (abst) ... S16-335
Glucose
adaptive responses to continuous *g.* infusion in chronic renal failure ... S16-121
generation of *g.* by rat liver in uremia (abst) ... S16-330
hepatosplanchnic production of *g.* related to chronic renal failure ... S16-115
g. interorgan exchange in chronic renal failure ... S16-115
intolerance of *g.* in children with chronic renal failure ... S15-22
g. metabolism in uremia ... S16-102
secondary hyperparathyroidism and *g.* intolerance in uremic children ... S16-128
Glucose clamp technique
used to study uremic children with secondary hyperparathyroidism ... S16-128
Glucose-U-^{14}C
during peritoneal dialysis in humans (abst) ... S16-332
Glutathione
in isolated perfused rat kidney ... 178
Glycosuria, primary renal
clinical features of autoimmune thyroiditis in (abst) ... 825
Graft
cadaver kidney *g.*
associated with genetic hypertension (abst) ... 132
improved *g.* prognosis by treatment of steroid resistant rejections with ATG and plasmapheresis (abst) ... 418
rejection
lymphocyte subpopulations involved in kidney *g. r.* (abst) ... 278
survival
after renal transplantation analyzed ... 516
statistical modeling of *g. s.* ... 516
Granulocytes
symptoms and activation of *g.* and complement with two dialysis membranes ... 758
Granulomatous hyperplasia
of gums and rapidly progressive glomerulonephritis associated with Fabry disease (abst) ... 130
Growth
affected by caloric supplementation in uremic children 205
Growth cartilage
in experimental uremia ... S15-53
Growth retardation
in Supplement on children with chronic renal failure .. S15

Guanidine
g. cycle (abst) ... S16-340
Guanidinosuccinic acid
regulation of biosynthesis of *g. a.* in isolated rat hepatocytes ... S16-224

Height
prediction of adult *h.* in children with chronic renal failure ... S15-48
Hematuria
macromolecular IgA in (abst) ... 408
Hemodiafiltration
kinetic modeling for *h.* hemodialysis, and hemofiltration ... 143
versus hemofiltration (abst) ... 127
Hemodialysis
acetate and energy metabolism during ... S16-97
acute acidosis syndrome in (abst) ... 269
aluminum hydroxide effects on (abst) ... 416
aluminum treatment in (abst) ... 405
anaphylatoxin formation during ... 764, 770
and hemofiltration in systemic portal encephalopathy ... S16-67
and indomethacin used to treat uremic pericarditis ... 663
androgen therapy in nonferropenic patients on (abst) . 269
h. biocompatibility (abst) ... 404
blood lipids, plasma toxicity, and effect of systemic heparinization on patients on *h.* and CAPD (abst) ... S16-341
carnitine loss during *h.* and hemofiltration ... S16-143
chronic *h.*
carbohydrate metabolism during fasting in ... 222
cardiovascular changes in ... 371
comparison of 1 α (OH) vitamin D_3 and calcium carbonate for control of hyperparathyroidism and hyperaluminemia in patients on (abst) ... 822
hepatitis B vaccination protocols in uremic patients treated with (abst) ... 138
high sodium bicarbonate and acetate *h.* ... 240
integrated metabolic and cardiorespiratory monitoring in *c. h.* and kidney transplant patients (abst) ... S16-338
long-term effects of essential amino acids in *c. h.* patients (abst) ... S16-345
malnutrition as factor in morbidity and mortality of *h.* patients ... S16-199
nutritional assessment of *h.* patients with computer-assisted model of solute kinetics (abst) ... S16-342
protein and energy requirements in children on ... S15-6
secondary hyperparathyroidism in patients on (abst) 417
clinical features of non-A, non-B hepatitis in patients and staff of *h.* center (abst) ... 137
comparison of
cellophane and cellulose acetate membranes used in single- and two-needle vascular access systems (abst) ... 758, 420
CAPD, and cellular immunity (abst) ... 420
different dialyzer membranes used to study leukopenia and complement system in ... 775
dopaminergic control of
prolactin, sympathetic tone, and BP in (abst) ... 828
sympathetic activity and BP in (abst) ... 412
effects of
acetate and bicarbonate *h.* on cardiac function ... 782
aluminum on calcium and PTH metabolism in *h.* and CAPD (abst) ... 269

amino acid infusions on cell metabolism in *h.* patients with uremia ... S16-87
effects on active and inactive renin in nephric and anephric patients (abst) ... 422
enhanced release of granulocyte proteinases in uremic intoxication and during ... S16-27
eosinophilia and pulmonary dysfunction during cuprophan *h.* ... 246
exercise training for *h.* patients ... S16-303
Hickman catheter used as new *h.* access device for infants and small children ... 694
in lupus nephritis (abst) ... 416
in polycystic kidney disease (abst) ... 406
infection of hepatitis B virus and immune status in (abst) ... 127
kinetic modeling of *h.* hemofiltration, and hemodiafiltration ... 143
leukocyte metabolism studied in *h.* patients ... S16-93
long- and short-term *h.* effects on coronary heart disease (abst) ... 420
muscle biopsy studies done on chronic uremic patients on ... S16-187
neutrophil accumulation in pulmonary vasculature during (abst) ... 420
new thrombin inhibitor (MD-805) suitable for (abst) ... 412
non-A-non-B hepatitis in (abst) ... 272, 416
h. osteodystrophy, affected by 24,25$(OH)_2D_3$ (abst) ... 128
PTH response to hypocalcemia in ... 364
plasma and dialysate aminograms in (abst) ... S16-347
plasma and muscle levels of carnitine in (abst) ... 125
protein malnutrition in (abst) ... 405
removal of metabolites in patients on (abst) ... 124
results of short-term *h.* (abst) ... 412
risks of orally administered $Al(OH)_3$ and withdrawal (abst) ... 421
sexual disturbances among uremic women on (abst) ... 129
simulation study on transcellular fluid shifts induced by 542
triiodothyronine and thyroxin in chronic renal failure patients on ... S16-180
urea kinetic model and hemofiltration in *h.* in children (abst) ... 421
vasoactive hormones in children with chronic renal failure on ... S15-27

Hemodynamic study
of magnesium sulfate in eclampsia (abst) ... 822

Hemofiltration
and hemodialysis in systemic portal encephalopathy S16-67
carnitine loss during hemodialysis and *h.* ... S16-143
hormones removed by (abst) ... 133
kinetic modeling of *h.*, hemodialysis, and hemodiafiltration ... 143
treatment of diabetic uremic patients (abst) ... 135
urea kinetics and dietary protein intake in (abst) ... 135
versus hemodiafiltration (abst) ... 127

Hemoperfusion
kinetics of ... 487

Henoch-Schönlein glomerulonephritis
IgA_1 and IgA_2 subclasses in (abst) ... 128
plasma exchange in (abst) ... 409

Heparin
compared to new anticoagulant (MD-805) (abst) ... 412
pharmacokinetics of ... 487
use in gastrointestinal blood loss in patients on dialysis ... S16-218

Hepatectomy
used to detect catabolism ... S16-58

Hepatitis B virus
and immune status in hemodialysis (abst) ... 127
h. B. vaccination
after renal allotransplantation (abst) ... 275
protocols used in patients treated with chronic hemodialysis (abst) ... 138
h. HbS vaccination
in dialysis and uremia (abst) ... 413
in renal transplantation (abst) ... 268
non-A, non-B
clinical features of *h.* in patients and staff of hemodialysis center (abst) ... 137
in hemodialysis (abst) ... 272, 416

Hepatocytes
affected by serine, dihydroxyacetone, and pyruvate in uremia (abst) ... S16-330
regulation of biosynthesis of guanidinosuccinic acid in isolated rat *h.* ... S16-224
serine effects on gluconeogenic ability of *h.* in acute uremia ... S16-48

Heterogeneity
problem in data collection of transplantation centers .. 507

Hickman catheter
used as new hemodialysis access device for infants and small children, Technical Note on ... 694

Hippuran
predictive value of *h.* uptake in acute renal failure (abst) ... 415

Hippurate
associated with inhibitors of ligand:albumin binding ... S16-238

Histamine
catabolism of ... 534

Holter monitoring
in study of cardiac arrhythmia in chronic dialysis patients (abst) ... 821

Hormones
associated with puberty in chronic renal failure S15-34
h. profile in women on hemodialysis (abst) ... S16-335
h. reactions to intravenous potassium loading in hemodialyzed patients (abst) ... S16-335
removed by hemofiltration (abst) ... 133
vasoactive *h.*
in children with chronic renal failure ... S15-27

Hyalinosis
new syndrome of systemic familial *h.* with mesangiolysis (abst) ... 406

Hydrocortisone
effects on proximal tubular inorganic phosphate reabsorption (abst) ... 276

Hydrogen ions
metabolic production and renal disposal of ... 709

Hydroxure
manages infected stone disease (abst) ... 425

Hydroxyeicosatetrenoic acids
associated with macrophages (abst) ... 404

Hypercalcemia
familial hypocalciuric *h.*
renal calcium handling in ... 353

Hypercalciuria
cellulose phosphate test in (abst) ... 283
difference between absorptive and renal *h.* (abst) ... 136
idiopathic *h.*
ambulatory evaluation of 112 *h.* patients (abst) ... 134
magnesium excretion in (abst) ... 136
relationship of sodium intake, proximal tubular function, and calcium excretion in (abst) ... 425

role of oxalate restriction in (abst) ... 820
study of familial generalized renal hyperexcretory state ... 549
renal *h.*
absence of secondary hyperparathyroidism in most patients with ... S16-175
urinary cyclic AMP as index of parathyroid function in (abst) ... 134
Hypercatabolism
role of proteases in *h.* patients with renal failure ... S16-37
Hypercoagulability
by angiotensin converting enzyme inhibition (abst) ... 283
Hyperfiltration
selective deep nephron *h.* in uninephrectomized hypertensive rats ... 185
Hyperglycemia
in children with chronic renal failure ... S15-22
Hyperglycemic clamp
in pathogenetic studies of carbohydrate disturbances in children with chronic renal failure ... S15-22
Hyperlipidemia
patient profile and dietary therapy effects on ... S16-147
Hyperparathyroidism
aluminum in (abst) ... 820
and hyperaluminemia in patients on chronic hemodialysis (abst) ... 822
familial normocalcemic primary *h.*
study of three patients (abst) ... 822
primary *h.*
calcium-phosphorus balance postparathyroidectomy associated with (abst) ... 274
cimetidine in (abst) ... 821
secondary *h.*
absence of *s. h.* in most patients with renal hypercalciuria ... S16-175
and glucose intolerance in uremic children ... S16-128
effects on
anemia of endstage renal failure (abst) ... 417
anemia of uremia ... S16-204
in chronic hemodialysis (abst) ... 417
of chronic renal failure treated with 1-alea-hydroxycholecalciferol (abst) ... 128
Hypertension
associated with
high sodium dialysate (abst) ... 827
renin-angiotensin-aldosterone system (abst) ... 409
epidemiology of *h.* in children (abst) ... 426, 826
erythrocyte sodium-potassium co-transport in (abst) ... 422
essential *h.*
alternative treatment concept for *e. h.* with verapamil (abst) ... 280
cold pressor test effects on baroreflex in (abst) ... 127
enalapril effects on BP and renal hemodynamics in (abst) ... 427
evolutive value of factor VIII plasmatic levels in severe *e.* arterial *h.* (abst) ... 273
furosemide effects in (abst) ... 826
natriuretic factor measured in plasma of (abst) ... 821
plasma dopamine-beta-hydroxilase in *e.* and borderline partial *h.* (abst) ... 268
exercise training for hemodialysis patients ... S16-303
experimental *h.*
and chemical renal medullectomy (abst) ... 426
functional modifications of unilateral *h.* kidney disease (abst) ... 125
genetic *h.*
role of kidney in blood pressure of (abst) ... 132
hemodynamics and mechanisms of *h.* in polycystic kidney disease (abst) ... 828
in children with chronic renal failure ... S15-27
in children with endstage renal disease on CAPD . S15-101
malignant *h.*
clinical course and prognosis in group of 52 patients with (abst) ... 268
natriuretic and antihypertensive effects of potassium in 731
plasma renin activity, blood uric acid, and plasma volume in pregnancy-induced *h.* (abst) ... 422
prorenin and beta blockade in (abst) ... 426
proteinuria and enzymuria in *h.* (abst) ... 130
renal function differences between young *h.* and normotensive patients (abst) ... 129
renal function in pregnant rats with two-kidney Goldblatt *h.* (abst) ... 422
renovascular *h.*
arterial smooth muscle cell proliferation in (abst) ... 127
diagnostic and therapeutic problems in (abst) ... 129
renal volume response to furosemide in (abst) ... 825
tests with SQ 14225 in transfemoral renal angioplasty in (abst) ... 132
treated with percutaneous angioplasty (abst) ... 427
treated with percutaneous transluminal dilatation (abst) ... 279
role of
hypothalamic natriuretic-pressor substance in (abst) 273
^{99}m TcDTPA in study of renal *h.* (abst) ... 131
selective deep nephron hyperfiltration in uninephrectomized *h.* rats ... 185
separate renal kallikrein excretions in two-kidney one-clip Goldblatt *h.* rats (abst) ... 124
Hypocalcemia
absence in nephrotic rats ... 336
PTH response to *h.* in hemodialysis ... 364
Hypocomplementia
in vasculitis (abst) ... 135
Hypogeusia
uremic neuropathy and *h.* improved with dialysate zinc supplementation ... S16-315
Hypomagnesemia
as symptom of cis-platin nephrotoxicity (abst) ... 130
in diabetes mellitus (abst) ... 272
Hyponatremia
Nephrology Forum on polyuria and ... 256
Hypothalamo-pituitary-gonadal axis
in children with chronic renal failure ... S15-34
Hypothalamus
changes in *h.*, sodium excretion, and BP (abst) ... 130

^{125}I-angiotensin II
specific binding of ^{125}I-*a.* II on human blood cells (abst) ... 426
Immersion
mechanisms of improvement of water and sodium excretion by *i.* in cirrhotic patients ... 788
Immune complex
circulating
decreased capacity of serum to solubilize *c. i. c.* in patients with chronic glomerulonephritis (abst) ... 826
IgA_1 and IgA_2 subclasses in *c. i. c.* and serum immunoglobulins of Berger and Henoch-Schönlein glomerulonephritis (abst) ... 128

containing IgA_1 and IgA_2 in alcoholic liver cirrhosis (abst) ... 825
i. c. disease
complement component deficiencies in ... 681
i. c. solubilizing capacity in immunologically mediated glomerular diseases (abst) ... 827
IgA containing *i. c.*
interaction between macrophage system and IgA *i. c.* in IgA nephropathy (abst) ... 827
role in IgA nephropathy and ankylosing spondylitis (abst) ... 408
Immune deficiency
associated with protein malnutrition in hemodialysis (abst) ... 405
Immune status, host
in uremia ... 66
Immunoelectronmicroscopy
used to detect antibody population in antiserum in membranous glomerulonephritis ... 303
Immunoglobulin
IgM deposits in nephrotic syndrome (abst) ... 274
mesangial IgM deposits in nephrotic syndrome (abst) ... 131
Immunologic terms
defined in **Appendix** ... 289
Immunology
disorders of *i.* in uremia ... S16-194
i. monitoring of viral infections in renal transplantation (abst) ... 417
nutrition and renal disease effects on ... S16-194
T cell regulation, anti-idiotypic immunity, and nephritogenic immune response ... 289
Immunopathology
in chronic serum sickness ... 160
Immunoreactivity
somatostatin-like *i.* in glomerulus of rat kidney ... 754
Immunosuppression
role of reduced *i.* in renal transplantation ... 210
suppressor cells in infection-induced *i.* in pyelonephritis ... 313
Indomethacin
and potassium chloride used to treat Bartter syndrome (abst) ... 822
effects in uremic pericarditis ... 663
Infection
associated with renal transplantation and CAPD (abst) 406
Infusion technique
to measure protein degradation in uremia ... S16-102
Insulin
i. action in uremia ... S16-336
in children with chronic renal failure ... S15-22
intraperitoneal injection of *i.* during CAPD (abst) ... S16-335
i. resistance in hemodialysis and hemofiltration (abst) ... S16-A39
role of basal *i.* in phosphate transport ... 10
use of artificial beta-cell in study of *i.* in uremic diabetic patients (abst) ... S16-336
Intestine, small
precarcinogen nitrosodimethylamine in *s. i.* in chronic renal failure ... S16-229
Intratubular pressure
affected by *p*-aminophenol ... 740
Iron
affected by androgen therapy in hemodialysis (abst) ... 269
overload of *i.* related to HLA antigens in dialyzed patients (abst) ... 412
removed during CAPD with deferoxamine ... 110
Ischemia
changes in renal outer medulla after *i.* renal injury (abst) ... 283
glomerular blood flow and filtration in different nephron populations after (abst) ... 280
Ischemic renal injury
potentiation of *i. r. i.* by amino acid infusion ... 620

Kallikrein
active and inactive *k.* during low and normal sodium intake ... 714
in rabbit microdissected nephron (abst) ... 134
regulated by isolated perfused rat kidney ... 58
Kalman filter, 4 State
used in statistical analysis of renal patients ... 474
Keto acids
and amino acid supplements
as treatment in chronic uremia ... S16-285
in children with chronic renal failure ... 95
low-protein diet supplemented by *k. a.* in chronic renal failure ... S16-263
Ketone body metabolism
sites along mouse nephron (abst) ... 277
Ketosis, chronic stable
pH regulation of acid production in (abst) ... S16-339
Kinetic modeling
applied in renal and related diseases ... 487
of hemodialysis, hemofiltration, and hemodiafiltration 143
Klebsiella pneumoniae
in uremia ... 66

Leukocytes
metabolism and function of *l.* in uremia ... S16-93
Leukopenia
associated with
complement system in hemodialysis ... 775
cuprophan hollow fiber dialyzers ... 770
Life-table analyses
in effects of age on endstage renal disease patient survival ... 691
in graft survival ... 516
in hemodialysis biocompatibility (abst) ... 404
Limb
altered ascending *l.* function during potassium depletion (abst) ... 278
Limb of Henle
isolation of cells from (abst) ... 406
Lipids
l. content
dietary effects of *l. c.* on chronic renal disease ... 579
effects of different dialysis techniques on *l.* patients in chronic uremia (abst) ... S16-331
l. metabolism
compared in acute and chronic renal failure ... S16-139
imbalances of *l. m.* treated with L-carnitine (abst) ... S16-324
recent advances in factors that alter *l. m.* in chronic renal failure ... S16-134
multicenter study on *l.*-lowering effect of carnitine in hemodialysis patients (abst) ... S16-329
plasma *l.* abnormalities in children with chronic renal failure (abst) ... S16-328
Lipoproteins
l. disorders in chronic uremia (abst) ... S16-327
intravenous fat tolerance and high density *l.* in renal insufficiency (abst) ... S16-328

l. changes in CAPD (abst) S16-331
serum *l.* in patients on CAPD (abst) S16-330
LiCl
structural and functional response of toad urinary bladder to 719
Liver cirrhosis, alcoholic
IgA membranoproliferative glomerulonephritis in (abst) 136
Liver cysts
prevalance and complications of *l. c.* in adult-type polycystic kidney disease 820
Liver dysfunction
in renal transplantation (abst) 268
Loops of Henle
chloride in cells of isolated perfused rabbit thick ascending limb segments of (abst) 277
Lymphocytes
B and T *l.* function in primary IgA glomerulonephritis (abst) 824
^{111}Indium-labelled autologous *l.* in diagnosis of kidney graft rejection (abst) 269
l. subpopulations in kidney graft rejection (abst) 278
l. subsets
detected in renal graft biopsy by monoclonal antibodies (abst) 414
l. transformation
improved in patients on CAPD (abst) 411

Macrophages
adherence to isolated glomeruli (abst) 404
interaction between *m.* system and IgA immune complexes in IgA nephropathy (abst) 827
Magnesium
m. and calcium tubular handling in stone formers (abst) 132
m. excretion in idiopathic hypercalciuria (abst) 136
Magnesium sulfate
hemodynamic effects of *m. s.* in eclampsia (abst) 822
Malignancy
in uremia (abst) 131
Mathematical aids
and statistics used to evaluate data on renal patients . 474
Mathematical models
of adult patients used to predict progression of chronic renal failure in children S15-2
Mathematics in nephrology
and computing, introduction to Symposium on 433
MD-805
new anticoagulant inhibitor suitable for dialysis (abst) 412
Medical record, computerized
in nephrology 446
Membrane biocompatibility
influenced by dialysis fluid (abst) 270
Mesangiolysis
Editorial Review on 1
new syndrome of systemic familial hyalinosis with (abst) 406
Metabolism
m. and nutrition in kidney disease, Supplement on S16
abnormal norepinephrine release in uremia S16-221
absence of secondary hyperparathyroidism in most patients with renal hypercalciuria S16-175
acetate and energy metabolism during hemodialysis S16-97
acute uremia effects on protein degradation and amino acid release in rat hemicorpus S16-43
adverse effect of proteins on remnant kidney ... S16-248
alterations of serum reverse triiodothyronine and thyroxine kinetics in chronic renal failure S16-180
amino acid and keto acid supplements in treatment of chronic uremia S16-285
biosynthesis of guanidinosuccinic acid regulated in isolated rat hepatocytes and in vivo S16-224
branched-chain amino acid *m.* in chronic renal failure S16-17
calcium-ATPase activity in endstage renal disease S16-167
carnitine loss during hemodialysis and hemofiltration S16-143
chronic renal failure effects on protein synthesis in rat liver and muscle S16-23
dietary protein and progression of renal disease . S16-243
diuretic-induced azotemia S16-58
early dietary restrictions used to delay chronic renal failure S16-273
effects of
amino acid infusions on cell metabolism in hemodialyzed patients with uremia S16-87
renal substitutive programs on amino acid patterns in chronic uremia S16-77
enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis S16-27
erythropoietin and uremic toxicity during CAPD S16-208
exercise training
effects on muscle protein catabolism in uremia . S16-52
for hemodialysis patients S16-303
factors that alter lipid metabolism in chronic renal failure S16-134
gastrointestinal blood loss in patients on maintenance dialysis S16-218
glucose interorgan exchange in chronic renal failure S16-115
glucose metabolism in chronic renal failure S16-121
improved dietary treatment with low protein and phosphorus restriction in uremic rats S16-254
improvement of uremic neuropathy and hypogeusia by dialysate zinc supplementation S16-314
insulin action in uremia S16-102
intracellular amino acids in uremia in S16-9
introduction to S16-1
isolation of inhibitors of ligand:albumin from uremic body fluids and normal urine S16-238
leukocyte metabolism and function in uremia S16-93
lipid metabolism in acute renal failure S16-139
low-protein diet supplemented by keto acids in chronic renal failure S16-263
malnutrition factor in morbidity and mortality of hemodialysis patients S16-199
muscle biopsy studies in chronic uremia S16-187
muscle intracellular electrolytes in uremic patients S16-153
muscle protein turnover in uremia in S16-2
nutrition, immunology, and renal disease S16-194
nutritional requirements for CAPD patients S16-295
pathogenesis of anemia of uremia S16-204
patient profile and effect of dietary therapy on post-transplant hyperlipidemia S16-147
peritoneal ammonia effects on blood amino acid loss S16-71
plasma ammonia effects on cellular release of branched-chain amino acids in systemic portal encephalopathy S16-67

precarcinogen nitrosodimethylamine in small intestine in chronic renal failure S16-229
prevention of focal glomerulosclerosis in obese Zucker rats S16-259
ratio of PTH to 1,25 dihydroxycholecalciferol in early renal failure S16-171
recovery in postischemic acute renal failure with captopril S16-324
relationship between branched-chain amino acids and α-keto acids in blood in uremia S16-61
renal insufficiency retarded with low-protein diets S16-268
restricted phosphorus and nitrogen intake to retard chronic renal failure S16-278
role of
intracellular calcium and calmodulin in cellular metabolism S16-161
proteases in hypercatabolic patients with renal failure S16-37
secondary hyperparathyroidism and glucose intolerance in children with uremia S16-128
serine effects on gluconeogenic ability of hepatocytes in acute uremia S16-48
skeletal myopathy in uremia S16-81
three low-nitrogen diets for severely uremic children S16-290
total parenteral nutrition with high or low nitrogen intakes in acute renal failure S16-319
zinc metabolism and taste acuity in renal transplant recipients S16-310
m. production and renal disposal of hydrogen ion 709
Metabolites
removal of *m.* in chronic renal failure (abst) 124
Methylguanidine
effects of dietary factors on metabolism of (abst) .. S16-338
Beta-2-microglobulin
renal handling of *m.* in human neonate 358
Microperfusion
used to study renal cystic disease 43
Micropuncture techniques
used to study nephron function after renal ischemia ... 27
Middle molecules
studied with anion exchange chromatography 250
Mitomycin C
treatment for renal lesions (abst) 128
Monoclonal antibody
reactive with human renal basement membranes 74
Motor nerve conduction velocity
in acute renal failure 170
Muscle
biopsy studies of *m.* in chronic uremia S16-187
Muscle DNA
in malnourished humans S16-187
Muscle RNA
in malnourished humans S16-187
Myeloma
m. kidney cast nephropathy in rat model of multiple *m.* 192
Myofibroblasts
in biopsy specimens of renal interstitial fibrosis (abst) 824
Myopathy, skeletal
in uremia S16-81

National Cooperative Dialysis Study
assessment of nutritional status of (abst) S16-342
Natriuresis
in hypertension (abst) 273
in urine of salt-loaded healthy subjects (abst) 279
possible relationship between hypothalamus and (abst) 130
Natriuretic factor
measured in plasma of essential hypertension patients (abst) 821
Necturus proximal tubule
paracellular shunt ultrastructure and changes in fluid transport in 610
Neonate, human
beta-2-microglobulin in 358
Nephrectomy
unilateral
and 1,25-dihydroxyvitamin D_3 37
focal glomerulosclerosis in patients with 649
Nephritides
acute and chronic *n.*
two different diseases? (abst) 424
Nephritis
experimental anti-tubular basement membrane *n.* tubular function in (abst) 275
experimental tubulointerstitial *n.*
investigated by surface microscopy in vivo and histology (abst) 279
granulomatous interstitial
drug-induced (abst) 415
immune complex *n.*
altered glomerular permeability in early phase of 632
immune response in 289
lupus *n.*
clinical course of renal insufficiency in (abst) 416
megalocytic interstitial *n.*
cause of acute renal failure (abst) 404
mercuric chloride-induced autoimmune *n.*
suppressor cell function in (abst) 406
nephrotoxic serum *n.*
amelioration of *n. s. n.* by dietary protein restriction 595
glomerular filtration barrier and basement membrane glycoproteins in (abst) 415
passive Heymann *n.*
new pattern of *p. H. n.* defined by amonoclonal antibody (abst) 824
systemic lupus erythematosus *n.*
chronic plasma exchange in (abst) 424
Nephroangiosclerosis
29-month experience of low-protein diet, keto analogues, and weekly hemodialysis treatment in (abst) S16-348
Nephrogenic diabetes insipidus
renal prostaglandins in children with (abst) 129
Nephrolithiasis
calcium-loading test and bone disease in patients with (abst) 425
uric acid and oxalate *n.*
Nephrology Forum on 392
Nephrology Forum on
acquired distal renal tubular acidosis 807
oncogenic hypophosphatemic osteomalacia 113
polyuria and hyponatremia 256
role of renal biopsy in management of idiopathic nephrotic syndrome 561
uremic bleeding 698
uric acid and calcium oxalate nephrolithiasis 392
Nephron
damaged by ethylene glycol (abst) 415

function of whole kidney and single *n.* in gentamicin nephrotoxicity 526
kallikrein activity in (abst) 134
n. function after renal ischemia 27
selective deep *n.* hyperfiltration in uninephrectomized hypertensive rats 185
sites of ketone body metabolism along mouse *n.* (abst) 277
Nephropathy
adult, primary IgA *n.*
prognosis of *p.* IgA in 74 patients (abst) 408
analgesic *n.*
ultrasonic findings in (abst) 416
diabetic *n.*
intraperitoneal insulin regimens and (abst) 427
IgA *n.*
and ankylosing spondylitis (abst) 408
associated with ankylosing spondylitis (abst) 129
associated with scleritis (abst) 405
interaction between macrophage system and IgA immune complexes in (abst) 423, 827
mesangial IgA *n.*
risk factors of (abst) 124
primary IgA *n.*
circulating macromolecular IgA-1 and mesangial secretory component-binding IgA-1 in (abst) 408
proteinuria of (abst) 408
7-year follow-up of IgA *n.* in French region of 250,000 (abst) 137
specific polymeric IgA immune complexes in patients with (abst) 424
study of 92 children (abst) 132
tonsillar plasma-cell dysregulation in (abst) 125
IgM *n.*
considered as clinical and morphological disease entity (abst) 276
myeloma kidney cast *n.*
in rat model of multiple myeloma 192
role of interstitial fibrosis in (abst) 824
tonsillectomy in Berger disease (abst) 125
Nephronophthisis
in uremia S15-27
Nephrosis
glomerular permeability and polyanion in Adriamycin *n.* 152
postvaccination lipoid *n.*
and allergy to egg proteins (abst) 821
vitamin D metabolism in 336
Nephrotic syndrome
childhood *n. s.*
associated with diffuse mesangial hypercellularity ... 87
coagulation disorders in (abst) 822
idiopathic *n. s.*
ocular changes in *n. s.* after corticosteroid therapy (abst) 271
role of renal biopsy in management of, Nephrology Forum on 561
mesangial IgM deposits in (abst) 131
plasma exchange in drug-resistant glomerulonephritis with (abst) 276
protein/calorie balance (abst) S16-349
role of plasma vasopressin in impairment of water excretion in (abst) 423
with IgM deposits (abst) 274
Nephrotoxicity
cis-platin *n.*
hypomagnesemia associated with (abst) 130
cyclosporin *n.*
differential diagnosis of *c. n.* versus rejection by fine needle aspiration biopsy (abst) 418
enzymuria used to evaluate *c. n.* (abst) 125
gentamicin *n.*
cortical and papillary absorptive defects in 526
induced by *p*-aminophenol 740
Nervous system
central and peripheral *n. s.* affected by chronic renal failure 170
sympathetic *n. s.*
in children with chronic renal failure on hemodialysis S15-27
increase in *s. n.* activity in patients with renal failure S16-221
Net acid excretion
associated with renal disposal of hydrogen ions 709
Neuropathy, uremic
improvement of *u. n.* and hypogeusia by dialysate zinc supplementation S16-314
Nitrogen
affected by sodium bicarbonate in patients with chronic renal failure (abst) S16-330
associated with growth in children with chronic renal failure S15-6
body composition and *n.* distribution in patients on chronic dialysis (abst) S16-342
restricted phosphorus and intake to retard chronic renal failure S16-278
three low-*n.* diets for severely uremic children S16-290
total parenteral nutrition with high or low *n.* intakes in acute renal failure S16-319
Nitroprusside
used to induce modification of peritoneal mass transfer coefficients (abst) 270
Nitrosodimethylamine
precarcinogen *n.* in small intestine in chronic renal failure S16-229
Norepinephrine
abnormal *n.* release in uremia S16-221
Nutrition
and metabolism
in children on CAPD S15-106
in kidney disease, Supplement on S16
abnormal norepinephrine release in uremia S16-221
absence of secondary hyperparathyroidism in most patients with renal hypercalciuria S16-175
acetate and energy metabolism during hemodialysis S16-97
acute uremia effects on protein degradation and amino acid release in rat hemicorpus S16-43
adverse effect of proteins on remnant kidney ... S16-248
alterations of serum reverse triiodothyronine and thyroxine kinetics in chronic renal failure S16-180
amino acid and keto acid supplements in treatment of chronic uremia S16-285
as therapy in uremia S16-9
biosynthesis of guanidinosuccinic acid regulated in isolated rat hepatocytes and in vivo S16-224
branched-chain amino acid metabolism in chronic renal failure in S16-17
calcium-ATPase activity in endstage renal disease S16-167
carnitine loss during hemodialysis and hemofiltration S16-143
chronic renal failure effects on protein synthesis in

rat liver and muscle ... S16-23
dietary protein and progression of renal disease . S16-243
diuretic-induced azotemia ... S16-58
early dietary restrictions used to delay chronic renal failure ... S16-273
effects of
amino acid infusions on cell metabolism in hemodialyzed patients with uremia ... S16-87
renal substitutive programs on amino acid patterns in chronic uremia ... S16-77
enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis ... S16-27
erythropoietin and uremic toxicity during CAPD S16-208
exercise training
effects on muscle protein catabolism in uremia . S16-52
for hemodialysis patients ... S16-303
factors that alter lipid metabolism in chronic renal failure ... S16-134
gastrointestinal blood loss in patients undergoing maintenance dialysis ... S16-218
glucose interorgan exchange in chronic renal failure ... S16-115
glucose metabolism in chronic renal failure ... S16-121
improved dietary treatment with low protein and phosphorus restriction in uremic rats ... S16-254
improvement of uremic neuropathy and hypogeusia by dialysate zinc supplementation ... S16-314
insulin action in uremia ... S16-102
intracellular amino acids in uremia in ... S16-9
introduction to ... S16-1
isolation of inhibitors of ligand:albumin binding from uremic body fluids and normal urine ... S16-238
leukocyte metabolism and function in uremia ... S16-93
lipid metabolism in acute renal failure ... S16-139
low-protein diet supplemented by keto acids in chronic renal failure ... S16-263
malnutrition as factor in morbidity and mortality of hemodialysis patients ... S16-199
muscle biopsy studies in chronic uremia ... S16-187
muscle intracellular electrolytes in uremic patients ... S16-153
muscle protein turnover in uremia in ... S16-2
nutrition, immunology, and renal disease ... S16-194
pathogenesis of anemia of uremia ... S16-204
patient profile and effect of dietary therapy on post-transplant hyperlipidemia ... S16-147
peritoneal ammonia effects on blood amino acid loss ... S16-71
plasma ammonia effects on cellular release of branched-chain amino acids in systemic portal encephalopathy ... S16-67
precarcinogen nitrosodimethylamine in small intestine in chronic renal failure ... S16-229
prevention of focal glomerulosclerosis in obese Zucker rats ... S16-259
ratio of PTH to 1,25 dihydroxycholecalciferol in early renal failure ... S16-171
recovery in postischemic acute renal failure with captopril ... S16-324
relationship between branched-chain amino acids and α-keto acids in blood in uremia ... S16-61
renal insufficiency retarded with low-protein diets ... S16-268
n. requirements for CAPD patients ... S16-295
restricted phosphorus and nitrogen intake to retard chronic renal failure ... S16-278
role of
intracellular calcium and calmodulin in cellular metabolism ... S16-161
proteases in hypercatabolic patients with renal failure ... S16-37
secondary hyperparathyroidism and glucose intolerance in children with uremia ... S16-128
serine effects on gluconeogenic ability of hepatocytes in acute uremia ... S16-48
serum levels of polyamines in patients with chronic renal failure ... S16-234
skeletal myopathy in uremia ... S16-81
three low-nitrogen diets for severely uremic children ... S16-290
total parenteral nutrition with high or low nitrogen intakes in acute renal failure ... S16-319
zinc metabolism and taste acuity in renal transplant recipients ... S16-310
associated with CAPD in children with chronic renal failure ... S15-101
BASIC computer program designed to set up *n.* profile of patients (abst) ... S16-343
in idiopathic hypercalciuria ... 549
protein and energy requirements in children on chronic hemodialysis ... S15-6
related to growth in experimental uremia ... S15-53
total parenteral *n.* in severe experimental uremia (abst) ... S16-334

Obesity
associated with focal glomerulonephritis ... S16-259
Ocular changes
after corticosteroid therapy in idiopathic nephrotic syndrome (abst) ... 271
during flumequine treatment (abst) ... 405
Oral glycin
and methionin effects on urinary litogenic substances (abst) ... 419
Osteodystrophy, hemodialysis
effects of $24,25(OH)_2D_3$ on (abst) ... 128
Osteodystrophy, renal
affected by low phosphorus intake in rats with reduced renal mass (abst) ... S16-333
and aluminum (abst) ... 820
Osteomalacia
oncogenic hypophosphatemic *o.*
Nephrology Forum on ... 113
PTH response to hypocalcemia in hemodialysis patients with ... 364
Osteonecrosis
prevented after renal transplantation by vitamin D_2 (abst) ... 415
Osteopathy, symptomatic
induced by aluminum in home hemodialysis (abst) ... 279
Ouabain
affected by furosemide in hypertension (abst) ... 826
used in study to measure natriuretic factor in plasma of essential hypertensive patients (abst) ... 821
Oxalate restriction
associated with calcium restriction in idiopathic hypercalciuria (abst) ... 820
role in idiopathic hypercalciuria (abst) ... 419
Oxalosis, severe renal
and xylitol infusion (abst) ... S16-334

p-Aminophenol
role in damaging glomerular filtration ... 740

Parathyroid function
examined in idiopathic hypercalciuria S16-175
in hypercalciuria (abst) 134
PTH
affected by
cimetidine in primary hyperparathyroidism (abst) ... 821
CAPD (abst) 270
and calcium response affected by aluminum in CAPD (abst) 126
effects of aluminum on calcium and PTH metabolism in hemodialysis and CAPD (abst) 269
of uremia S16-204
response to hypocalcemia in hemodialysis 364
role of excess PTH in skeletal myopathy S16-81
serum PTH assessment in primary hyperparathyroidism and recurrent calcium nephrolithiasis (abst) 138
vascular effects of PTH after parathyroidectomy in hypertension (abst) 422
Parathyroidectomy
calcium-phosphorus balance after (abst) 274
treatment suggested by biochemical effects of (abst) ... 137
Pathogenetic mechanisms
analysis of *p. m.* in experimental acute renal failure ... 16
Patient care
role in renal transplantation 210
Patient survival
effects of age on endstage renal disease *p. s.* 691
Pediatric nephrology
amino acid and keto acid supplements in children with chronic renal failure 95
childhood nephrotic syndrome associated with diffuse mesangial hypercellularity 87
comparison of children on hemodialysis and CAPD (abst) S16-344
early CAPD in children with hemolytic uremic syndrome (abst) S16-343
epidemiology of hypertension in children (abst) 826
growth and nutrition in children
analysis of growth and food intake in uremic *c.* (abst) S16-344
dietary management of children less than 12 kg with severe renal failure (abst) S16-343
effects of caloric supplementation on growth in uremic children 205
longitudinal study of food intake in children on hemodialysis (abst) S16-343
on CAPD (abst) S16-344, 345, 345
with renal failure on low-protein diets (abst) S16-345
hemofiltration in children (abst) S16-344
Hickman catheter as new hemodialysis access device in infants and small children 694
hypertension versus normotension in (abst) 129
beta-2-microglobulin in human neonate 358
renal prostaglandins in children with nephrogenic diabetes insipidus (abst) 129
renin-angiotensin-aldosterone system in infancy and childhood (abst) 409
secondary hyperparathyroidism and glucose intolerance in uremic children S16-128
study of 92 children with Berger disease (abst) 132
Supplement on chronic renal failure in children S15
cadaveric renal transplantation in children under 6 years of age S15-111
cardiac function in children with chronic renal failure S15-77
glucose intolerance in children with chronic renal failure S15-22
growth and development of nondialyzed children with chronic renal failure S15-40
hypothalamo-pituitary-gonadal axis in children with chronic renal failure S15-34
introduction to S15-1
metabolism of orally administered branched-α-keto acids S15-11
nutritional/metabolic studies in children on CAPD S15-106
peritoneal transport in rabbits related to chronic renal failure in children S15-89
predictability of progression of chronic renal failure in children S15-2
prediction of adult height in children with chronic renal failure S15-48
protein and energy requirements in children on chronic hemodialysis S15-6
serum erythropoietin levels in 64 children with chronic renal failure S15-70
skeletal growth in experimental uremia related to children S15-53
taurine metabolism in experimental renal failure related to children S15-16
transperitoneal solute movement in children S15-95
20-month experience of CAPD in pediatric patients S15-101
vasoactive hormones in children with chronic renal failure S15-27
vitamin D metabolites in renal insufficiency and other vitamin D disorders of children S15-63
three low-nitrogen diets for severely uremic children S16-290
Perfused kidneys
glutathione in isolated *p. k.* 178
Pericarditis
uremic *p.*
treated with indomethacin 663
Peritoneal mass transfer coefficients
modification of *p. m. t. c.* induced by nitroprusside (abst) 270
Peritoneal transport
experimental observations on *p. t.* in rabbits S15-89
Peritonitis
prevented by "Y" connector in CAPD (abst) 411
treated with peritoneal dialysis (abst) 130
pH
acid pH of deionized water as cause of acute acidosis syndrome in hemodialysis (abst) 269
Phosphate
hydrocortisone effects on proximal tubular inorganic *p.* reabsorption (abst) 276
impaired energy metabolism in skeletal muscle during *p.* depletion 53
p. transport
affected by somatostatin 10
renal threshold *p.* concentration in patients with idiopathic nephrolithiasis correlations with tubular functions, serum PTH, and $1,25(OH)_2D$ (abst) 424
Phosphorus
analysis of body *p.* in uremic patients (abst) 826
dietary effects of *p.* on chronic renal disease 579
dietary restriction of low protein and *p.* in uremia . S16-254
early dietary protein and *p.* restriction used to delay chronic renal failure S16-273

pyelonephritis and infection-induced stones prevented by reducing urinary *p.* (abst) 824
restricted *p.* and nitrogen intake to retard chronic renal failure S16-278
Physical activity
and employment status of United States CAPD patients (abst) 412
Pituitary-testicular axis
in hemodialyzed uremic patients (abst) S16-336
Plasma
effect of diet *p.* acid-base composition in normal humans 670
natriuretic factor measured in *p.* of essential hypertensive patients (abst) 821
Plasma ammonia
effects on cellular release of branched-chain amino acids in systemic portal encephalopathy S16-67
Plasma dopamine-beta-hydroxylase
response of *p. d.* in hypertension (abst) 268
Plasma exchange
effects on complement-mediated functions in immunologically mediated glomerulus diseases (abst) 827
in drug-resistant glomerulonephritis with nephrotic syndrome (abst) 276
in glomerular diseases (abst) 133
in Henoch-Schönlein glomerulonephritis (abst) 409
in myeloma renal failure (abst) 131
Plasma lactoferrin
levels of *p. l.* assayed in comparison of cellophane and cellulose acetate membranes in hemodialysis 758
Plasmapheresis
single needle *p.* (abst) 138
therapy in 41 patients (abst) 134
Plasmodium yoeli
glomerular infiltration during *P. y.* infection (abst) 132
Podocytes
"foot-process fusion" of *p.* in proteinuria (abst) 276
Polyamines
serum levels of *p.* (putrescine, cadaverine, spermidine, spermine) in patients with chronic renal failure . S16-234
Polyarteritis nodosa
cyclophamide effects on peripheral T cell subsets in (abst) 273
Polycystic kidney disease
hemodialysis or transplantation as treatment of (abst) 406
hemodynamic and mechanisms of hypertension in (abst) 828
prevalence and complications of liver cysts in adult-type *p. k. d.* (abst) 820
rate of functional deterioration in (abst) 276
Polycythemia
and Bartter syndrome (abst) 822
feedback regulation of erythropoiesis in kidney transplant patients with 227
Polyuria
Nephrology Forum on *p.* and hyponatremia 256
Potassium
altered ascending limb function during *p.* depletion (abst) 278
arginine vasopressin effects on BP in *p.* deficiency 342
blunted kaliuresis after acute *p.* load in chronic renal failure 656
effects on chloride reabsorption in diluting segment of Amphiuma (abst) 281
in chronically uremic muscle S16-153
metabolism of *p.* affected by epinephrine (abst) 272
natriuretic and antihypertensive effects of *p.* in hypertension 731
Potassium citrate
and sodium citrate effects on stone-forming salts 348
Prednisone
randomized trial of high versus low oral dose post-renal transplantation (abst) S16-331
Proceedings
of the Third International Congress on Nutrition and Metabolism in Kidney Disease, September 1–4, 1982, Marseilles, France S16
Prostacyclin consumption
in hemolytic uremic syndrome, disseminated intravascular coagulation, SLE, and spontaneous abortive pathology of pregnancy (abst) 137
Prostaglandins, renal
affected by cerebro-spinal fluid sodium content (abst) . 273
associated with macrophages (abst) 404
biosynthesis of *p.* by isolated rat glomeruli (abst) 283
defective *r. p.* synthesis in hypertensive patients with morbid obesity (abst) S16-337
E_2
effects in postischemic acute renal failure (abst) 281
effects of dietary sodium on metabolism of F_2 and E_2 (abst) 126
inhibition of *r. p.* in children with nephrogenic diabetes insipidus (abst) 129
synthesis
in isolated cells and collecting tubules of rabbit kidney (abst) 282
Proteases
role in hypercatabolic patients with renal failure ... S16-37
Protein
acute uremia effects on *p.* degradation and amino acid release in rat hemicorpus S16-43
adverse effects on remnant kidney S16-243
amelioration of experimental glomerulonephritis by dietary *p.* restriction 595
and energy requirements in children on chronic hemodialysis S15-6
chronic renal failure effects on *p.* synthesis in rat liver and muscle S16-23
dietary *p.*
and progression of renal disease S16-243
early *p.* and phosphorus restriction used to delay chronic renal failure S16-273
effects of *p.* on chronic renal disease 579
low-*p.* diet supplemented by keto acids in chronic renal failure S16-263
low-*p.* diets used as therapy in renal insufficiency S16-268
restriction of low-*p.* and phosphorus in uremia S16-254
effects of
essential amino acids on *p.* in chronic renal failure in children S15-11
exercise training on muscle *p.* catabolism in uremia S16-52
p. losses during hemofiltration (abst) S16-329
p. malnutrition
in hemodialysis patients (abst) 405
muscle *p.* turnover in uremia S16-2
p. synthesis and degradation affected by insulin in uremia S16-102
Proteinases

release of granulocyte in uremic intoxication and during hemodialysis ... S16-27
Proteinuria
affected by uninephrectomy ... 185
and enzymuria in hypertension (abst) ... 130
associated with diagnosis of Fabry disease (abst) ... 405
"foot-process fusion" of podocytes in (abst) ... 276
induced by Adriamycin ... 152
of IgA nephropathy (abst) ... 408
possible development of *p.* after nephrectomy ... 649
Proteoglycans
in glomerular basement membrane (abst) ... 279
Proteus mirabillus
used to induce urinary infection (abst) ... 824
Pseudomonas aeruginosa
in uremia ... 66
Psychological development
of children with chronic renal failure ... S15-40
Puberty
development of *p.* in children with chronic renal failure ... S15-34
Pulmonary dysfunction
during cuprophan hemodialysis ... 246
Pyelonephritis
and infection-induced stones prevented by reducing urinary phosphorus (abst) ... 824
experimental *p.*
prevented by low-phosphorus diet (abst) ... S16-347
suppressor cells in ... 313
Pyridoxine
as therapy
in patients on regular dialysis therapy (abst) ... S16-346
in patients with renal calcium oxalate calculi (abst) ... 419

Receiver-operator-characteristic curve
used to evaluate renal function ... 474
Rehabilitation
exercise training for hemodialysis patients ... S16-303
Rejection
diagnosed early in renal transplantation with urinary disc-electrophoresis (abst) ... 279
fibronectin useful in detection of renal *r.* (abst) ... 827
histological-cytological monitoring in early and late *r.* crises after renal transplantation (abst) ... 278
kidney graft *r.* diagnosed with ^{111}Indium-labelled autologous lymphocytes (abst) ... 269
lymphocyte subpopulations in kidney graft *r.* (abst) ... 278
Renal amyloidosis
study of 118 patients with (abst) ... 125
Renal angioplasty, transfemoral
tests with SQ 14225 in (abst) ... 132
Renal artery
renal revascularization in 36 patients with total occlusion of (abst) ... 427
Renal artery stenosis
3-year follow-up after percutaneous transluminal dilatation of (abst) ... 279
Renal basement membranes
monoclonal antibodies reactive with human *r. b. m.* ... 74
RBF
affected by *p*-aminophenol ... 740
distribution of RBF during infusion of adenosine (abst) 272
reduction of RBF and proximal reabsorption in rats by gentamicin ... 638
Renal calcium handling
in familial hypocalciuric hypercalcemia ... 353
Renal cystic disease
induced by diphenylthiazole ... 43
Renal disease
chronic *r. d.*
role of dietary factors in ... 579
determinants of serum 1,25(OH)$_2$D levels in ... 104
dietary protein and progression of ... S16-243
endstage *r. d.* (ESRD)
carbohydrate metabolism during fasting in ... 222
chronic *ESRD*
gastrointestinal blood loss in patients on dialysis with ... S16-218
computerized medical record for patients with ... 464
effects of age on *ESRD* patient survival ... 691
effects on responsiveness to calmodulin and thyroid hormone of calcium-ATPase in human erythrocytes ... S16-167
open heart surgery in (abst) ... 413
6-month study of *ESRD* patients on unrestricted diet with protein (abst) ... S16-347
human
immune regulation in ... 289
intracellular amino acids in uremia in ... S16-9
kinetic model applied to *r.* and related diseases ... 487
muscle protein turnover in uremia in ... S16-2
nutrition and immunology in ... S16-194
patterns of serum urate levels in (abst) ... S16-339
Supplement on nutrition and metabolism in ... S16
Renal epithelium
adaptation of *r. e.* to altered dietary sulfur amino acid intake at luminal brushborder membranes ... 588
Renal failure
associated with leukocyte metabolism in uremia ... S16-93
induced by 9 hydroxy 2 methylellipticinum (abst) ... 406
nutritional requirements for CAPD patients ... S16-295
role of intracellular calcium and calmodulin in cellular metabolism in ... S16-161
selection, presentation, and interpretation of biochemical data in ... 438
Renal failure, acute
caused by megalocytic interstitial nephritis (abst) ... 404
effects of PGE_2 in postischemic *a. r. f.* (abst) ... 281
a. experimental *r. f.*
induced by cis-diamminedichloroplatinum (abst) ... S16-351
high nitrogen intake in (abst) ... S16-351
induced by gentamicin ... 638
a. ischemic
affected by preventive administration of verapamil (abst) ... 415
lipid metabolism in ... S16-139
nutrition in (abst) ... S16-351
pathologic concept of (abst) ... 278
postischemic *a. r. f.*
captopril effects on ... S16-324
predictive value of hippuran uptake in (abst) ... 415
renal tubular obstruction in ... 330
role of proteases in hypercatabolic patients with ... S16-37
total parenteral nutrition with high or low nitrogen intakes in ... S16-319
Renal failure, chronic
acceptance of protein and amino acid diets by patients with (abst) ... S16-350
acidosis and glycosylated hemoglobin in (abst) ... S16-338
aluminum in joint tissues of patients with (abst) ... 405
amino acid and keto acid supplements in children with 95

as cause of death in malignant hypertension (abst) 268
blunted kaliuresis after acute potassium load in 656
branched-chain amino acid metabolism in S16-17
branched-chain keto acids in nutritional therapy of (abst) S16-350
comparison between essential amino acid- and keto-acid-substituted diet in (abst) S16-350
dietary restriction of low protein and phosphorus in uremia in S16-254
early dietary protein and phosphorus restriction used to delay chronic renal failure S16-273
effective aluminum free intestinal phosphate binder in (abst) 417
effects on
central and peripheral nervous system 170
protein synthesis in rat liver and muscle S16-23
erythropoietin and uremic toxicity during CAPD in S16-208
essential amino acid supplementation in (abst) S16-348
evaluation of
dietary treatment in predialysis patients (abst) .. S16-346
nutritional therapy in (abst) S16-348
factors that alter lipid metabolism in S16-134
glucose interorgan exchange in S16-115
glucose metabolism in S16-121
low-protein diet supplemented by keto acids in ... S16-263
humoral immunodepression in (abst) 413
keto acid treatment effects on residual renal function in (abst) S16-350
lactulose in (abst) S16-341
low protein diet supplemented by keto acids in (abst) S16-348
multicenter study of 105 patients with cystinosis in Federal Republic of Germany (abst) 277
precarcinogen nitrosodimethylamine in small intestine in S16-229
removal of metabolites in (abst) 124
restricted phosphorus and nitrogen intake to retard chronic renal failure S16-278
role of insulin resistance in glucose intolerance of uremia in S16-102
serum levels of polyamines in patients with chronic renal failure S16-234
skeletal myopathy in uremia in S16-81
Supplement on chronic renal failure in children S15
cadaveric renal transplantation in children under 6 years of age S15-111
cardiac function in experimental uremia associated with chronic renal failure in children S15-83
cardiac function of children with S15-77
glucose intolerance in children with S15-22
growth and development of nondialyzed children with S15-40
hypothalamo-pituitary-gonadal axis in children with S15-34
introduction to S15-1
metabolism of orally administered branched-chain α-keto acids S15-11
nutritional/metabolic studies in children with chronic renal failure on CAPD S15-106
peritoneal transport in rabbits related to children with S15-89
predictability of progression of S15-2
prediction of adult height in children with S15-48
protein and energy requirements in children on chronic hemodialysis S15-6
serum erythropoietin levels in 64 children with... S15-70
taurine metabolism in experimental chronic renal failure S15-16
transperitoneal solute in children with S15-95
20-month experience of CAPD in children with . S15-101
vasoactive hormones in children with S15-27
vitamin D metabolites in *c. r. f.* and other vitamin D disorders of children S15-63
treated with 1-alea-hydroxycholecalciferol (abst) 128
triiodothyronine and thyroxine kinetics in S16-180
Renal failure, diabetic
renal and pancreatic transplantation in treatment of (abst) 428
treated with protein-reduced diet in (abst) S16-346
Renal failure, early
ratio of PTH to 1,25 dihydroxycholecalciferol in .. S16-171
Renal failure, endstage
e. chronic *r. f.*
and uremic pericarditis treated with indomethacin... 663
in report on regular dialysis and transplantation in Europe XIII, 1982, Parts I, II, and III (abst) 411
low-protein diets used to retard S16-337
secondary hyperparathyroidism effects on anemia of (abst) 417
use of European Registries in treatment of 507
Renal failure, experimental
e. acute *r. f.*
theoretical analysis of pathogenetic mechanisms in . 16
induced by ligation of ureters S15-89
taurine metabolism in S15-16
Renal failure, ischemic acute
role of amino acids to sensitive kidneys to 620
Renal failure, moderate
congestive cardiomyopathy with *m. r. f.* treated with CAPD (abst) 136
Renal failure, myeloma
plasma exchange in (abst) 131
Renal failure, polyuric acute
induced for study of gentamicin nephrotoxicity 526
Renal failure, terminal
caused by mesangial IgA glomerulonephritis (abst) 408
increase in serum potassium caused by beta-2 adrenergic blockade in (abst) 427
Renal function
impact of age on effects of ureteral obstruction on 602
Renal glucosuria
questioned as a benign condition (abst) 427
Renal ischemia
nephron function after 27
Renal kallikrein
r. k. excretions in two-kidney one-clip Goldblatt hypertensive rats (abst) 124
Renal lesions
in patients treated with mitomycin C (abst) 128
Renal net acid excretion
associated with effect of diet on plasma acid-base composition 670
Renal osteodystrophy
diagnosed with bone scintigraphy (abst) 126
Renal outer medulla
changed after ischemic renal injury (abst) 283
Renal parenchymal diseases
diagnosed by modified open kidney biopsy technique . 804
Renal patients
mathematical/statistical aids to evaluate data from 474
Renal radionuclide investigation
of urinary tract obstruction (abst) 407

Renal release
in IgA mesangial deposit glomerulonephritis (abst) 138
regulated by isolated perfused rat kidney..... 58
Renal stone disease
dietary animal protein and urinary supersaturation in (abst) 419
Renal stone formers
calcium and magnesium tubular handling in (abst)..... 132
Renal toxicity
of 9 hydroxy 2 methylellipticinum (abst) 406
Renal tubular acidosis
treatment of renal lithiasis associated with (abst)..... 425
Renal tubular obstruction
effects on stop-flow pressure and glomerular deposition of fibrin 323
role in acute renal failure..... 330
Renal venulitis
in vasculitis (abst)..... 135
Renin-angiotensin system
clipped kidney of rat during and after blockade of *r.-a. s.* (abst)..... 277
inhibited by captopril in postischemic acute renal failure S16-324
Renin-angiotensin-aldosterone system
in infancy and childhood (abst) 409
role of dopaminergic receptors in regulation of (abst) . 826
Restenosis
of renal artery after percutaneous transluminal angioplasty (abst) 423
Reticulo-endothelial function
in systemic lupus erythematosus, Wegener disease, and idiopathic membranous glomerulopathy (abst) 410
Retransplantation, renal
prognostic factors at *r. r.* at Swedish center, 1969 to 1980 (abst)..... 418
Rupture
in renal allograft (abst)..... 268

Scandiatransplant
computerized methodologies used in..... 507
Scleritis
associated with IgA nephropathy or glomerulonephritis (abst) 405
Serine
effects on gluconeogenic ability of hepatocytes in acute uremia S16-48
role in glycogen metabolism in acute uremia (abst) S16-331
Serum
decreased capacity of *s.* to solubilize circulating immune complexes in patients with chronic glomerulonephritis (abst)..... 826
vasoactive factor in normal rat *s.* effects on glomerular polyanion (abst)..... 410
Serum albumin
in glomerular permeability..... 632
Serum erythropoietin
s. e. levels in 64 children with chronic renal failure. S15-70
Serum hPRL
in uremic hyperprolactinemia (abst) 271
Serum sickness
chronic *s. s.* immunopathology in 160
cortical infarction in *s. s.* after cyclosporin A treatment (abst) 416
Sexual disturbances
among uremic women on hemodialysis (abst)..... 129
Shunt
effects of peritoneo-venous LeVeen's *s.* in sodium tubular handling in cirrhosis (abst) 271
Skeletal growth
in experimental uremia..... S15-53
Skeletal muscle
impaired energy metabolism in *s. m.* during phosphate depletion 53
Skin test
as index for pretransplant transfusions (abst) 418
Sodium
active and inactive kallikrein during low and normal *s.* intake..... 714
and water management affected by captopril in cirrhosis (abst) 271
s. balance
affected by captopril..... 233
s.-dependent transcellular water shift during dialysis (abst) 820
effects of peritoneo-venous LeVeen's shunt in *s.* tubular handling of cirrhotic patients (abst)..... 271
effects of progressive dietary *s.* restriction on uremic acidosis (abst) 410
in idiopathic hypercalciuria..... 549
intrarenal *s.* handling in Dahl "R" and "S" rats (abst) 409
mechanisms of improvement of water and *s.* excretion by immersion in cirrhotic patients..... 788
response of plasma dopamine-beta-hydroxylase to *s.* depletion in hypertension (abst)..... 268
s. transport system
s. convective *t.* related to Donnan effect (abst) 133
s.-dependent *t. s.* used to transport taurine into membrane vesicles 588
in ultrastructure of Necturus proximal tubule..... 610
urinary excretion of *s.*
affected by cerebro-spinal fluid *s.* content (abst) 273
in cirrhotic patient before and after peritoneovenous shunt insertion (abst) 821
Sodium citrate
and potassium citrate effects on stone-forming salts ... 348
Sodium, dietary
effects on renal PGE_2 and PGF_2 metabolism (abst) 126
Sodium ion
in hemodialysis 542
Solute kinetics
small *s. k.* in CAPD (abst)..... 270
Somatostatin
effects on phosphate transport 10
s.-like immunoreactivity in glomerulus of rat kidney... 754
Southwest Pediatric Nephrology Study Group
report on childhood nephrotic syndrome associated with diffuse mesangial hypercellularity..... 87
SQ 14225
used to perform tests in transfemoral renal angioplasty (abst) 132
Steroid therapy
in childhood nephrotic syndrome..... 87
Stone-forming salts
potassium citrate and sodium citrate effects on 348
Stop-flow pressure
affected by renal tubular obstruction..... 323
Sulphur amino acid
renal adaptation to altered dietary *s. a. a.* intake at luminal brushborder membrane..... 588
Systemic amyloidosis
renal involvement in (abst) 423

Systemic lupus erythematosus
reticulo-endothelial function in (abst) 410

T cell function
associated with anti-idiotypic immunity and nephritogenic immune response 289
T cell subsets, peripheral
affected by cyclophosphamide in polyarteritis nodosa (abst) 273
^{99}m TcDPTA
used to study renal hypertension (abst) 131
Taste
zinc metabolism and *t.* acuity in renal transplant recipients S16-310
Taurine
metabolism of *t.* in experimental renal failure S15-16
Thiazides
used to prevent recurrent idiopathic renal calcium oxalate stones (abst) 426
Thrombin
used to induce intravascular coagulation 323
Thrombocytes
activity in glomerulonephritis (abst) 275
Thromboxane
in hemodialysis biocompatibility (abst) 404
Thyroid hormone
goiter and circulating *t. h.* levels in dialyzed uremic patients (abst) S16-335
reduced serum concentration of *t. h.* in chronic renal failure (abst) S16-336
Thyroiditis, symptomless autoimmune
in primary renal glycosuria (abst) 825
Thyroxine
kinetics of *t.* in chronic renal failure S16-180
Tissue
in situ *t.* impedance studies of renal electrolyte gradient 800
TMR data system
in nephrology 446
Tonsillectomy
in Berger disease (abst) 125
Toxemia
effects of head-out water immersion on renin-angiotensin-aldosterone system, vasopressin, and BP in women with late pregnancy *t.* (abst) 426
Toxic oil syndrome
renal involvement in (abst) 273
Transperitoneal movement
of solute and water in children with endstage renal disease S15-95
Transplantation, renal
analysis of graft survival after 516
and CAPD (abst) 406
as treatment of polycystic kidney disease (abst) 406
associated with
humoral immunodepression (abst) 413
mesangial IgA nephropathy (abst) 408
B ymphocyte antibodies developed after (abst) 269
cadaveric *r. t.*
in children under 6 years of age S15-111
compared to dialysis in study of effects of age on end-stage renal disease patient survival 691
computerized clinical data for 455
cyclosporin A used to treat (abst) 280
de novo membranous glomerulonephritis after (abst) . 414
different prednisolone pharmacokinetics in cushingoid and noncushingoid *r. t.* recipients (abst) 418
effects on amino acid patterns in chronic uremia S16-1
factors to improve graft survival in 210
feedback regulation of erythropoiesis in *r. t.* patients with polycythemia 227
graft function loss with *r. t.* artery stenosis after captopril treatment (abst) 414
histological-cytological monitoring in early and late rejection crises after (abst) 278
hyperimmune immunoglobulin therapy for cytomegalovirus infections in (abst) 417
immunological monitoring of viral infections in (abst) . 417
in situ formation of immune-complex glomerulonephritis after allogenic *r. t.* (abst) 283
interleukin-2 production after blood transfusions in prospective *r. t.* recipients (abst) 418
liver dysfunction in (abst) 268
metabolic patterns after (abst) S16-340
osteonecrosis after *r. t.* prevented with vitamin D_2 (abst) 415
patient profile and dietary therapy effects on post-*t.* hyperlipidemia S16-147
prognostic significance of vascular changes in (abst) ... 281
report on regular dialysis and *t.* in Europe XIII, 1982, Parts I, II, and III (abst) 411
study of 300 consecutive *r. t.* 210
ultrasound detects obstructed ureter in (abst) 414
urinary disc-electrophoresis used to diagnose rejection of (abst) 279
vitamin D metabolites in hypercalcemic and hypophosphatemic adults after (abst) 421
zinc metabolism and taste acuity in *r. t.* recipients S16-310
Transplantectomy
indications and hazards of (abst) 272
Triiodothyronine
alterations of serum reverse *t.* in chronic renal failure S16-180
Trypsin
effects on kallikrein activity 58
Tryptophan
serum protein binding by metabolites of (abst) S16-337
Tubular function
effects of ureteral obstruction on proximal and distal *t. f.* 602
in experimental antitubular basement membrane nephritis (abst) 275
Tubules
active and inactive kallikrein in rabbit connecting *t.* and urine 714
catabolism of histamine in isolated glomeruli and *t.* of rat kidney 534
collecting *t.*
prostaglandin synthesis in isolated cells and *c. t.* of rabbit kidney (abst) 282
proximal
human kidney *p. t.* affected by cis-platinum (abst) .. 131
Tubuloglomerular feedback
responses unaffected by captopril (abst) 282
Tubulointerstitial disease
renal handling, plasma potassium, and aldosterone responses to potassium loading evaluated in 656

Ultrafiltration
in single isolated human glomeruli 748

Ultrasound
findings in analgesic nephropathy (abst) ... 416
u. study of renal volume response to furosemide in renovascular hypertension (abst) ... 825
used to detect obstructed ureter in renal transplantation (abst) ... 414
Uninephrectomy
effects on nephron hemodynamics and proteinuria in hypertension ... 185
United Kingdom Transplant Service
computerized methodologies in ... 507
Urea
u. cycle
associated with guanidinosuccinic acid ... S16-224
individual determinants of *u.* generation rate (abst) S16-327
u. kinetics
and dietary protein in hemofiltration (abst) ... 135
u. k. model
described ... 487
used to evaluate nutritional status of 120 hemodialysis patients ... S16-199
u. permeability
affected by vasopressin ... 719
Uremia
abnormal norepinephrine release in ... S16-221
acute *u.*
effects on protein degradation and amino acid release in rat hemicorpus ... S16-43
metabolic changes in rats with *a. u.* after potassium depletion (abst) ... S16-329
serine effects on gluconeogenic ability of hepatocytes in ... S16-48
analysis of body phosphorus in (abst) ... 826
associated with malignancy (abst) ... 131
beta adrenergic modulation of potassium in (abst) ... 272
chronic *u.*
amino acid infusions used to correct cellular protein synthesis, amino acids, and energy levels in (abst) ... S16-339
biopterin metabolism in (abst) ... 138
effects of renal substitute programs on amino acid patterns in ... S16-77
low-protein diet for *c. u.* patients (abst) ... S16-346
muscle biopsy studies in ... S16-187
supplements containing amino acids and keto acids in treatment of ... S16-285
dietary restrictions of low protein and phosphorus in ... S16-254
effects of
amino acid infusions on cell metabolism in hemodialyzed patients with ... S16-87
caloric supplementation on growth in uremic children 205
exercise training on muscle protein catabolism in S16-52
u. and dietary protein on small intestinal dipeptidase and disaccharidase activities (abst) ... S16-340
vaccination schedule and dialysis on HbS vaccination response in (abst) ... 413
experimental *u.*
cardiac function in ... S15-83
skeletal growth in ... S15-53
host immune status in ... 66
hypofibrinolysis as risk factor in (abst) ... 133
insulin action in ... S16-102
insulin resistance in (abst) ... 427
intracellular amino acid concentration in (abst) ... S16-341
intracellular amino acids in ... S16-9
low-protein diet and supplements in essential amino acids or keto analogues in (abst) ... S16-328
metabolism and function of leukocytes in ... S16-93
muscle intracellular electrolytes in *u.* patients ... S16-153
muscle protein turnover in ... S16-2
pancreatic exocrine function in *u.* patients on regular dialysis (abst) ... S16-339
pathogenesis of anemia of ... S16-204
pharmacokinetics of trimethoprim and sulfamethoxazole in (abst) ... S16-340
relationship between branched-chain amino acid and α-keto acids in blood in ... S16-61
release of granulocyte proteinases in *u.* intoxication and during hemodialysis ... S16-27
role of low-protein diet, essential amino acids, and keto analogues in (abst) ... S16-348
sexual disturbances among *u.* women on hemodialysis (abst) ... 129
skeletal myopathy in uremia ... S16-81
taurine content of liver, brain, heart, and skeletal muscle in acute and chronic *u.* ... S15-16
terminal *u.*
erythrocyte glyceraldehydephosphate dehydrogenase activity in (abst) ... S16-339
three low-nitrogen diets for severely *u.* children ... S16-290
treated with dietary fiber (abst) ... S16-347
Uremic acidosis
progressive dietary salt restriction effects on (abst) ... 410
Uremic bleeding
Nephrology Forum on ... 698
Uremic encephalopathy
associated with computer methods and dialysis ... 496
Uremic hyperprolactinemia
serum hPRL and size heterogeneity in (abst) ... 271
Uremic hypofibrinolysis
as increased risk for vascular access survival (abst) ... 133
Uremic pericarditis
treated with indomethacin ... 663
Uremic toxicity
and erythropoietin during CAPD ... S16-208
inhibitors of ligand:albumin binding related to ... S16-238
Ureogenic lithiasis
acetohydroxamic acid in treatment of (abst) ... 124
Ureter
ultrasound detects obstructed *u.* in renal transplantation (abst) ... 414
Ureteral obstruction
impact of age on effects of *u. o.* on renal function ... 602
Urinary bladder
structural and functional response of toad *u. b.* to LiCl 719
Urinary calculi
placebo versus allopurinol for (abst) ... 419
Urinary cytology
used to diagnose acute allograft rejection (abst) ... 284
Urinary disc-electrophoresis
used to make early diagnosis of transplant rejection (abst) ... 279
Urinary tract obstruction
renal radionuclide investigation of (abst) ... 407
Urine
active and inactive kallikrein in rabbit connecting tubules and *u.* ... 714
physico-chemical studies of *u.* by computer system (abst) ... 134
Urine sediment
in glomerular hematuria (abst) ... 135

Urolithiasis, idiopathic calcium
biochemical assays and crystalluria study used to follow-up *i. c. u.* (abst) 127

Vascular changes
significance in renal transplants (abst) 281
Vascular damage
and coagulation and fibrinolytic pathways as factors in Berger glomerulonephritis (abst) 137
Vasculitis, hypocomplementemic urticarial
with glomerulopathy and renal venulitis (abst) 135
Vasoactive drugs
effects on peritoneal transport in experimental renal failure S15-89
Vasopressin
effects on physiological and morphological response of toad urinary bladder 719
Verapamil
offers alternative treatment for essential hypertension (abst) 280
preventive *v.* on acute ischemic renal failure in dogs (abst) 415
Viral infections
monitored immunologically in renal transplantation (abst) 417
Vitamin B_6
deficiency of B_6 in uremia (abst) S16-329
Vitamin D
D_2
prevents osteonecrosis after renal transplantation (abst) 415
effects of chronic metabolic acidosis on *v. D* metabolism in humans 644
in experimental uremia S15-53
metabolism of *v. D*
abnormalities in *v. D m.* in skeletal myopathy uremia S16-81
in nephrotic rats 336
v. D metabolites
in renal insufficiency and other *v. D* disorders of children S15-63
1α (OH) vitamin D_3 and calcium carbonate compared as treatment for hyperparathyroidism and hyperaluminemia (abst) 822
$1\alpha,25(OH)_2D$
intestinal absorption and serum half-life of (abst) S16-336
1,25 dihydroxycholecalciferol
ratio of PTH to 1,25 *d.* in early renal failure S16-171
1,25-dihydroxyvitamin D_3
and unilateral nephrectomy 27
$1,25\text{-}(OH)_2\text{-D}$
bone resorption stimulated by elevated *v. D* concentrations 555
$1,25(OH)_2D$
determinants of serum $1,25(OH)_2D$ levels in renal disease 104
$24,25(OH)_2D_3$
effects on hemodialysis osteodystrophy (abst) 128
24R,25-dihydroxyvitamin D_3 extrarenal formation of (abst) 274

Water
mechanisms of improvement of *w.* and sodium excretion by immersion in cirrhotic patients 788
sodium-dependent transcellular *w.* shift during dialysis (abst) 820
Wegener disease
reticulo-endothelial function in (abst) 410
Weight
as factor in renal transplantation for children under 6 years of age S15-111

"Y" connector system
used to prevent peritonitis in CAPD (abst) 411

Zinc
improvement of uremic neuropathy and hypogenusia by dialysate *z.* supplementation S16-315
z. metabolism and taste acuity in renal transplant recipients S16-310



KIDNEY INTERNATIONAL

Volume 24, Number 1, July 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Mesangiolysis. *Takashi Morita and Jacob Churg* 1

LABORATORY INVESTIGATION

Effects of somatostatin on phosphate transport: Evidence for the role of basal insulin. *Kai Lau, Jay Guntupalli, and Bonnie Eby* 10

Theoretical analysis of pathogenetic mechanisms in experimental acute renal failure. *Donald E. Oken* 16

Disparity between surface and deep nephron function early after renal ischemia. *June Mason, Johanna Welsch, and Toshikazu Takabatake* 27

Unilateral nephrectomy and 1,25-dihydroxyvitamin D_3. *Carol M. Taylor, Joseph Caverzasio, André Jung, Ulrich Trechsel, Herbert Fleisch, and Jean-Philippe Bonjour* 37

Renal cystic disease induced by diphenylthiazole. *Kenneth D. Gardner, Jr., and Andrew P. Evan* .. 43

Impaired energy metabolism in skeletal muscle during phosphate depletion. *Nachman Brautbar, Christopher Carpenter, Ryszard Baczynski, Ricardo Kohan, and Shaul G. Massry* 53

Regulation of kallikrein and renin release by the isolated perfused rat kidney. *Jiro Misumi, François Alhenc-Gelas, Michel Marre, Jeanine Marchetti, Pierre Corvol, and Joel Menard* 58

Host immune status in uremia. V. Effect of uremia on resistance to bacterial infection. *Isabel A. Clarke, Douglas J. Ormrod, and Thomas E. Miller* 66

Monoclonal antibodies to human renal basement membranes: Heterogenic and ontogenic changes. *Alfred F. Michael, Ji-Yun Yang, Ronald J. Falk, Martha J. Bennington, Jon I. Scheinman, Robert L. Vernier, and Alfred J. Fish* 74

CLINICAL INVESTIGATION

Childhood nephrotic syndrome associated with diffuse mesangial hypercellularity. A report of the Southwest Pediatric Nephrology Study Group 87

Oral essential aminoacid and ketoacid supplements in children with chronic renal failure. *Robert Jones, Neil Dalton, Charles Turner, Kathryn Start, George Haycock, and Cyril Chantler* 95

Determinants of serum $1,25(OH)_2D$ levels in renal disease. *Alfred K. Cheung, Stavros C. Manolagas, Bayard D. Catherwood, Coleman A. Mosely, Jr., John A. Mitas II, Roland C. Blantz, and Leonard J. Deftos* 104

TECHNICAL NOTE

Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine. *Ronald J. Falk, William D. Mattern, Roger W. Lamanna, Hillel J. Gitelman, Nancy C. Parker, Robert E. Cross, and John R. Rastall* 110

NEPHROLOGY FORUM

Oncogenic hypophosphatemic osteomalacia. *Zalman S. Agus* 113

ABSTRACTS

Joint meeting of the Italian, Spanish, and French Societies of Nephrology, Lyon, France, October 22–23, 1982 124

ANNOUNCEMENTS 140

KIDNEY INTERNATIONAL

Volume 24, Number 2, August 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Kinetic modeling of hemodialysis, hemofiltration, and hemodiafiltration. *Kuno Bernt Gerhard Sprenger, Werner Kratz, Anthony Evan Lewis, and Ulrich Stadtmüller* 143

LABORATORY INVESTIGATION

Glomerular permeability and polyanion in Adriamycin nephrosis in the rat. *Jan J. Weening and Helmut G. Rennke* 152

Relationship of kidney function to immunopathology in chronic serum sickness of rats. *Judith B. Van Liew, Jan R. Brentjens, and Bernice Noble* 160

Central and peripheral nervous system effects of chronic renal failure. *Cynthia A. Mahoney and Allen I. Arieff* 170

Selective glutathione depletion on function and structure of the isolated perfused rat kidney. *Mayer Brezis, Seymour Rosen, Patricio Silva, and Franklin H. Epstein* 178

Selective deep nephron hyperfiltration in uninephrectomized spontaneously hypertensive rats. *Norman Bank, Lloyd Alterman, and Hagop S. Aynedjian* 185

Myeloma kidney cast nephropathy in a rat model of multiple myeloma. *Peter Smolens, Manjeri Venkatachalam, and Jay H. Stein* 192

CLINICAL INVESTIGATION

Effects of caloric supplementation on growth in children with uremia. *Watson C. Arnold, Darla Danford, and Malcolm A. Holliday* 205

Factors contributing for improved graft survival in recipients of kidney transplants. *K. Venkateswara Rao, Robert C. Andersen, and Timothy J. O'Brien* 210

Carbohydrate metabolism during fasting in chronic hemodialysis patients. *Steven L. Dumbauld, Edwin A. Rutsky, and Huey G. McDaniel* 222

Deficient feedback regulation of erythropoiesis in kidney transplant patients with polycythemia. *Frank Thevenod, Heinz W. Radtke, Peter Grützmacher, Elisabeth Vincent, Karl-M. Koch, Wilheim Schoeppe, and Winfried Fassbinder* 227

Response of the kidney to furosemide. II. Effect of captopril on sodium balance. *Ralph A. Kelly, Christopher S. Wilcox, William E. Mitch, Timothy W. Meyer, Paul F. Souney, Carolyn M. Rayment, Paul A. Friedman, and Stephen L. Swartz* 233

High sodium bicarbonate and acetate hemodialysis: Double-blind crossover comparison of hemodynamic and ventilatory effects. *William L. Henrich, Terry D. Woodard, Barry D. Meyer, Timothy R. Chappell, and Lewis J. Rubin* 240

TECHNICAL NOTES

Eosinophilia and pulmonary dysfunction during Cuprophan hemodialysis. *Edward A. Michelson, Leonard Cohen, Rand E. Dankner, and Anthony Kulczycki, Jr.* 246

Anion exchange chromatography and double-diffusion cells for the study of middle molecules. *Stephen R. Ash, Zindoga T. J. Bungu, and Fred E. Regnier* 250

NEPHROLOGY FORUM

A patient with polyuria and hyponatremia. *Rex L. Jamison* 256

ABSTRACTS

Spanish Society of Nephrology, Alicante, Spain, November 28–December 1, 1982 268

German-speaking Society of Nephrology, Basel, Switzerland, September 12–15, 1982. 275

ANNOUNCEMENTS 285

Indexed in Current Contents, SCI, ASCA, and ISI/BIOMED

KIDNEY INTERNATIONAL

Volume 24, Number 3, September 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

T cell regulation, anti-idiotypic immunity, and the nephritogenic immune response. *Eric G. Neilson and Bruce Zakheim* 289

LABORATORY INVESTIGATION

Membranous glomerulonephritis in the mouse. *Karel J. M. Assmann, Martina M. Tangelder, Will P. J. Lange, Thea M. Tadema, and Robert A. P. Koene* 303

Infection-induced immunosuppression in pyelonephritis: Characteristics of the suppressor cell(s). *Thomas E. Miller, Elaine Marshall, and Jan Nelson* 313

Effect of renal tubular obstruction on stop-flow pressure and glomerular deposition of fibrin during intravascular coagulation in the rat. *Erik Ståhl, Ulf Boberg, Lars Larsson, Lennart Rammer, and A. Erik G. Persson* 323

Role of tubular obstruction in acute renal failure due to gentamicin. *Joel Neugarten, Hagop S. Aynedjian, and Norman Bank* 330

Vitamin D metabolism in nephrotic rats. *Yuk-Luen Chan, Rebecca S. Mason, Marc Parmentier, Elliott Savdie, Dianne Lissner, and Solomon Posen* 336

Role of vasopressin in support of blood pressure in potassium deficient rats. *Mark S. Paller and Stuart L. Linas* 342

CLINICAL INVESTIGATION

Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. *Khashayar Sakhaee, Michael Nicar, Kathy Hill, and Charles Y. C. Pak* 348

Renal calcium handling in familial hypocalciuric hypercalcemia. *Hiroko Watanabe and Roger A. L. Sutton* 353

Renal handling of beta-2-microglobulin in the human neonate. *William D. Engle and Billy S. Arant, Jr.* 358

Parathyroid hormone response to hypocalcemia in hemodialysis patients with osteomalacia. *Dennis Andress, Arnold J. Felsenfeld, Anne Voigts, and Francisco Llach* 364

Cardiovascular changes in chronic hemodialysis patients. *Hamid Ikram, Kelvin L. Lynn, Ross R. Bailey, and Peter J. Little* 371

Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. *J. Charles Jennette, Samy S. Iskandar, and Frederic G. Dalldorf* 377

TECHNICAL NOTE

Animal model to study the effect of adrenal hormones on epithelial function. *Rodolfo S. Martin, Wil J. Jones, and John P. Hayslett* 386

NEPHROLOGY FORUM

Uric acid and calcium oxalate nephrolithiasis. *Fredric L. Coe* 392

ABSTRACTS

French Society of Nephrology, Paris, France, January 26, 1983 404

Dutch Society of Nephrology, Gent, Belgium, March 5, 1983 408

XX Congress of the European Dialysis and Transplant Association, London, England, June 19–22, 1983 411

ANNOUNCEMENTS 429

Indexed in Current Contents, SCI, ASCA, and ISI/BIOMED

KIDNEY INTERNATIONAL

Volume 24, Number 4, October 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

SYMPOSIUM ON COMPUTING IN CLINICAL NEPHROLOGY

Introduction: Computing, mathematics, and the nephrologist. *Martin S. Knapp* 433

Introduction: Evolution of technology brings computers to the bedside. *William W. Stead* 436

Selection, presentation, and interpretation of biochemical data in renal failure. *D. Brian Morgan and Eric J. Will* 438

Practicing nephrology with a computerized medical record. *William W. Stead, Leland E. Garrett, Jr., and William E. Hammond* 446

Experience in the computer handling of clinical data for dialysis and transplantation units. *Michael Gordon, J. Conrad Venn, Peter E. Gower, and Hugh E. de Wardener* 455

Computerization of the medical record: Use in care of patients with endstage renal disease. *Victor E. Pollak* 464

Mathematical and statistical aids to evaluate data from renal patients. *Martin S. Knapp, Adrian F. M. Smith, Ian M. Trimble, Roy Pownall, and Kerry Gordon* 474

Kinetic modeling: Applications in renal and related diseases. *Peter C. Farrell* 487

Computer methods, uremic encephalopathy, and adequacy of dialysis. *John R. Bourne and Paul E. Teschan* 496

Evolving methodologies in computerized European Registries. *Antony J. Wing, Joe D'Amaro, Lars U. Lamm, and Neville H. Selwood* 507

Graft survival after renal transplantation: Agenda for analysis. *Sheila M. Gore* 516

LABORATORY INVESTIGATION

Cortical and papillary absorptive defects in gentamicin nephrotoxicity. *Robert Safirstein, Peter Miller, and Thomas Kahn* 526

Catabolism of histamine in the isolated glomeruli and tubules of the rat kidney. *Hanna E. Abboud* 534

CLINICAL INVESTIGATION

A simulation study on transcellular fluid shifts induced by hemodialysis. *Genjiro Kimura, John C. Van Stone, John H. Bauer, and Prakash R. Keshaviah* 542

Idiopathic hypercalciuria: A familial generalized renal hyperexcretory state. *Mordechay Aladjem, Michaela Modan, Ayala Lusky, Rina Georgi, Sarah Orda, Aliza Eshkol, Danny Lotan, and Hayim Boichis* 549

Bone resorption stimulated by elevated serum 1,25-$(OH)_2$-vitamin D concentrations in healthy men. *William J. Maierhofer, Richard W. Gray, Herman S. Cheung, and Jacob Lemann, Jr.* 555

NEPHROLOGY FORUM

Is renal biopsy necessary for optimal management of the idiopathic nephrotic syndrome? *Jerome P. Kassirer* 561

ANNOUNCEMENTS 576

KIDNEY INTERNATIONAL

Volume 24, Number 5, November 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Role of dietary factors in the progression of chronic renal disease. *Saulo Klahr, John Buerkert, and Mabel L. Purkerson* 579

LABORATORY INVESTIGATION

Renal adaptation to altered dietary sulfur amino acid intake occurs at luminal brushborder membrane. *Russell W. Chesney, Naomi Gusowski, and Aaron L. Friedman* 588

Amelioration of experimental glomerulonephritis by dietary protein restriction. *Joel Neugarten, Helen D. Feiner, Robert G. Schacht, and David S. Baldwin* 595

Impact of age on effects of ureteral obstruction on renal function. *Masafumi Taki, David I. Goldsmith, and Adrian Spitzer* 602

Paracellular shunt ultrastructure and changes in fluid transport in Necturus proximal tubule. *Arvid B. Maunsbach and Emile L. Boulpaep* 610

Potentiation of ischemic renal injury by amino acid infusion. *Richard A. Zager and Manjeri A. Venkatachalam* 620

Cell renewal of glomerular cell types in normal rats. An autoradiographic analysis. *Reinhard Pabst and R. Bernd Sterzel* 626

Altered glomerular permeability in the early phase of immune complex nephritis. *Tito Cavallo, Michel Goldman, Kerry Graves, and Paul-Henri Lambert* 632

Reduction of renal blood flow and proximal bicarbonate reabsorption in rats by gentamicin. *Paul E. Klotman and William E. Yarger* 638

CLINICAL INVESTIGATION

Effect of chronic metabolic acidosis on vitamin D metabolism in humans. *Jeffrey A. Kraut, Earl M. Gordon, John C. Ransom, Ronald Horst, Eduardo Slatopolsky, Jack W. Coburn, and Kiyoshi Kurokawa* 644

Focal glomerulosclerosis in patients with unilateral nephrectomy. *Pietro Zucchelli, Leonardo Cagnoli, Silvia Casanova, Ugo Donini, and Sonia Pasquali* 649

Blunted kaliuresis after an acute potassium load in patients with chronic renal failure. *Guido O. Perez, Rene Pelleya, James R. Oster, David C. Kem, and Carlos A. Vaamonde* 656

A controlled study of the effect of indomethacin in uremic pericarditis. *David Spector, Howard Alfred, Michael Siedlecki, and Gary Briefel* 663

Effect of diet on plasma acid-base composition in normal humans. *Ira Kurtz, Terry Maher, Henry N. Hulter, Morris Schambelan, and Anthony Sebastian* 670

Inherited complement component deficiencies in membranoproliferative glomerulonephritis. *Thomas H. Coleman, Judith Forristal, Takao Kosaka, and Clark D. West* 681

TECHNICAL NOTES

Survival of endstage renal disease patients: Age-adjusted differences in treatment outcomes. *George W. Williams, John M. Weller, C. William Ferguson, Sarah B. Forsythe, and Shu-Chen Wu* 691

The Hickman catheter: A new hemodialysis access device for infants and small children. *John D. Mahan, Jr., S. Michael Mauer, and Thomas E. Nevins* 694

NEPHROLOGY FORUM

Uremic bleeding. *Daniel Deykin* 698

ANNOUNCEMENTS 706

KIDNEY INTERNATIONAL

Volume 24, Number 6, December 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Metabolic production and renal disposal of hydrogen ions. *Mitchell L. Halperin and Robert L. Jungas* 709

LABORATORY INVESTIGATION

Active and inactive kallikrein in rabbit connecting tubules and urine during low and normal sodium intake. *Ken Omata, Oscar A. Carretero, Sadayoshi Itoh, and A. Guillermo Scicli* 714

Structural and functional response of toad urinary bladder to LiCl. *Emma Fernandez-Repollet, Ann LeFurgey, Marcos A. Hardy, and C. Craig Tisher* 719

Natriuretic and antihypertensive effects of potassium in DOCA-salt hypertensive rats. *Toshiro Fujita and Yuji Sato* 731

Early functional and morphological changes in renal tubular necrosis due to *p*-aminophenol. *John M. Davis, Kerry R. Emslie, Ronald S. Sweet, Lesley L. Walker, Robert J. Naughton, Sandford L. Skinner, and John D. Tange* 740

Ultrafiltration in single isolated human glomeruli. *Virginia J. Savin* 748

Somatostatin-like immunoreactivity in the glomerulus of rat kidney. *Kiyoshi Kurokawa, Gregory W. Aponte, Shigeru Fujibayashi, and Tadataka Yamada* 754

CLINICAL INVESTIGATION

Symptoms and activation of granulocytes and complement with two dialysis membranes. *Peter Ivanovich, Dennis E. Chenoweth, Reinhard Schmidt, Horst Klinkmann, Laurence A. Boxer, Harry S. Jacob, and Dale E. Hammerschmidt* 758

Anaphylatoxin formation during hemodialysis: Effects of different dialyzer membranes. *Dennis E. Chenoweth, Alfred K. Cheung, and Lee W. Henderson* 764

Anaphylatoxin formation during hemodialysis: Comparison of new and re-used dialyzers. *Dennis E. Chenoweth, Alfred K. Cheung, David M. Ward, and Lee W. Henderson* 770

Hemodialysis leukopenia and complement function with different dialyzers. *Alberto Amadori, Paolo Candi, Mauro Sasdelli, Graziella Massai, Stefania Favilla, Angelo Passaleva, and Mario Ricci* 775

Effects of acetate and bicarbonate hemodialysis on cardiac function in chronic dialysis patients. *B. Rai Mehta, Diane Fischer, Masood Ahmad, and Thomas D. Dubose, Jr.* 782

Mechanisms of improvement of water and sodium excretion by immersion in decompensated cirrhotic patients. *Daniel G. Bichet, Bertron M. Groves, and Robert W. Schrier* 788

TECHNICAL NOTES

Acid-base status of awake rats after cannulation of aorta and vena cava. *Pierre Girard, Monique Brun-Pascaud, and Jean-Jacques Pocidalo* 795

Dynamic evaluation of renal electrolyte gradient by in situ tissue impedance studies. *Janusz Sadowski and Ewa Portalska* 800

Diagnosis of renal parenchymal diseases by a modified open kidney biopsy technique. *Gerald W. Chodak, William B. Gill, Vernonica Wald, and Benjamin Spargo* 804

NEPHROLOGY FORUM

Acquired distal renal tubular acidosis. *Neil A. Kurtzman* 807

ABSTRACTS

French Society of Nephrology, Paris, France, May 9, 1983 820

Italian Society of Nephrology, Chieti, Italy, June 9–11, 1983 824

ANNOUNCEMENTS 829

INDEXES 835

Indexed in Current Contents, SCI, ASCA, and ISI/BIOMED

KIDNEY INTERNATIONAL

Volume 24, Supplement 15

International Workshop on
CHRONIC RENAL FAILURE IN CHILDREN
Heidelberg, Germany, May 1982

Table of contents

Introduction. *Karl Schärer, Otto Mehls, and Malcolm A. Holliday* S-1

Predictability of the progression of chronic renal failure. *Norbert Gretz, Friedrich Manz, and Manfred Strauch* S-2

Protein and energy requirements in children receiving chronic hemodialysis. *Warren E. Grupe, William E. Harmon, and Nancy S. Spinozzi* S-6

Metabolism of orally administered branched-chain α-keto acids. *R. Neil Dalton and Cyril Chantler* .. S-11

Taurine metabolism in experimental renal failure. *Dietrich V. Michalk, Hans-Joachim Essich, Hans J. Böhles, and Karl Schärer* S-16

Glucose intolerance in children with chronic renal failure. *Robert H. K. Mak, George B. Haycock, and Cyril Chantler* S-22

Vasoactive hormones in children with renal failure. *Wolfgang Rauh, Ernst Hund, Gisela Sohl, Wolfgang Rascher, Otto Mehls, and Karl Schärer* S-27

Hypothalamo-pituitary-gonadal axis in children with chronic renal failure. *Peter J. Oertel, Klaus Lichtwald, Sigrid Häfner, Wolfgang Rauh, Dietrich Schönberg, and Karl Schärer* S-34

Growth and development of nondialyzed children with chronic renal failure. *Claire Kleinknecht, Michel Broyer, Danièle Huot, Carles Marti-Henneberg, and Anne-Marie Dartois* S-40

Prediction of adult height in children with chronic renal insufficiency. *Giulio Gilli, Otto Mehls, Birgit Wallstein, and Karl Schärer* S-48

Skeletal growth in experimental uremia. *Otto Mehls and Eberhard Ritz* S-53

Vitamin D metabolites in renal insufficiency and other vitamin D disorders of children. *Russell W. Chesney, Alan J. Hamstra, Mary Phelps, and Hector F. DeLuca* S-63

Serum erythropoietin levels in children with chronic renal failure. *Dirk E. Müller-Wiefel and Karl Schärer* S-70

Echocardiographic assessment of cardiac function in children with chronic renal failure. *Sean O'Regan, D. Matina, G. Ducharme, and A. Davignon* S-77

Cardiac function in experimental uremia. *Wilhelm Kreusser, Johannes Mann, Michael Rambausek, Pieter Klooker, Otto Mehls, and Eberhard Ritz* S-83

Experimental observations on peritoneal transport in rabbits. *Artur L. Schneider, Lutz Wacarda, Egbert von Klitzing, Walter Kochen, and Dieter Hellenbrecht* S-89

Transperitoneal solute movement in children. *Alan B. Gruskin, Howard Rosenblum, H. Jorge Baluarte, Bruce Z. Morgenstern, Martin S. Polinsky, and Sharon A. Perlman* S-95

Continuous ambulatory peritoneal dialysis in pediatric patients: A 20-month experience. *Isidro B. Salusky, Joel D. Kopple, and Richard N. Fine* S-101

Nutritional and metabolic studies in children on continuous ambulatory peritoneal dialysis. *Michel Broyer, Patrick Niaudet, Gérard Champion, Geneviève Jean, Nicole Chopin, and Paul Czernichow* .. S-106

Cadaveric renal transplants in children under 6 years of age. *Gerald S. Arbus, Brian E. Hardy, J. Williamson Balfe, Bernard M. Churchill, Brian T. Steele, Reuben Baumal, and Ruth N. Curtis.* S-111

KIDNEY INTERNATIONAL

Volume 24, Supplement 16, December 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

Proceedings of the Third International Congress on NUTRITION AND METABOLISM IN KIDNEY DISEASE

September 1–4, 1982, Marseilles, France

Introduction. *J. D. Kopple, S. G. Massry, and M. Olmer* S-1

Muscle protein turnover in uremia. *W. E. Mitch and A. S. Clark* S-2

Intracellular amino acids in uremia. *A. Alvestrand, P. Furst, and J. Bergström* S-9

Branched-chain amino acid metabolism in chronic renal failure. *A. Tizianello, G. Deferrari, G. Garibotto, C. Robaudo, M. Lutman, G. Passerone, and M. Bruzzone* S-17

Influence of chronic renal failure on protein synthesis in rat liver and muscle. *A. Ando, H. Mikami, Y. Orita, M. Fujii, A. Okada, H. Abe, K. Chiku, and Y. Natori* S-23

Proteolytic enzymes and catabolism: Enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis. *August Heidland, Walter H. Hörl, Norbert Heller, Hartmut Heine, Siegfried Neumann, and Ekkehard Heidbreder* S-27

Role of proteases in hypercatabolic patients with renal failure. *Walter H. Hörl, Jan Stepinski, Roland M. Schäfer, and August Heidland* S-37

Effect of acute uremia on protein degradation and amino acid release in the rat hemicorpus. *Isidro B. Salusky, Reinhild M. Flugel-Link, Michael R. Jones, and Joel D. Kopple* S-43

Effect of serine on gluconeogenic ability of hepatocytes in acute uremia. *Werner Riegel, Jan Stepinski, Michael Münchmeyer, and Walter H. Hörl* S-48

Effects of exercise training on muscle protein catabolism in uremia. *Teresa A. Davis, Irene E. Karl, Andrew P. Goldberg, and Herschel R. Harter* S-52

Diuretic-induced azotemia: Unmasking the role of increased peripheral catabolism through evisceration-hepatectomy. *Donald E. Kamm, M. Gennin, B. Kuchmy, and J. Hollander* S-58

The relationship between branched-chain amino and α-keto acids in blood in uremia. *R. Neil Dalton and Cyril Chantler* S-61

Increased plasma ammonia may inhibit cellular release of branched-chain amino acids in systemic portal encephalopathy. *H. A. Jahn, D. C. Schohn, C. Koehl, and R. L. Schmitt* S-67

Peritoneal ammonia, a possible inhibitor for blood amino acid loss. *C. Giordano, G. Mazzola, R. Esposito, R. Longhi, G. Vecchio, V. A. Di Leo, M. Pluvio, and C. Cirillo* S-71

Effects of renal substitutive programs on amino acid patterns in chronic uremia. *Maria Piera Scolari, Sergio Stefoni, Giovanni Mosconi, Luigi Coli, Giorgio Feliciangeli, Leopoldo Baldrati, Andrea Buscaroli, Rita Prandini, and Vittorio Bonomini* S-77

Skeletal myopathy in uremia: Abnormal energy metabolism. *Nachman Brautbar* S-81

Effects of amino acid infusions on cell metabolism in hemodialyzed patients with uremia. *Jack Metcoff, Seshachalam Dutta, Gayle Burns, James Pederson, Billy Matter, and Owen Rennert* .. S-87

The Third International Congress on Nutrition and Metabolism in Renal Disease was supported by the following institutions: The Chronic Renal Diseases Program, National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, National Institutes of Health; and The National Nephrology Foundation, Inc.; as well as by the following companies: Abbott Laboratories, Allard Laboratories, Amicon, Bayer Pharma, Bellco France, Bernas Medical, Biosedra Laboratories, Bristol Laboratories, Commerical Center for Specialized Books, Choay Laboratories, Ciba Laboratories, Cordis Dow, Cutter Laboratories, Delagrange Laboratories, Dubernard Hospital, Egic Laboratories, Eutherapie Laboratories, Evian Mineral Waters, Extracorporeal Laboratories, Fournier Laboratories, Fresenius Laboratories, Gambro, Geigy Laboratories, Glaxo Laboratories, Hemo-France, Henkel Corporation, Hoechst Laboratories, Hoffmann-La Roche, Institut Merieux, Jacques Pfrimmer-Gedächtnisstiftung, Kabivitrum, La Maison du Medecin, Le Britannia, Leo Laboratories, Maupetit Librairie, Merck Sharp & Dohme-Chibret Laboratories, Miles Laboratories, Millot-Solac Laboratories, Organon Nutritional Products, Organon Teknika, Pharma ICI, Physio Control, Robert and Carriere Laboratories, Roche Products, Roger Bellon Laboratories, Ross Laboratories, Roussel Laboratories, Sandoz Laboratories, Semca A.B.G., Service Marketing France, Smith Kline & French Laboratories, Sorin France, Specia Laboratories, Squibb Laboratories, Stedim Laboratories, Technico-Commercial Engineers, Terumo, The Green Cross Corporation, Theraplix Laboratories, Travenol Laboratories, Unilabo Laboratories, Vittel Mineral Waters, Volvic, Wellcome Laboratories, and Winthrop Laboratories.

Leukocyte metabolism and function in uremia. *William A. Briggs, Dale H. Sillix, Sudesh Mahajan, and Franklin D. McDonald* S-93
Acetate and energy metabolism during hemodialysis. *Miles H. Sigler, Charles L. Skutches, Brendan P. Teehan, Joseph H. Cooper, and George A. Reichard* S-97
Insulin action in uremia. *Ralph A. DeFronzo, Douglas Smith, and Anders Alvestrand* S-102
Glucose interorgan exchange in chronic renal failure. *Giacomo Deferrari, Giacomo Garibotto, Cristini Robaudo, Maurizio Lutman, Giorgio Viviani, Rita Sala, and Alberto Tizianello* S-115
Glucose metabolism in chronic renal failure: Adaptive responses to continuous glucose infusion. *Edmond S. Ricanati, Kou-Yi Tserng, and Satish C. Kalhan* S-121
Secondary hyperparathyroidism and glucose intolerance in children with uremia. *Robert H. K. Mak, Charles Turner, George B. Haycock, and Cyril Chantler* S-128
Recent advances in factors that alter lipid metabolism in chronic renal failure. *Tilman Drüeke, Bernard Lacour, Jean-Baptiste Roullet, and Jean-Louis Funck-Bretano* S-134
Lipid metabolism in acute renal failure. *W. Druml, A. Laggner, K. Widhalm, G. Kleinberger, and K. Lenz* S-139
Quantitative assessment of carnitine loss during hemodialysis and hemofiltration. *Matthias Leschke, K. Wolfgang Rumpf, Thomas Eisenhauer, Christoph Fuchs, Klaus Becker, Ute Köthe, and Fritz Scheler* S-143
Patient profile and effect of dietary therapy on post-transplant hyperlipidemia. *Steven Y. Shen, Carolyn W. Lukens, Sheila V. Alongi, Roger E. Sfeir, Fuad J. Dagher, and John H. Sadler* S-147
Muscle intracellular electrolytes in patients with uremia. *Jonas Bergström, Anders Alvestrand, Peter Fürst, Eric Hultman, and Ulla Widstam-Attorps* S-153
Role of intracellular calcium and calmodulin in cellular metabolism: Possible implications for renal failure. *Eberhard Ritz* S-161
Effect of end-stage renal disease on responsiveness to calmodulin and thyroid hormone of calcium-ATPase in human red blood cells. *Lynnette K. Nieman, Faith B. Davis, Paul J. Davis, Eugene E. Cunningham, Steven Gutman, Susan D. Blas, and Marion Schoenl* S-167
Ratio of parathyroid hormone to 1,25 dihydroxycholecalciferol in early renal failure. *P. A. Lucas, R. C. Brown, J. S. Woodhead, and G. A. Coles* S-171
Absence of secondary hyperparathyroidism in most patients with renal hypercalciuria. *M. Olmer, Y. Berland, and B. Argemi* S-175
Alterations of serum reverse triiodothyronine and thyroxine kinetics in chronic renal failure: Role of nutritional status, chronic illness, uremia, and hemodialysis. *Elaine M. Kaptein, Eben I. Feinstein, John T. Nicoloff, and Shaul G. Massry* S-180
Muscle biopsy studies in chronically uremic patients: Evidence for malnutrition. *Gianfranco Guarnieri, Gabriele Toigo, Roberta Situlin, Luigi Faccini, Ugo Coli, Silvano Landini, Giorgio Bazzato, Franco Dardi, and Luciano Campanacci* S-187
Nutrition, immunology and renal disease. *Richard J. Glassock* S-194
Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. *Sergio R. Acchiardo, Linda W. Moore, and Paul A. Latour* S-199
Pathogenesis of the anemia of uremia: Role of secondary hyperparathyroidism. *Shaul G. Massry* S-204
Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis. *Tor-Erik Wideröe, Truls Sanengen, and Sverre Halvorsen* S-208
Gastrointestinal blood loss in patients undergoing maintenance dialysis. *Volker Wizemann, Peter Buddensiek, Julia de Boor, Siegfried Grebe, and Georg Schütterle* S-218
Abnormal norepinephrine release in uremia. *Joseph L. Izzo, Jr., and Richard H. Sterns* S-221
Regulation of biosynthesis of guanidinosuccinic acid in isolated rat hepatocytes and in vivo. *Kazumasa Aoyagi, Shoji Ohba, Mitsuharu Narita, and Shizuo Tojo* S-224
Evidence for generation of the precarcinogen nitrosodimethylamine in the small intestine in chronic renal failure. *Pramod S. Lele, Stephen R. Dunn, Michael L. Simenhoff, Walter Fiddler, and John W. Pensabene* S-229
Serum levels of polyamines in patients with chronic renal failure. *Akira Saito, Toyomi Takagi, Tai Gi Chung, and Kazuhiro Ohta* S-234
Isolation of inhibitors of ligand-albumin-binding from uremic body fluids and normal urine. *Paul F. Gulyassy, Albert T. Bottini, Elizabeth A. Jarrard, and Linda A. Stanfel* S-238

Dietary protein and the progression of renal disease. *Timothy W. Meyer, Willie E. Lawrence, and Barry M. Brenner* S-243
Adverse effect of proteins on remnant kidney: Dissociation from that of other nutrients. *Denise Laouari, Claire Kleinknecht, Marie-Claire Gubler, and Michel Broyer* S-248
Improved dietary treatment with low protien and phosphorus restriction in uremic rats. *Hiroaki Kikuchi, Toshiaki Matsushita, and Kiyofumi Hirata* S-254
Focal glomerulosclerosis in obese Zucker rats and prevention of its development. *Tetsuo Shimamura* S-259
Low-protein diet supplemented by keto acids in chronic renal failure: A prospective controlled study. *Norbert Gretz, Elisabeth Korb, and Manfred Strauch* S-263
Retardation of the progression of renal insufficiency in patients treated with low-protein diets. *Anders Alvestrand, Marianne Ahlberg, and Jonas Bergström* S-268
Early dietary protein and phosphorus restriction is effective in delaying progression of chronic renal failure. *Giuseppe Maschio, Lamberto Oldrizzi, Nicola Tessitore, Angela D'Angelo, Enrico Valvo, Antonio Lupo, Carmelo Loschiavo, Antonia Fabris, Linda Gammaro, Carlo Rugiu, and Giovanni Panzetta* S-273
Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: A controlled trial. *G. Barsotti, E. Morelli, A. Giannoni, A. Guiducci, S. Lupetti, and S. Giovanetti* ... S-278
Supplements containing amino acids and ketoacids in the treatment of chronic uremia. *Mackenzie Walser, William E. Mitch, and Elias Abras* S-285
Comparison of three low-nitrogen diets containing essential amino acids and their alpha analogues for severely uremic children. *M. Broyer, M. Guillot, P. Niaudet, C. Kleinknecht, A. M. Dartois, and G. Jean* S-290
Nutritional requirements for patients undergoing continuous ambulatory peritoneal dialysis. *Joel D. Kopple and Michael J. Blumenkrantz* S-295
Therapeutic benefits of exercise training for hemodialysis patients. *Andrew P. Goldberg, Edward M. Geltman, James M. Hagberg, James R. Gavin, III, James A. Delmez, Robert M. Carney, Anna Naumowicz, Mary Haynes Oldfield, and Herschel R. Harter* S-303
Zinc metabolism and taste acuity in renal transplant recipients. *Sudesh K. Mahajan, Judith Abraham, Thomas Hessburg, Ananda S. Prasad, Stephen D. Migdal, Daoud K. Abu-Hamdan, William A. Briggs, and Franklin D. McDonald* S-310
Improvement of uremic neuropathy and hypogeusia by dialysate zinz supplementation: A double-blind study. *Kuno B. G. Sprenger, Dieter Bundschu, Kay Lewis, Bruno Spohn, Johannes Schmitz, and Hans-Eduard Franz* S-315
Total parenteral nutrition with high or low nitrogen intakes in patients with acute renal failure. *Eben I. Feinstein, Joel D. Kopple, Howard Silberman, and Shaul G. Massry* S-319
Enhancement of recovery in postischemic acute renal failure with captoril. *Mangus O. Magnusson, S. J. Rybka, N. T. Stowe, A. C. Novick, and R. A. Straffon* S-324

ABSTRACTS

The Third International Congress on Nutrition and Metabolism in Renal Disease, Marseilles, France, September 1–4, 1982 ..... S-327